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Abstract
The aim of this work was to develop tri-modal cell labels for tracking immune cells
in vivo, particularly for longitudinal studies of immune cell therapies. Localisation and
quantification of the cells is invaluable in determining the e ectiveness of these treatments,
so imaging agents for fluorescence, 1H MRI and 19F MRI were combined.
Four combinations of agents in a robust sca old were investigated: luminescent dyes
and a 1H MRI contrast agent were trapped electrostatically in a silica matrix; lumines-
cent dyes and proton MRI agents were bound to silica and gold nanoparticle surfaces;
a fluorinated fluorescent dye was investigated briefly; and all three modalities’ agents
were combined by filling and functionalising a silica shell. All of these combinations were
characterised and imaged using a clinical 3T MRI scanner.
Lead compounds from each section were incubated with white blood cells, examining
uptake in monocytes and lymphocytes, with preliminary observations of viability. Detec-
tion of labelled cells by their luminescence and MRI contrast enhancement was possible
in some cases, though 19F MRI still poses some challenges.
Detection limits by 19F MRI were determined for a range of fluorinated compounds,
elucidating the possibilities of translating 19F MRI into the clinic with current technology.
ACKNOWLEDGEMENTS
I would like to thank all my supervisors for their advice and support: Professor M.
J. Hannon; Professor Z. Pikramenou; Dr. N. P. Davies; Dr. J. P. Dicks; Professor D. H.
Adams; Dr. S. M. Curbishley.
To Mike and Zoe, thank you for your advice and support on chemistry and nanotech-
nology aspects, and to Mike for your feedback on this thesis. To Nigel and James, thank
you for your help and training in using the scanner and advice on MRI. To Stuart, thank
you for your patient help and advice in the cell work, flow cytometry and microscopy.
Thanks also to Ela Claridge for her support and advice on computational aspects of
this work.
I would like to thank Dr. N. J. Rogers for our joint work on the gold nanoparticles and
providing the IrBpySAc, and Dr. D. J. Lewis for his advice and help on the silica nanopar-
ticles and providing the GdQSH. Also thanks to S. Adams for providing the ruthenium
tris-phenathroline and for carrying out all the luminescence lifetime measurements.
Many thanks also to Dr. R. Williams for facilitating use of the furnace for calcination,
and for carrying out the nanoparticle density measurements. Thanks also to Professor L.
M. Grover for use of his furnace.
I would also like to thank Paul Stanley and Theresa Morris from the Centre for Electron
Microscopy for their training and advice in TEM and SEM, and the preparation of the
cell samples for TEM.
Thanks to Eva Valsami-Jones from the School of Earth Sciences for generously allowing
use of her Zetasizer. Thanks also to the Analytical Facilities in the School of Chemistry
for mass spectrometry measurements.
Thanks to Michael Clancy and Siobhan King for their contributions to this work
through their PSIBS mini-projects.
On a more personal note, thanks to the other PSIBS 4th years. Special thanks to
Joscelyn Sarsby for her support and for keeping me going. Thanks also to Stephen
Cardinal for looking after me through the less-good times and for proof reading this!
Finally I would like to thank the EPSRC for funding through the PSIBS DTC and
the University of Birmingham for the chance to carry out this work.
CONTENTS
Acronyms ix
1 Introduction 1
1.1 Project background summary . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Immune cell therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2.1 Stem cell therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.2.2 Dendritic cell vaccines . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.2.3 T cell therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.2.4 Current trends in immune cell therapies . . . . . . . . . . . . . . . 13
1.2.5 Clinical need for new cell tracking agents . . . . . . . . . . . . . . . 14
1.2.6 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.3 Imaging techniques . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
1.3.1 Luminescence imaging . . . . . . . . . . . . . . . . . . . . . . . . . 22
1.3.2 Magnetic resonance imaging . . . . . . . . . . . . . . . . . . . . . . 23
1.4 Imaging agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
1.4.1 Luminescent probes . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
1.4.2 1H MRI contrast agents . . . . . . . . . . . . . . . . . . . . . . . . 30
1.4.3 19F MRI tracers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
1.4.4 Multimodality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
1.5 Nanotechnology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
1.5.1 Silica nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
1.5.2 Gold nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
1.6 Multimodal molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
1.6.1 Fluorinated fluorescent dyes . . . . . . . . . . . . . . . . . . . . . . 38
1.7 Project design and aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
1.7.1 System design: imaging agent requirements . . . . . . . . . . . . . . 41
1.7.2 System design: delivery vehicle requirements . . . . . . . . . . . . . 42
1.7.3 Project aims: MR imaging capabilities investigation . . . . . . . . . 42
1.7.4 Project aims: imaging agent development . . . . . . . . . . . . . . . 43
1.7.5 Project aims: Cellular interactions investigations . . . . . . . . . . . 43
2 General Experimental Details and Imaging Capabilities 45
2.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
2.1.1 Common reagents and solvents . . . . . . . . . . . . . . . . . . . . 45
2.1.2 Imaging agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
2.1.3 Other equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
2.2 Instrumental details and methods . . . . . . . . . . . . . . . . . . . . . . . 46
2.2.1 Preparation and analysis of samples by DLS . . . . . . . . . . . . . 46
2.2.2 Preparation and analysis of samples by TEM . . . . . . . . . . . . . 47
2.2.3 Density analysis of nanoparticles . . . . . . . . . . . . . . . . . . . 47
2.2.4 Preparation of samples for ICP-MS analysis . . . . . . . . . . . . . 47
2.2.5 Preparation and analysis for luminescence measurements . . . . . . 48
2.2.6 Preparation and analysis for UV-visible spectroscopy . . . . . . . . 48
2.2.7 NMR characterisation . . . . . . . . . . . . . . . . . . . . . . . . . 49
2.2.8 MR imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
2.3 Cell preparation and analysis . . . . . . . . . . . . . . . . . . . . . . . . . 50
2.3.1 Peripheral blood mononuclear cell isolation and treatment . . . . . 50
2.3.2 Cell analysis by flow cytometry . . . . . . . . . . . . . . . . . . . . 50
2.3.3 PBMC analysis by light microscopy . . . . . . . . . . . . . . . . . . 51
2.3.4 Cell analysis by TEM . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2.3.5 Cell analysis by MRI . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2.4 1H MR capabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
2.4.1 Imaging with the birdcage coil . . . . . . . . . . . . . . . . . . . . . 53
2.4.2 1H imaging with the 19F coil . . . . . . . . . . . . . . . . . . . . . . 55
2.5 19F MR capabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
2.5.1 Fluorine imaging background . . . . . . . . . . . . . . . . . . . . . 56
2.5.2 Coil capabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
2.6 Detection limits of various molecules by 19F MRI at 3 T . . . . . . . . . . 60
2.6.1 Molecules with 3 equivalent fluorines . . . . . . . . . . . . . . . . . 60
2.6.2 Molecules with 6 equivalent fluorines . . . . . . . . . . . . . . . . . 61
2.6.3 Molecules with 9 equivalent fluorines . . . . . . . . . . . . . . . . . 62
2.6.4 Molecules with 24 equivalent fluorines . . . . . . . . . . . . . . . . . 64
2.6.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3 Trapping Imaging Agents in a Nanoparticle Matrix 67
3.1 Background and design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
3.2 Experimental details . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
3.2.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
3.2.2 Nanoparticle synthesis . . . . . . . . . . . . . . . . . . . . . . . . . 70
3.2.3 Nanoparticle characterisation . . . . . . . . . . . . . . . . . . . . . 72
3.3 Synthesis and characterisation results . . . . . . . . . . . . . . . . . . . . . 73
3.3.1 Negatively charged silica nanoparticles . . . . . . . . . . . . . . . . 73
3.3.2 Primary aminated silica nanoparticles . . . . . . . . . . . . . . . . . 77
3.3.3 Quaternary aminated nanoparticles . . . . . . . . . . . . . . . . . . 88
3.4 Cell treatment results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
3.4.1 Flow cytometry results . . . . . . . . . . . . . . . . . . . . . . . . . 93
3.4.2 Microscopy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
3.4.3 MR imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
3.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
4 Binding Imaging Agents to a Nanoparticle Surface 104
4.1 Background and introduction . . . . . . . . . . . . . . . . . . . . . . . . . 104
4.1.1 Gold nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
4.1.2 Silica nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
4.1.3 Other nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
4.1.4 Project plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
4.2 Experimental details . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
4.2.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
4.2.2 APTES-DTPA conjugation . . . . . . . . . . . . . . . . . . . . . . 110
4.2.3 Nanoparticle syntheses . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.3 Synthesis and characterisation results . . . . . . . . . . . . . . . . . . . . . 112
4.3.1 Silica nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
4.3.2 Gold nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
4.4 Cell treatment results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
4.4.1 Silica nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
4.4.2 Gold nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
4.5 Summary and conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
4.5.1 Silica nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
4.5.2 Gold nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . 144
4.5.3 Cell treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145
5 Multiple Imaging Agent Capabilities in Molecular Structures 146
5.1 Background and introduction . . . . . . . . . . . . . . . . . . . . . . . . . 146
5.2 Characterisation results . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
5.2.1 Luminescence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
5.2.2 MRI signal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
5.3 Cell treatment results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
5.3.1 Flow cytometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
5.3.2 Fluorescence microscopy . . . . . . . . . . . . . . . . . . . . . . . . 154
5.3.3 MRI detection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
5.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
6 Trapping Imaging Agents in a Nanoparticle Core 157
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
6.2 Overview and system design . . . . . . . . . . . . . . . . . . . . . . . . . . 158
6.3 Experimental details . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
6.3.1 Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
6.3.2 Hollow silica nanoparticle syntheses . . . . . . . . . . . . . . . . . . 164
6.3.3 Hollow nanoparticle characterisation . . . . . . . . . . . . . . . . . 167
6.4 Synthesis and characterisation results . . . . . . . . . . . . . . . . . . . . . 168
6.4.1 Hollow particle synthesis by dissolution-regrowth . . . . . . . . . . 169
6.4.2 Hollow particle synthesis by latex templating . . . . . . . . . . . . . 172
6.4.3 Hollow particle synthesis by selective etching . . . . . . . . . . . . . 180
6.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201
7 Image Analysis Methods 203
7.1 Automated particle sizing from TEM images . . . . . . . . . . . . . . . . . 203
7.1.1 Background and overview . . . . . . . . . . . . . . . . . . . . . . . 204
7.1.2 Algorithm I: Rapid circle detection (RCD) . . . . . . . . . . . . . . 205
7.1.3 Algorithm 2: Compass gradients edge detection (CGED) . . . . . . 211
7.1.4 Combined algorithms: StarRCD . . . . . . . . . . . . . . . . . . . . 215
7.2 Automated relaxation time calculation from MR images . . . . . . . . . . . 225
7.2.1 Background and overview . . . . . . . . . . . . . . . . . . . . . . . 225
7.2.2 Algorithm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226
7.2.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228
7.3 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229
8 Conclusions and Further Work 230
8.1 Trapping imaging agents in a nanoparticle matrix . . . . . . . . . . . . . . 231
8.2 Binding imaging agents to a nanoparticle surface . . . . . . . . . . . . . . 233
8.3 Multimodal imaging agent molecules . . . . . . . . . . . . . . . . . . . . . 234
8.4 Trapping imaging agents in nanoparticle cores . . . . . . . . . . . . . . . . 235
8.5 Image analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 237
8.5.1 Electron microscopy image analysis . . . . . . . . . . . . . . . . . . 237
8.5.2 MRI image analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 238
8.6 Future directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 238
Appendices 240
A Flow cytometry of IrGdAuNPs in PBMCs 241
B Characterisation data for synthesised molecules 243
B.1 Diethylenetriamine tetraacetic acid 3-amidopropyl triethoxysilane . . . . . 244
B.1.1 NMR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244
B.1.2 ESI-MS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245
B.1.3 FT-IR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245
List of References 246
ACRONYMS
C18TMS Octadecyltrimethoxysilane.
Me3APTMS trimethyl[3-(trimethoxysilyl)propyl]ammonium chloride.
Me3ASiNPs quaternary aminated silica nanoparticles.
AFC 7-amino-4-trifluoromethyl coumarin.
APTES 3-aminopropyl triethoxysilane.
AuNPs gold nanoparticles.
CEST chemical exchange saturation transfer.
CGED compass gradients edge detection.
DCs dendritic cells.
DLS dynamic light scattering.
EMA European Medicines Agency.
ESI-MS electrospray ionisation mass spectrometry.
FDA Food and Drug Administration.
FITC fluorescein isothiocyanate.
FT-IR Fourier transform infrared spectroscopy.
HFC 7-hydroxy-4-trifluoromethyl coumarin.
HPCs haematopoietic progenitor cells.
HSCs haematopoietic stem cells.
HSiNPs hollow silica nanoparticles.
ICP-MS inductively coupled plasma mass spectrometry.
MRI magnetic resonance imaging.
NMR nuclear magnetic resonance spectroscopy.
PBMCs peripheral blood mononuclear cells.
PBS phosphate bu ered saline.
PET positron emission tomography.
PFC perfluorocarbon.
PFCE perfluoro-15-crown-5-ether.
PFOB perfluorooctyl bromide.
RCD rapid circle detection.
ROIs regions of interest.
RuGdSiNPs gadolinium-functionalises RuSiNPs.
RuSiNPs ruthenium tris-phenanthroline-doped silica nanoparticles.
SiNPs silica nanoparticles.
SNR signal to noise ratio.
SPECT single photon emission computed tomography.
SPIOs superparamagnetic iron oxide nanoparticles.
TEOS tetraethyl orthosilicate.
TMOS tetramethyl orthosilicate.
UTE ultrashort echo time.
CHAPTER 1
INTRODUCTION
This thesis explores multimodal imaging agents for the in vivo tracking of immune cell
therapies. Imaging agents for multinuclear MRI and fluorescence techniques have been
designed and used to treat immune cells in this work. The theory and background behind
the project is described in this chapter.
1.1 Project background summary
Cellular therapies are a relatively recent field in healthcare. Under normal condi-
tions the innate functionality and capabilities of cells are e ective at restoring the body.
When these natural processes become ine ective, cellular therapies use cultured and pos-
sibly modified cells to correct them. Examples range from stem cell therapies for the
regeneration of tissue, such as heart tissues after myocardial infarction [1] to immune cell
therapies, such as dendritic cell vaccines for cancers [2] or autoimmune diseases [3]. This
work focuses on immune cell therapies, but the principles are similar for other forms.
The modification of cells for these therapies often occurs in vitro, before they are
administered to the patient. Once they have been administered however there is no label-
free way of distinguishing them from the rest of the cells in the body in situ, so evaluation
of the treatment has previously been based on outcomes, such as in some early trials [4, 5],
or through antigen challenge or cytokine testing [6]. If the cells are labelled such that they
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can be tracked through the body however, then information about the cells themselves
can be included in the evaluation. For example, the location of the cells will inform as to
whether they reach and remain in crucial sites such as the lymph nodes.
In this project, the aim is to develop labels that will simultaneously allow the location
and quantification of the cells. The principles used here are transferable to functional
information, so similar work could be developed for observing the longevity or e ectiveness
of therapeutic cells, which would show whether they have enough time and capability to
produce the observed outcomes.
The preferred label would depend on the technique being used to track the cells.
Non-invasive imaging techniques are ideal for this; they do not involve surgery, or risk
the removal of any of the therapeutic cells, and they are relatively unobtrusive for the
patient.
Currently nuclear imaging techniques are the ‘gold standard’ for tracking cells, for
which radiotracers are taken up by the cells and imaged in vivo by single photon emission
computed tomography (SPECT) or positron emission tomography (PET). The radiotracer
lifetime will however limit the length of the tracking study, so in this project the aim is
to create an alternative label whose detectability will not decay.
Magnetic resonance imaging (MRI) is increasingly of interest too [7], and has been used
here since it is a widely clinically available alternative to nuclear imaging. The isotopes
used are stable, and so the signal decay will depend mainly on the cellular concentration
and retention of the label.
At present no single MRI technique will provide e ective information on both the
location and number of cells at a given site. Data from multiple modes of MRI could
however be combined to do this; 1HMRI can provide localization information, as discussed
in Section 1.3.2, while 19F MRI can provide quantification, also discussed in Section
1.3.2. Multinuclear MRI is therefore an invaluable combination to be added to clinical
capabilities. This project investigates the possibilities of using these two techniques with
one label for immune cell tracking, with a long-term view of its e ectiveness in the clinic.
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These methods however only provide information on the tissue level. Observing the
location of tracers within the cells is also necessary in order to examine the interaction
of the label with the cells. More sensitive techniques than MRI are needed for this, so
the incorporation of a fluorescent tag is also highly beneficial. This will allow the use of
fluorescence microscopies, as well as flow cytometry, which can provide bulk rather than
microscopic information on the label uptake and retention.
One essential component for clinical translatability is the robustness of the proposed
system. For a dual modal imaging agent to be accepted, the results by both modalities
must be reliable. Incorporating the imaging agents into one vehicle is a logical step that
will ensure that the two agents are delivered and retained at the same rates.
Nanotechnology, as discussed in Section 1.5 provides a means for this, in that the
imaging agents can be built or added into a structure on the scale of tens or hundreds of
nanometres. There has been much research into the interaction of nano-sized materials
with cells [8, 9, 10], so this can be drawn on in the design of vehicles for imaging agents.
Chemistry also provides some answers to this problem. The di erent agents could be
components of one molecule, covalently combined into one robust structure, as discussed
in Section 1.6.
In this project therefore, the incorporation of proton and fluorine MRI agents and
fluorescent tags into nanoparticles was investigated. Three methods of trapping these
agents in nanostructures were considered, as well as the vehicle simply being a molecule.
Immune cells were treated with the lead vehicles from these experiments to observe
the uptake and localization within the cells. Of particular interest was whether the
labels were taken up to a high enough concentration for MR imaging at realistic cellular
concentrations.
Much research into this area has used pre-clinical scanners with high field strengths
[11, 12, 13, 14], partly due to MRI being a relatively insensitive technique. Studies
which have used lower field strengths have generally used custom-made setups such as
small solenoid coils, or small surface coils on small animals [15, 16, 17]. Although these
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studies demonstrate that 19F MRI is possible at clinical field strengths, the choice of coil
to demonstrate the clinical feasibility is questionable. Considering that the aim of the
research is eventual use in humans, the capabilities of a standard clinical MRI scanner,
equipped with a large surface coil designed for liver imaging, were explored here.
Automated analysis of the images obtained was implemented in order to produce a
reliable and high-throughput method of analysing the TEM and MRI data.
The TEM images required the measurement of particle sizes, which is a lengthy task
when carried out manually, and subject to some user bias in terms of edge selection. Au-
tomated analysis processes a series of images and combines the measured sizes, thus vastly
reducing analysis time and providing a reproducible and reliable method of analysing the
images.
The MRI data is a stack of images, though usually these are not arranged in the
correct order. The automated method orders them from information in the metadata,
then analyses the stacks it creates. After selection of the regions of interest (ROIs), which
is semi-automated, the algorithm fits the intensity values to a model equation, which thus
determines the relaxation times for each ROI. The relaxation times quantify the contrast
enhancement, so allow quantitative comparison between contrast agents.
1.2 Immune cell therapies
Cellular immunotherapies were first developed using stem cells as a way to regenerate
particular parts of the body. The immune system, for example, could be reconstituted
after destruction by radiation or drug treatment to remove blood cancers [18], or in cases
of severe genetic immunodeficiency [19].
Other immune cell therapies have grown from this, with the specific aim of treating
diseases by ex vivo treatment and readministration of cells. The modification of the cells
can be specialised so as to target the disease, such as a tumour, but by using the body’s
own resources.
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Haematopoietic stem cell therapies, dendritic cell vaccines and T cell therapies, dis-
cussed below, are based on this principle of using the cells’ innate capabilities to intercept
and rectify problems in the immune pathway.
1.2.1 Stem cell therapies
Stem cells are a crucial range of cells in the body which are responsible for the regen-
eration of tissues. They are specialised so as to generate a subset of cell types by division
and di erentiation, such as haematopoietic stem cells (HSCs), which di erentiate into
all the various blood and immune cells. Patients who are genetically highly immunode-
ficient can therefore have their immune cells produced by infused HSCs [19]. Similarly,
haematopoietic cancers, including some leukemias and myelomas, are treated by destruc-
tion of the patient’s immune system, including the cancer, followed by regeneration of a
theoretically healthy immune system with HSCs [18, 20].
Only one stem cell therapy has been approved for marketing by the time of writing in
the European Union. Holoclar, a treatment of autologous ex vivo expanded limbal stem
cells for regenerating the cornea in cases of ocular burns, was approved by the European
Medicines Agency (EMA) in December 2014.
A range of HSC transplantation therapies have been given orphan designation by the
EMA, which allows clinical investigation and later protection on the market to incentivise
development for rare conditions. They have not, to date, been given market approval.
In the USA, the Food and Drug Administration (FDA) has approved immunotherapies
including products such as Hemacord (New York Blood Center, Inc), and Allocord (SSM
Cardinal Glennon Children’s Medical Center). These use haematopoietic progenitor cells
(HPCs), which can di erentiate into the immune cells in a similar way to HSCs, in order
to reconstitute the immune system. They are also approved in cases of severe immunod-
eficiency, either for genetic reasons or after destruction of the immune system, referred to
as myeloablation.
After the therapeutic stem cells are administered in these treatments, they must cir-
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culate throughout the blood. In mesenchymal stem cell therapies however, a loss of
therapeutic cells has been noted as a result of their becoming stuck in the lung and other
small capillaries [21]. For HSCs, the cells should localise in bone marrow niches, which
regulates their di erentiation [22, 23]. Tracking the cells can therefore verify the location
of the stem cells [22] and how they di erentiate [24].
Labelling of stem cells for tracking is however complicated by their proliferation in
vivo diluting many of the typical imaging agents. Exceptions to this involve engineering
to make the cells express reporter genes, a sequence encoding a fluorophore, such as green
fluorescent protein [24, 22] or a lysine-rich protein as a chemical exchange saturation
transfer (CEST) agent [25], which are passed on to the progeny. Alternatively, both
bioluminescence and SPIO-enhanced MRI have been used in animal models to track
neural stem cells [26].
In terms of immunotherapies, HSC transplantation was a revolutionary step in being
able to treat blood cancers and restore immune systems. It is however a highly aggres-
sive and risky process, leaving the patient vulnerable to minor infections. More targeted
approaches have therefore been explored, as discussed below, which use specific cell pop-
ulations.
1.2.2 Dendritic cell vaccines
Dendritic cells (DCs) are antigen-presenting cells acting as part of the immune system.
In the body they are derived from HSCs, existing initially as immature dendritic cells.
They sample their environment for pathogens until they are activated; this involves a
process of phagocytosis, processing of possible antigens, and antigen presentation on the
cell surface. Once activated the dendritic cells mature and migrate to the lymphoid tissues
(the lymph nodes and spleen), where they in turn activate T cells, which continue the
chain of immune responses [27].
Immunotherapies have been developed which use the antigen-presenting abilities of
DCs to induce an immune response [28, 29]. DCs are however naturally spread around
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the body, and circulate in low concentrations, so direct isolation would yield very low cell
counts. Monocytes from peripheral blood were found to also derive into DCs with suitable
stimulation [30, 31], and are naturally found in much higher counts. Monocyte-derived
DCs have consequently been used for generating ex vivo vaccines.
In vaccine production, monocytes from a peripheral blood sample are isolated, de-
rived into immature DCs, treated with tumour antigens to activate them and matured
in culture. Upon administration to the patient, the cells should migrate to the lymph
nodes and spleen, and similarly induce an immune response against a tumour or infection
[32, 5, 33]. This process is illustrated in Figure 1.1.
Figure 1.1: Illustration of a simplified workflow for preparing dendritic cell vaccines.
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Various forms of this therapy have been developed and moved into clinical use or
clinical trials.
A formulation of autologous DCs, sipuleucel T (marketed as Provenge by Dendreon)
is licensed for prostate cancer therapy. It is approved for use in the USA by the FDA (BL
125197), and the European Medicines Agency (EMA) (EMEA/H/C/002513). In the UK
it is not recommended by the National Institute for Health and Clinical Excellence (NICE)
on the basis that it is not more e ective than other treatments for the price (ID573). On
the contrary, it was approved by Germany’s equivalent to NICE, the IQWiG, which noted
some added benefits.
Due to di culties in the manufacturing process however, the company producing
Provenge, Dendreon, filed for bankruptcy and was recently taken over by the pharma-
ceutical company Valeant. This indicates that there are still significant challenges in
the development of these processes, but that there is also still commercial motivation to
overcome them.
A number of DC vaccine clinical trials are underway in the USA. Some of these trials
are referenced in Table 1.1.
8
Condition Phase Trial reference
Glioblastoma III NCT00045968
II NCT00576537
Renal cell cancer III NCT01582672
Melanoma III NCT01875653
II NCT00197912
Breast cancer II NCT00622401
II NCT01431196
Soft tissue sarcoma II NCT01883518
Early stage HIV-1 II NCT00402142
II NCT00833781
Metastatic colorectal cancer II NCT01348256
II NCT01413295
II NCT00228189
Ovarian cancer II NCT00799110
Table 1.1: Examples of dendritic cell vaccines in clinical trials in the USA for a range of
diseases. Source: https://clinicaltrials.gov.
Similarly in the UK there are a number of trials underway, some being carried out in
both the UK and the USA, listed in Table 1.2.
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Condition Phase Trial reference
Glioblastoma III NCT00045968
II NCT00576537
Renal cell cancer III NCT01582672
Hepatocellular carcinoma II ISRCTN11889464
Rheumatoid arthritis I NCT01352858
Table 1.2: Examples of dendritic cell vaccines in clinical trials in the UK. Source:
https://clinicaltrials.gov.
The number of conditions this therapy is undergoing trials for shows its versatility.
From cancers of the brain, skin, liver and kidneys, to autoimmune diseases such as rheuma-
toid arthritis and HIV, the potential of these therapies is wide ranging and revolutionary
for healthcare.
The work in this thesis was being carried in connection with the trial for the treatment
of hepatocellular carcinoma, and consequently the focus of future tissue and in vivo studies
would have particular regard to the liver tissues and associated pathways.
Dendritic cell vaccines rely on the cells reaching the lymphoid tissues, which can be
assessed by the outcome, such as tumour regression. This however provides no quantifiable
information on the therapy’s direct e ectiveness, so tracking of the DCs in vivo by a range
of imaging techniques, which are discussed in detail in Section 1.2.5, would demonstrate
that a given number of cells at a given site are suitably placed to produce the outcome.
The need for cell tracking has been emphasised by a study using a 111In oxinate
as a radiotracer, which showed that after intradermal injection, fewer than 4% of the
DCs reached the lymph nodes [34]. Current DC vaccine research is therefore focused on
improving the DC migratory capacity, such as by priming the injection site so cytokines
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associated with migration are upregulated [35], or by using fresher natural DCs rather
than monocyte-derived DCs [36].
It has also been noted that multiple approaches to restoring the immune system may
be necessary to boost the clinical e cacy. DC vaccines are therefore now being considered
in combination with other immunotherapies [37, 38], as discussed in more detail in Section
1.2.4.
1.2.3 T cell therapies
An alternative point to intercept the immune response is the T cells themselves. T
lymphocytes are immune cells that recognise pathogens via the antigens receptors on their
surface. They must generally be activated and only recognise the specific antigens they
have been primed with. Recognition occurs through simultaneous binding to the T cell
receptor and to another, co-stimulatory, receptor.
Some T cell therapies involve modifying the surface receptors, usually by genetic en-
gineering to recognise the target pathogens [39, 40, 41]. The T cell receptor can either
be modified alone to improve its a nity, or it can be engineered to be combined with an
artificial co-stimulatory receptor to form a chimeric antigen binding site that is specific
to its target [42, 40].
No T cell therapies have currently been approved to the author’s knowledge at the
time of writing, but many clinical trials are underway. Some of these are listed in Table
1.3.
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Condition Phase Trial reference
Leukemia III NCT00914628
II NCT01013441
Probable multiple sclerosis III NCT00228228
Glioblastoma III NC00807027
Hepatocellular carcinoma III NCT00699816
Metastatic breast cancer III NCT01741038
II NCT01431196
Adenocarcinomas (gastric, colorectal,
lung and solid tumour)
II NCT01723306
HIV II NCT00407836
Progressive multiple sclerosis II NCT01448252
Metastatic melanoma II NCT00871481
Table 1.3: Examples of T cell therapies in clinical trials. Source: https://clinicaltrials.gov.
As can be seen from the range of clinical trials, T cell therapies are versatile in that
they can be applied to many disease states. As with the dendritic cell vaccines, they hold
the potential to tackle conditions that are at present otherwise incurable, such as multiple
sclerosis.
T cell therapies have the advantage of avoiding the need for migration to the lymph
nodes, since the T cells themselves are active. The disadvantage is that the small circu-
lating numbers of lymphocytes require expansion of the T cell population either in vivo or
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in vitro in order to generate therapeutic numbers rapidly [43, 44]. Conversely, dendritic
cells can each activate many T cells, so have an intrinsically multiplying e ect.
As with dendritic cell vaccines there is no label-free way of detecting modified T cells in
vivo, so the therapies su er from similar tracking problems to dendritic cells, as discussed
in Section 1.2.5. The interest lies in whether the primed T cells arrive at the tumour site,
and so could therefore a ect the local immune response. For example, engineered T cells
were labelled with 111In-oxinate (see Figure 1.2 for the structure) and tracked by SPECT
to the bone marrow and other sites of interest in patients with acute myeloid leukemia.
In another example, engineered T cells were tracked using 111In-oxinate (also referred to
as 111In-oxine) in a phase I trial for ovarian cancer. Most of the radiation was seen in the
lungs, liver and spleen [45] however, showing that either only a small portion is reaching
the tumour, or that the tracer is being tra cked out of the cells soon after injection [46].
MRI has also been used to track T cells, mostly using superparamagnetic iron oxide
nanoparticles (SPIOs). Splenocytes (lymphocytes from the spleen) labelled with SPIOs
were tracked in mice using MRI at 7T. Similarly, T cells labelled with fluorescent peptide-
coated SPIOs were tracked in mice at 4.7T [47]. See Section 1.2.5 for more information
on the use of SPIOs.
Small animal PET has similarly been used to track genetically-engineered T cells in
vivo by transfecting them with a reporter gene designed to specifically accumulate a PET
probe [48, 49].
1.2.4 Current trends in immune cell therapies
As mentioned above, current immunotherapy trends involve combining di erent treat-
ments, thus targeting multiple aspects of the immune response in the same treatment
[37, 38, 35].
One development is the removal of immune suppression by checkpoint blockade [50].
Under normal conditions checkpoints are cell surface receptors that prevent the immune
system from responding to self-antigens, which would otherwise lead to autoimmune re-
13
sponses and excessive T cell proliferation. Cancer cells possess these self-antigens, so
similarly suppress the immune response, and can exploit this mechanism by checkpoint
up-regulation [51]. This locally inhibits T lymphocyte activity, resulting in decreased
reaction to the tumour’s other antigens [50].
A modern trend is therefore to use inhibitors for these receptors to re-stimulate the
immune response, with reported durable clinical e ects [52]. Several checkpoint inhibitors
have been approved for clinical use in the USA; examples include Ipilimumab (Bristol-
Myers Squibb Company), a monoclonal antibody targeting the CTLA-4 receptor, and
Pembrolizumab (Merck Sharp & Dohme Corp.), a monocloncal antibody binding to the
PD-1 receptor. In the EU Ipilimumab also has marketing authorisation, while Nivolumab
(Bristol-Myers Squibb International Corp.), another PD-1 inhibitor, is authorised for a
paediatric investigation, though not yet market approval.
There is however a proportion of patients who do not respond to checkpoint inhibitors
as a single therapy [53], and it is thought that this could be in patients with weak immune
systems. The current movement is therefore towards using other therapies to boost the
immune system, as well as the checkpoint blockade to remove the suppression [52, 54,
53]. Since immune cell therapies such as DC vaccines and T cell therapies will enhance
the immune response, they are a vital component of therapy innovation, making robust
tracking and quantification of their in vivo distribution all the more pressing.
1.2.5 Clinical need for new cell tracking agents
Currently, the clinical gold standard for immune cells tracking in vivo is nuclear imag-
ing, though preclinically other techniques are of interest too. This section examines a
few examples of the current clinical imaging agents used for tracking, and explores others
which are under investigation.
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Labelling with clinically approved agents
Radiotracers Radiolabelling is attractive because it is not limited by depth, as light
microscopy techniques are, and gives real-time information on the cells in situ. It can also
provide a quantifiable signal, indicating the number of cells that reach target sites in the
body.
The standard method for tracking cells is SPECT. This requires a suitable radioisotope
to be created, incorporated into a metal complex, and incubated with the cells.
Labelling with indium chelates such as indium oxinate (also known as indium oxine,
see Figure 1.2e) allows tracking by SPECT, and some of the lighter isotopes such as 18F-
fludeoxyglucose (FDG), by PET. Some examples of the clinically approved formulations
are listed in Table 1.4, with the structures of the more complex ones shown in Figure 1.2.
Isotope Generic name Imaging technique Indicated condition
99mTc 99mTc sestamibi SPECT Myocardial perfusion
99mTc exametazime SPECT Cerebral perfusion
18F Florbetapir PET Amyloid plaques
111In 111In pentetreotide SPECT Neuroendocrine tumours
with somostatin receptors
111In oxine SPECT Leukocyte labelling
82Rb 82Rb chloride PET Myocardial perfusion
13N Ammonia-13N PET Myocardial perfusion
Table 1.4: Examples of radioisotopes, their formulations, and their associated imaging
modality and condition. These are all currently licensed for use in clinics.
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(a) 99mTc≠sestamibi (b) 99mTc≠exametazime
(c) 18F-florbetapir
(d) 111In-pentetreotide
Figure 1.2: Structures of the example clinical radiotracers presented in Table 1.4.
111In-oxine, an oxyquinoline complex shown in Figure 1.2e, is the most widely used
for cell tracking, being the only approved complex for cell labelling, and a gold standard
against which new methods are compared [55, 56, 57]. It localises in the cytoplasm of
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(e) 111In-oxine
Figure 1.2: Structures of the example clinical radiotracers presented in Table 1.4 (contin-
ued).
platelets [58], but in leukocytes is more concentrated around the nucleus [59].
99mTc-HMPAO, also known as 99mTc-exametizime, shown in Figure 1.2b, has been
loaded into DCs, but was found in one study to be unsuitable for DC labelling [60].
In leukocytes there were more promising results reported, though radioactivity in other
organs such as the bladder was also noted [61]. Like the indium complexes, it also appears
to localise in the cytoplasm, possibly towards the nucleus [62, 63].
18F, 13N and 82Rb have not been used for immune cell tracking, probably due to their
short half lives (109.8 minutes, 10 minutes and 75 seconds respectively). 18F-labelled
compounds have been used to track cardiac stem cells after myocardial infarction, but
not for long periods [64, 65], whereas the half lives of the other two are too short for any
cell tracking.
When compared to other techniques nuclear imaging does have some advantages. In
one study the higher sensitivity of radiolabelling provided better cell tracking by SPECT
than T2-weighted MRI [66]. In a dog model of myocardial infarction, HSCs were co-
labelled with SPIOs and 111In≠oxine before infusion. While the indium was visible by
SPECT and scintigraphy, the SPIOs were not detected using MRI. This study highlights
the challenges of optimising co-label concentrations, and the limited sensitivity of MRI
compared to nuclear imaging.
With a half-life of 2.8 days for 111In, tracking is only usually feasible for up to 4 days
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after labelling [67]. Radiotracers therefore do not allow tracking in longer term studies
after ex vivo labelling. There is also limited resolution using SPECT, making precise
localisation within lymph nodes only possible using scintigraphy after resection [34].
There are also risks from labelling cells with ionising radiation. For example, HPCs
were labelled with 111In≠oxine and tracked by scintigraphy in a rat myocardial infarction
model [68]. Although the conclusion from this study was that the tracking was feasible,
a loss of proliferation was noted in the labelled HPCs, suggesting that the tracer was
a ecting the cells. In a similar way in a di erent study, T cell proliferation was limited by
the same tracer until the complex had been depleted from the cells [46], indicating that
label concentrations may need to be optimised to balance these e ects.
Gadolinium complexes Gadolinium chelates, which are discussed in detail in Sec-
tion 1.4.2, have also been used for cell tracking, though with modified formulations or
functionalisation compared to the clinical preparations. Reformulation of the clinically
available compound GdDTPA by addition of transfection agents improved uptake into
stem cells, producing su cient labelling for imaging by MRI [25]. Similarly, a mem-
brane translocation peptide was conjugated to GdDOTA, leading to detectable uptake
into lymphocytes [69], and with further modification, to the nucleus of cancer cells [70].
Pre-clinical labelling
SPIOs SPIOs have attracted considerable interest as alternative MRI contrast agents
to the standard gadolinium chelates. They are typically iron oxide cores of 2-3 nm trapped
in a hydrophilic coating of dextrans or other polymers, but the cores can be much larger,
reaching the micrometre range for particular applications [71]. The coatings make the
particles hydrophilic, enabling cell treatments and the tuning of uptake. There is never-
theless often a need for transfection agents, though this can be overcome by amination of
the SPIO surface [72].
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SPIOs are reported to provide e ective negative contrast in MRI, and a further func-
tionalisable surface [73, 74]. An extra advantage is the potential for magnetic manipula-
tion, such as magnetic sorting of labelled cells [75]. The disadvantage is that they do only
provide negative contrast, making them less distinguishable from other short-T2 image
regions, and leading to local distortion which could mask other structures. They have
previously been clinically approved, but are currently withdrawn from the market due to
a combination of lack of demand [76] and concern about e cacy expressed by the EMA
and manufacturers.
SPIOs have been used to track dendritic cell vaccines [55], though this required in-
tranodal injection of the DCs in order to achieve su cient contrast, followed by ex vivo
quantification in a higher strength MR scanner. They have also been used as haematopoi-
etic stem cell labels [77] and for in vivo tracking [78], as well as for lymphocyte tracking
[57, 79].
An alternative method for tracking cells by T2 negative contrast is to engineer the
cells to over-express ferritin. This up-regulates iron storage when the cells are incubated
in iron-enriched medium, leading to a T2 contrast that is detectable by MRI [80, 81].
Ferritin up-regulation has been used for tracking of neurons and glial cells [82], car-
diac stem cells [83], and as a label for embryonic stem cells [84]. When compared with
SPIO-labelling, ferritin up-regulation was found to produce lower signals, but to give the
advantage of distinguishing between live and dead grafts [85]. This is therefore a poten-
tially very interesting technique for dendritic cells, and has been demonstrated using a
transduction of the gene into a DC line [86], though both the sensitivity, and the e ect
of the cytological changes would need to be thoroughly investigated.
Hyperpolarised MRI Hyperpolarised MRI has also received increasing interest
recently. The normal limitation of MRI is its sensitivity, which is due to only a small excess
of nuclei contributing to the net magnetization. If however the nuclei are hyperpolarised
at the time of imaging, there will be a significantly larger excess of nuclei in one spin state,
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leading to an increase in the net magnetization and hence the signal. Xenon has been
investigated as it can be readily hyperpolarised before being inhaled for lung imaging [87],
or perfused into cell medium for cell labelling [88].
The problem with this technique at present is that it involves subjecting the nuclei to
extreme conditions such as low temperature and high magnetic fields, to optical pumping,
or to catalytic hydrogenation with hyperpolarised parahydrogen, none of which could be
carried out in vivo. Since the lifetime of the hyperpolarisation is limited to minutes [89], or
at most hours [90], this would be a problem for longitudinal studies. While hyperpolarized
MRI has been used for a number of applications [91], it would not be suitable for in vivo
cell tracking unless the technology or techniques develop further.
CEST agents An alternative MRI method which is being increasingly explored is
chemical exchange saturation transfer (CEST) agents. These are molecules with exchange-
able protons, where one frequency is excited until the protons are saturated. During this
pulse however there is a rapid exchange of the saturated protons with the surrounding
water. As a result, a much higher number of protons than the concentration of the agent
are excited in the local area, and the saturated magnetisation is transferred to the bulk,
thus decreasing the water signal and leading to negative contrast. This means that one or
more specific frequencies can be excited, leading to hotspot imaging and the potential for
multicolour imaging [92, 93], and that the e ect on the image is amplified by the rapid
exchange [94, 95].
CEST can be achieved either through the saturation of exchangeable protons such as
hydroxyl or amine hydrogens, or through paramagnetic complexes, which are spectrally
further separated from the water peak. Both have been explored for cell tracking, either
through the introduction of a reporter gene, such as a lysine-rich protein [93], or through
modifications to common lanthanide metal complexes [96, 97].
While CEST agents are therefore an interesting option, especially if a dual-modal
CEST and luminescence compound could be designed, di culty in quantifying the cells
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and the negative MRI contrast make them less useful than other methods discussed below.
Ultrasound Ultrasound is an attractive technique because it is widely available,
non-intrusive and relatively inexpensive. The disadvantages are that it has low resolution,
highly localised signals and is largely not quantitative [98]. Therefore, although it has be
used for guidance in cell administration (and even this has come under scrutiny for its
e ectiveness [99]), it is not ideal for tracking.
Optical imaging In vivo fluorescence techniques have been explored for cell tracking
[7], usually involving intravital fluorescent microscopy [100], and labelling with organic
fluorophores [101], quantum dots [102, 103], or genetic engineering to introduce fluorescent
proteins [104] or luciferase [105]. They are however limited by the depth penetration of
light through tissue, i.e. a few hundred micrometres, and consequently they require
the cells to be close to the skin or to be accessible by endoscopy. These techniques
are therefore intrinsically restricted to certain volumes of the body, or require a highly
invasive procedure [7]. Moreover, these procedures all involve either fluorophores with
limited photostability, high toxicity, or they involve modifying the genome of the cells,
the consequences of which have not been fully investigated.
1.2.6 Summary
Current therapies have been shown to be e ective in a range of cases by their out-
comes, as discussed above, and some longer-term cell tracking has been carried out using
radiotracers. In order to track these cells for longer than the decay time of a radiotracer
however, ideally for more than a week, longer-lived tracers are required. This would allow
observation of the cell migration through the body on a scale of weeks rather than days.
While the techniques used clinically and pre-clinically have some advantages, none
of them alone provides an e ective solution to this. One notably absent item from this
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section is fluorine containing agents for 19F MRI, which are discussed in detail in Section
1.4.3.
The imaging modalities selected for tracking in this work are discussed below, with a
discussion about the benefits of combining them for cell tracking.
1.3 Imaging techniques
This section explores some of the theory and research in imaging techniques of interest
for novel methods of cell tracking: luminescence-based techniques, 1H MRI, and 19F MRI.
1.3.1 Luminescence imaging
Fluorophores are detected by various imaging techniques. Essentially, a sample is
illuminated with a light source at the wavelength of maximum fluorescence excitation.
The emitted light is then collected, often with filtering to remove the excitation light,
and formed into an image either by scanning and detection by a photomultiplier tube or
wide-field imaging and detection by a camera (usually a charge-coupled device, CCD).
Fluorescence microscopy is widely used in research, with many biological and clinical
laboratories having the necessary equipment already in place. This makes it a useful tech-
nique to use in novel processes. For example, if an immune cell is fluorescently labelled,
the sub-cellular location of the label can be readily determined [106]. Of particular inter-
est are whether the fluorophore is in the cytoplasm, whether it has entered the nucleus
and might be interacting with the DNA, or whether it is trapped inside vesicles, and
therefore is being tra cked through the cell.
Luminescence imaging is intrinsically limited by the interaction of light with tissue.
The water and haemoglobin in tissues will absorb and scatter light to di erent degrees
depending on its wavelength, thus limiting the penetration depth to millimetres [107] and
restricting the in vivo use of light microscopy. Methods such as two-photon microscopy try
to overcome this by using multiple low energy photons hitting the sample simultaneously
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to excite it to high energy states. This enables the use of near IR excitation, where
the scattering and absorption e ects are minimised, but produces emission in a readily
detectable blue region of the visible spectrum. Even with this technique however the
depth penetration is very limited [108, 109].
Flow cytometry is also an attractive technique because it allows the quantification of
the probe within a population of cells. The population is distinguished by co-labelling
with a suitable fluorescent tag. The number of cells containing the probe of interest is
then counted (denoted as the percent of positive cells), and the amount of probe per cell
quantified by the median fluorescence of the gated-channel.
1.3.2 Magnetic resonance imaging
Magnetic resonance imaging (MRI) is a non-invasive, non-ionising medical imaging
technique. It uses radio frequency pulses to excite the nuclei in the sample, and detects
their relaxation back to equilibrium. The relaxation rate is dependent on environment,
so di erent tissues will often relax at di erent rates, thus creating image contrast.
Proton MRI is by far the most widespread form of MRI. Clinical scanners are tuned to
the frequency of 1H nuclei, and the properties and abundance of protons make them ideal
for imaging. It is very e ective in the discrimination between soft tissues, contrasting
with and complementing techniques such as computed tomography.
19F nuclei also have useful magnetic properties, and are considered to be a viable
alternative mode of MRI. Fluorine has an advantage over protons since the concentration
of fluorine endogenously present in the body is below the detection limit of MRI, being
reportedly less than a nanogram per gram of wet tissue [110]. Clinical equipment tends
not to be tuned to the frequency of the 19F nuclei however, so extra hardware is usually
required for imaging.
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1H MRI
Three factors are the main properties of the tissues which a ect the image produced
by MRI; they are the proton density, the T1 and the T2.
Various longitudinal recovery pulse sequences are used to measure the T1 of a sample.
The two used in this work are inversion recovery and a fast low angle saturation recovery.
Inversion recovery involves a 180¶ pulse, then various inversion times, TI, before a 90¶
pulse to tip the spins into the imaging plane, which is perpendicular to the static field,
traditionally denoted as B0. The spins will relax from their excited states by di erent
degrees during TI depending on their T1. By using a range of TIs the T1 can be calculated
according to the equation (1.1) [111].
Intensitysample,IR(TI) =M0
5
e≠
TI
T1 (≠2 + e≠TRT1 ) + 1
6
(1.1)
Saturation recovery with a low flip angle consists of rapid low flip angle pulses and a
spoiler gradient to destroy the transverse magnetisation between them. The advantage
is that the repetition time, TR (the time between repetitions of the pulse sequence) is
significantly reduced. There is however a greater susceptibility to artefacts, which must
also be accounted for in the sequence preparation. A range of TRs are used, which allow
the calculation of T1 according to equation (1.2) [111].
Intensitysample,SR(TR) =M0
5
1≠ e≠TRT1 + k
6
(1.2)
The high tissue penetration capabilities, versatility and lack of ionising radiation make
MRI a highly suitable technique for in vivo clinical use. It is widely used and understood
in clinical settings, meaning that it can be readily applied to a range of applications. MR
images moreover have high tissue contrast, allowing high accuracy localisation within a
body.
The main disadvantage of MRI is low sensitivity. Since the magnetisation being de-
tected is only a slight net excess, most of the proton spins are intrinsically unavailable for
24
imaging as their spins are equalled by spins in the opposite direction.
There are also general disadvantages of MRI scans such as that they can be unsuitable
for some patients with metal implants. A contrast agent is also often required, which can
be contraindicated in patients with renal problems. Contrast agents are discussed in
Section 1.4.2.
19F MRI
19F MRI uses the same principles as proton MRI. The nuclei are aligned and excited
in the same way, though the frequency used to excite them is slightly lower (Ê = “*B0,
where Ê is the Larmor frequency, “ is the gyromagnetic ratio and B0 is the static magnetic
field. “(1H) is 42.58 MHz/T as opposed to “(19F), which is 40.08 MHz/T). Fluorine also
has a 100% natural abundance of the 19F isotope and a spin 1/2 nucleus, resulting in no
intrinsic isotopic splitting or quadrupolar splitting in the signal.
Fluorine can therefore also be imaged in a similar way to protons. The sequence
does however need to be selected and optimised carefully based on the environment of
the fluorine. Ultrashort echo time (UTE), steady state free precession (SSFP) and rapid
acquisition with refocused echoes (RARE) sequences have all been used with fluorine
imaging in the past.
Fluorine is an interesting nucleus specifically for in vivo MRI because of the low
endogenous concentrations of fluorine [110]. The highest levels that are present are in
solid tissues such as teeth and bone, and thus have such short relaxation times that they
would not generally interfere with samples with fluid properties.
Consequently any fluorine introduced into the body (provided that it is in a fluid form)
will have no background signal, and should therefore be quantifiable. This contrasts con-
veniently with proton MRI which is not quantifiable, but does provide in vivo localisation,
and can be imaged with the same equipment.
One main disadvantage of the use of fluorine is that it generally does require extra
equipment, such as multi-frequency transmit and receive coils. While these can be incor-
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porated into current clinical setups, an initial investment is necessary.
The other disadvantage is that fluorine-containing molecules can carry some risks,
either in the toxicity of the compounds themselves or their degradation products. Mean-
while perfluorocarbons (PFCs), which have been used clinically in the past, are di cult
to formulate, since PFCs are immiscible with water.
One formulation of a perfluorocarbon, a crown ether with 20 MR-equivalent nuclei, has
been marketed and has undergone early phase clinical trials particularly for cell tracking.
In research other groups have also made perfluorocarbon emulsions for cell tracking. These
are discussed in detail in Section 1.4.3.
1.4 Imaging agents
Imaging agents are chemical compounds that aid in imaging by a given modality. They
can be either contrast agents or tracers.
A contrast agent improves the contrast of an image in its environment. Examples
include gadolinium chelates in proton MRI and microbubbles in ultrasound imaging. The
tissues of the body will already have some inherent contrast, but an additional contrast
agent can help to highlight lesions or objects of interest. The advantage of contrast agents
is that the inherent image contrast provides information on their relative anatomical
localisation.
Tracers are used when there is no or little inherent contrast in an image, and hence any
signal observed is considered to come from the tracer. Examples include radionuclides for
positron emission tomography (PET) such as fluorodeoxyglucose (FDG). The advantage
of tracers is that due to the low background in the signal, provided the modality detects
all the relevant response, the signals are assumed to be quantitative. The disadvantage is
that with a single modality there is usually no indication of the anatomical localisation.
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1.4.1 Luminescent probes
Luminescent probes can be either a tracer or a contrast agent depending on the modal-
ity by which they are observed, and the spectral properties of both the probe and the
sample.
Fluoresceins Fluorescein and its derivatives are among the most common of fluo-
rescent probes. Microscopes and flow cytometers even with a small range of filter sets will
generally include settings suitable for the detection of fluorescein isothiocyanate (FITC).
The ease of imaging and its low price make it appealing as an imaging agent. It is more-
over known to be biocompatible, being used un opthalmic eye drops and for angiography.
The disadvantage is that in solution it is highly susceptible to photobleaching, making
modifications to stabilise the molecule desirable.
The fluorescence profile of fluorescein depends on its environment, principally on the
pH [112], and on any appended moieties [113]. FITC was used in early investigations of
lymphocyte tracking, showing no e ect on viability [114]. It was superseded however by
other derivatives [115]. Its succinimidyl ester derivative, CFSE, has been used for tracking
lymphocyte proliferation by flow cytometry [116], and its diacetate dervative, CFDA, has
been used for leukocyte tracking in eye vasculature [117], though CFDA was found to leak
out of the cells so to be unsuitable for longer term tracking [118].
Coumarins The coumarin dyes form another range of organic fluorophores. Various
coumarins have been found to a ect mononuclear cells and have pharmacological e ects
[119]. 7-amino-4-trifluoromethyl coumarin (AFC) is frequently conjugated to a peptide
and used as a marker of apoptosis (see [120] and commercial products, e.g. CAS number
201608-14-2). It is mentioned particularly here because of its bifunctional nature; the
molecule is fluorescent but also possesses three MR equivalent fluorines, making it intrin-
sically a dual modal agent. No examples were found of it being used as a general cell
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label, for tracking or otherwise.
Charge transfer complexes Charge transfer complexes are also an interesting
variety of luminescent dye. They are reported to show good photostability and strong
luminescence with a large Stokes shift [121].
Ruthenium trisphenanthroline is a readily available and well-studied example complex.
Its main charge transfer band has maximum absorption around 450nm, with emission
between 500 and 700nm [122]. It binds to DNA [122, 123], but has not been found
reported as a cell label, except to note that it is cytotoxic to mouse lymphocyte leukaemic
cells [124]. An analogous complex with enhanced lipophilicity has been demonstrated as
cell probe, though it was designed for lifetime imaging to probe binding rather than for
cell tracking [125].
Iridium polypyridyl based complexes have also been found to emit bright luminescence,
with a range of colours and binding properties depending on the ligands [126, 127, 128].
Several of these complexes have been tested as environment-sensitive cell labels [129, 130]
which can be targeted to particular cellular compartments [127, 131, 129]. They have
not, at the time of writing, been previously used for in vivo cell tracking, or for labelling
immune cells.
The iridium complex used, [Ir(Bpy)2(BpySH)]+, was specifically designed for stable
luminescence and binding to a gold surface. The complex and subsequent nanoparticle
development were carried out by Dr. N.J. Rogers [132].
The structures of the luminescent dyes used in this project are shown in Figure 1.3.
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Figure 1.3: Structures of various luminescent dyes used in this project.
These dyes are usually incorporated simply by incubation with the cells [133], though
extra factors such as pendant peptides and serum free conditions can a ect both the
uptake and sub-cellular localisation [134]. Some lipophilic ruthenium complexes appear
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to enter the cells by passive di usion [135], and others by a non-endocytotic temperature
dependent route [133, 136], indicating dependence not only on cell type and the available
transporters, but also on the complex itself.
1.4.2 1H MRI contrast agents
A number of 1H MRI contrast agents are clinically available, which makes these at-
tractive for research. Some of these are presented in Figure 1.4. The ligands are changed
to suit their particular indications, which is one consideration for the choice of complex.
For example, Gd-EOB-DTPA, marketed as Primovist, specifically targets hepatocytes,
thus improving liver contrast in MRI scans [137].
The other major consideration for gadolinium contrast agents is the balance between
the water access to the inner sphere of the gadolinium centre, and the kinetic stability of
the complex. High kinetic stability is necessary to minimise patient risk, since the free
ion is considered to be toxic [138]. Generally however higher ligand denticity is associated
with lower toxicity [138, 139].
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Figure 1.4: Structures of various 1H MRI contrast agents used currently in clinics.
In terms of cell labelling, uptake of simple gadolinium complexes is often very low
[140], though [Gd-HP-DO3A]2≠ (see Figure 1.4) has been used to label pancreatic islets
by co-incubation, which was then imaged in vivo in a 7 T scanner [141]. It was noted
however that with a less stable complex, a transmetallation process led to Gd3+ ions,
rather than the whole complex, being taken up by two types of cancer cells, leading to a
significant fall in cell viability [140].
In an attempt to boost the e ect of the agent, GdDTPA complexes were conjugated to
31
a fluorescent dextran, creating a dual-modal stem cell label. The compound was diluted
out of proliferating cells within seven days, but remained within non-proliferating cells,
with little or no reuptake by surrounding cells [142]. Other attempts to improve contrast
using MR images have included trapping gadolinium ions in fullerene cages [143], and
binding to nanoparticles, which is explored in Section 1.5.
The main 1H MRI agent used in this project was a gadolinium DTPA derivative used
for hepatic imaging, marketed as Primovist. The ligand has a pendant ethoxybenzyl group
as shown in Figure 1.4. This is a clinically available compound with known properties,
which would be helpful for clinical translatability.
The other 1H MRI agent used here is a gadolinium bound to a derivative of DTPA,
denoted as APTES-DTPA, which has been conjugated to a silane moiety to allow binding
to a silica surface (see Chapter 4).
1.4.3 19F MRI tracers
19F MRI tracers are a relatively novel concept. The lack of clinical setups capable of
imaging 19FMRI and the small range of tracers available make it a more challenging option
than some other contrast agents. The potential benefits nevertheless make investigation
worthwhile.
There are three fields in which fluorinated compounds have been used clinically:
medicines and anaesthetics [144], blood substitutes [145], and ultrasound contrast agents
[146].
Medicines and anaesthetics have obvious disadvantages as imaging agents in their lack
of biological inertness. Both blood substitutes and ultrasound contrast agents, consisting
of perfluorocarbon (PFC) emulsions or bubbles, are a promising avenue for imaging re-
search [146]. It should be noted though that these frequently have several MR-inequivalent
fluorines, which lead to chemical shift artefacts in MRI [147]. They are nevertheless bio-
compatible and MRI active, and would be strong choices when considering translatability.
On the other hand, as mentioned above, the higher the degree of fluorination, the higher
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the immiscibility in water, making processing for human use more di cult.
One of the most widely used perfluorocarbons is perfluorooctyl bromide (PFOB),
which has been used as a blood substitute [148], as a fluorine MRI tracer in small animals
[149], and as a multimodal agent for ultrasound, fluorine MRI and CT [150, 151].
One set of commonly used agents for fluorine MRI are the perfluoropolyethers. They
are often a linear chain form that, due to the low symmetry, has split peaks in its spectrum
[152], which could result in chemical shift artefacts in the images.
One significant development in perfluoropolyethers for MRI was perfluoro-15-crown-
5-ether (PFCE), which has 20 equivalent fluorines [153]. PFCE has been emulsified by
trapping it in a PVA-stabilised PLGA nanoparticles of 200 or 2000nm in size, which could
simultaneously be co-labelled with fluorescent dyes [147]. It has also been emulsified, and
co-labelled with fluorophores for the tracking of DCs in vivo [154].
Immune cell labelling with PFCs is summarised in [147], with all the PFC molecules
discussed above reported for ex vivo labelling of dendritic cells and stem cells. The
structures of PFOB, PFCE and an example PFPE are shown in Figure 1.5.
Figure 1.5: The structures of PFOB, PFCE and an example perfluoropolyether (PFPE).
A highly fluorinated suspension of molecular aggregates has recently been reported for
therapeutic cell tracking [155]. The molecule possesses 36 MR-equivalent fluorines, and is
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attractive due to the consequently strong 19F MR signal it produces. This structure will
not readily be modified to produce a multimodal system without losing the strong fluorine
signal. Its incorporation into a multimodal vehicle could however prove an interesting
avenue for future research.
In this work various 19F tracers are examined. PFOB is used as it has been widely
studied and is readily available. Trifluoromethylated molecules have also been explored,
as well as some weakly coordinating anions such as hexafluorophosphate (which has 6 fluo-
rines split into two peaks by the phosphorous) and tetrakis 3,5-bis(trifluoromethyl)phenyl
borate (which has 24 equivalent fluorines, though some weak splitting by the boron).
1.4.4 Multimodality
Using more than one imaging technique on a sample or patient provides at least
confirmatory if not complementary information. This results in higher confidence for
diagnosis and therapy.
For example, 1H MRI will non-invasively produce anatomical localisation, and 19F
MRI would enable the quantification of a tracer at that location. This is similar to
the combination of positron emission tomography and computed tomography (PET/CT)
which is current clinical practice, but avoids the use of ionising radiation.
If therefore tracers and contrast agents can be combined into a single vehicle and deliv-
ered as a unit, the multimodal probe will be more readily located and traced quantifiably
in vivo.
This however requires a reliable method of combining the imaging agents at consistent
proportions in a form robust enough to withstand physiological environments. This can
be challenging, depending on the imaging agents in questions.
For example, fluorinated substances as might be used for 19F MRI will often be im-
miscible with water, forming a separate fluorous phase. Solutions to this have involved
forming emulsions with fluorinated surfactants or surfactant cocktails, or encapsulating
the PFC in a polymer shell [156]. Both the liposomes and polymer shells have been
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modified to include fluorophores, making them dual modal [147, 157, 11]. Forming such
nano-sized emulsions however often requires specialised equipment such as microfluidizers,
and can nevertheless be susceptible to Ostwald ripening [158], so a more robust system is
desirable.
1.5 Nanotechnology
Nanotechnology is often defined as involving structures with at least one dimension
between 1 and 100nm in size. The definition is sometimes extended to particles below
1 micron in one dimension. The term nanoparticles will be used here in the more loose
sense of spheres having diameters between 1nm and 1 micron.
The size of nanoparticles, along with various other properties such as their sur-
face charge, can significantly a ect their interaction with biological systems. Small
nanoparticles are reported to be able to enter cells by di usion through the membrane
[159, 160, 161], whereas most nanoparticles enter by an endocytotic, usually phagocy-
totic, pathway [162]. Treatments usually involve simple incubation of the cells with the
nanoparticles.
Nanotechnology is a versatile field with many possibilities for combining di erent com-
ponents into one self-contained vehicle. Methods explored in this work include; trapping
molecules inside nanoparticles in Chapter 3, using the nanoparticles’ surface as a sca old
in Chapter 4, and carrying molecules in the cores of the particles in Chapter 6.
1.5.1 Silica nanoparticles
Amethod for the controlled synthesis of silica nanoparticles (SiNPs) were first reported
by Stober in 1968 [163]. They are solid silica spheres with a generally regular morphology,
though varying size distributions.
SiNPs are formed, according to the Stober method [163], by the basic hydrolysis of
tetraethylorthosilicate (TEOS). Reagent concentrations are varied to control the size and
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shape of the SiNPs, along with other factors such as the temperature and reaction time.
Modifications of Stober’s method have involved replacing some of the TEOS with
functionalised silanes, thus incorporating the functional groups into the bulk matrix or on
to the surface of the NPs [164, 165, 166, 167], as discussed in Chapters 3 and 4 respectively.
The morphology of SiNPs can also be changed by adding porogenic molecules, fre-
quently surfactants, to the synthesis mixture. This can create well-ordered pore systems
widely considered useful for drug delivery and some imaging applications [168, 169, 170].
The disadvantage of these methods is that the template molecules need to be removed
after the synthesis, without disrupting the structure of the particle, without losing any
added functional groups, and ensuring that all of the template has been removed. The
usual method is to extract the surfactant into a solvent, but this can lead to incomplete
removal, and so poorly characterised micro-environments in the pores [171, 172, 173].
Even with a more comprehensive method such as calcination [174], which would de-
stroy any organic functionalisation, there would still be a risk of micro-environments
within the structure with di erent properties to the bulk, e.g. pH surface functional
groups [170]. While there could be advantages to systems with micro-environments, they
would need to be reliably characterised, especially if it might have clinical applications.
An extension of these porous systems is hollow silica nanoparticles (HSiNPs), which
have been formed by a number of methods, as discussed in detail in Chapter 6. They
consist simply of silica shells with a higher loading capacity than mesoporous structures,
and a single cavity, making them easier to characterise.
SiNPs are inert, robust and highly versatile in terms of their functionalisation. Their
surface can be modified with silanes, allowing conjugation to most biomolecules of interest.
These properties are valuable for cell tracking applications. An inert vehicle is im-
portant as the cell label should ideally not have any e ect on the activity of the cell.
The ability to functionalise the surface moreover means that SiNPs can be targeted to
particular biological vectors [175, 176, 177]. Imaging agents can readily be incorporated
into them in various modes, as explored through this thesis.
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1.5.2 Gold nanoparticles
Gold nanoparticles (AuNPs) are often found in the 10-30 nm diameter range. They are
formed readily by the reduction of tetrachloroaureate in the presence of citrate molecules
[178, 179]. though other synthetic methods are also described in Chapter 4.
AuNPs are particularly useful because of their versatility in functionalisation through
gold-sulphur bonds [180]. Being relatively small for nanoparticles they have a high surface
area to volume ratio, allowing high levels of surface modification. They are dense heavy
metal structures which can consequently be easily discerned by electron microscopy, thus
providing another mode of intracellular localisation, uptake and release [181, 182]. One
disadvantage is that the metal surface can quench luminescence, so a spacer is necessary
to distance dyes from the nanoparticle surface [183, 184].
AuNPs are generally considered to be biocompatible [181], although some cytotoxic-
ity has been observed with cationic AuNPs [185] and small (1-2nm) AuNPs [186], which
should be taken into account in the design. The particles must also be colloidally sta-
bilised, which somewhat limits the functionalisation capacity. For example, it is di cult
to change the surface charge from the negatively charged citrate groups to a positively
charged species without significant aggregation.
There is consequently much research on gold nanoparticles for many applications,
ranging from drug delivery [187, 188, 180], photothermal and photodynamic therapy [189,
190], and combinations of diagnostic and therapeutic agents (so called ‘theranostics’)
[191, 192, 193].
Gold nanoparticles are of interest for cell tracking because of the high surface loading
capacity for imaging agents. Any molecules that has, or can be modified to have, a thiol
group could potentially bind to a gold nanoparticle surface. They have been explored in
the context of photoacoustic imaging of melanoma cells, with the notion that the technique
could be extended to circulating cancer cells [194]. They have also been functionalised
with fluorescent and gadolinium labelled DNA to create dual-modal labels [195], and with
sugars for receptor-mediated targeting to particular cells [196].
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1.6 Multimodal molecules
Nanotechnology can be an e cient and elegant solution to the problem of designing
a multimodal imaging agent system, as discussed above. It can however have several
disadvantages: in the loss of colloidal stability in salt or protein solutions such as cell
medium [197]; leakage of imaging agents; and the size distribution of the nanoparticles,
coupled with the size dependent response of biological systems [186, 198, 199].
Multimodal alternatives to nanotechnology were therefore considered; these could in-
clude small molecules where multiple functional moieties are present on one structure. For
example, having a fluorophore with a conjugated gadolinium complex, or a gadolinium
complex with a conjugated fluorine group, could potentially allow multimodal detection
of the label.
1.6.1 Fluorinated fluorescent dyes
Numerous fluorinated fluorescent dyes (FFDs) exist. The electron withdrawing e ects
of the fluorines can have significant e ects on the fluorescence [113, 200]. Two FFDs, the
first marketed by Life Technologies, are fluorescein derivatives: Oregon Green 488 and
Pennsylvania Green. Both have reported improved photostability compared to fluorescein
[201]. The advantage of the fluorines is largely limited to the fluorescence properties,
since the inequivalent placement and low number of the fluorines make these molecules
unsuitable for 19F MRI.
BODIPY dyes are also a popular set of fluorinated fluorophores [202, 203]. The at-
tachment of the fluorines to the boron will however result in quadrupolar splitting of the
fluorine signal, risking chemical shift artefacts in 19F MRI.
The fluorinated coumarin dyes mostly look more promising. 6,8,difluoro-7-hydroxy
coumarin would su er from similar artefacts to the fluorescein dyes. The three equiv-
alent fluorines on AFC, 7-hydroxy-4-trifluoromethyl coumarin (HFC) and coumarin 153
however make them attractive FFDs for further investigation.
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Similarly, Atto514, marketed by Atto-tec, might potentially be promising, especially
considering the presence of the six fluorines, but would be prohibitively expensive to use
at the concentrations required for 19F MRI in preliminary experiments
The structures of these dyes are shown in figures 1.6 and 1.7.
Figure 1.6: Structures of some fluorinated fluorescent dyes.
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Figure 1.7: Structures of some fluorinated fluorescent dyes (cont.).
These coumarin dyes are not significantly water soluble, possibly in part due to the
presence of the fluorine groups. They are however soluble in alcohols and DMSO, so can
be dissolved su ciently for use in cell studies.
Atto514 has higher water solubility and a good excitation and emission range for
multicolour fluorescence imaging, but is a proprietary brand as in considerably more
expensive than the coumarin dyes.
In this project therefore AFC was primarily used, since it o ered an inexpensive dual
modal molecule with the potential to be functionalised further through the amine group.
1.7 Project design and aims
The broad aim of this work is to create and explore vehicles for the simultaneous
delivery of multiple imaging agents. The required concentrations of the various agents
are investigated, and the design optimised where possible to account for the sensitivity of
the di erent modalities.
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1.7.1 System design: imaging agent requirements
The design requirement of the various imaging agents has been described in Table 1.5,
which has guided the strategies used.
Requirements Fluorophores Gadolinium chelates Fluorinated agents
Structure Aromatic moiety not
disrupted
E ective chelation of
metal centre
High 19F NMR-
equivalence
Freedom of
movement
None Rotational correlation Rotational correlation
Solvent access None preferably Access to water None
pH control Depends on structure Necessary None
Table 1.5: Table specifying design considerations for the three classes of imaging agents
in this project
In practice the requirements described in Table 1.5 can be implemented as follows.
Fluorophores can be incorporated into any part of a nanoparticle structure as long as
the particles are not disrupted by the process. They may benefit from a pH-controlled
environment if their fluorescent properties depend upon this.
The toxicity of gadolinium-based contrast agents is highly dependent on a minimal
presence of free gadolinium ions. These agents require that e ective chelation of the
gadolinium is maintained both during the incorporation into a nanoparticle structure, so
limiting the usable pH range that can be withstood during the synthesis, and through
foreseeable pH changes the system will undergo physiologically. Moreover, these contrast
agents require access to the water, so cannot be trapped in a non-aqueous medium in an
impermeable shell. There must also be su cient rotation to ensure a rotational correlation
with the surrounding molecules, thus enabling faster relaxation.
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Fluorinated agents have few requirements, but do need enough freedom of rotation to
allow relaxation of the spins by interaction with surrounding molecules. The only other
consideration is ensuring that the NMR-equivalence of any fluorine species is maintained,
ensuring a high signal and avoiding the introduction of chemical shift artefacts.
1.7.2 System design: delivery vehicle requirements
For the design of the delivery vehicle, the most important property is that the final
system should be bioinert. The vehicle should enter the immune cells, but interact mini-
mally with them to reduce any e ects on the cell functionality. It should be a stable and
robust system, which also has a minimal e ect on the capabilities of the imaging agents,
as discussed above.
The aim is therefore to investigate various delivery systems, mainly consisting of silica
or gold nanoparticles, but also to explore other options.
1.7.3 Project aims: MR imaging capabilities investigation
19F MRI is not currently used clinically, but modifications to clinical equipment to
expand the nuclear analysis capabilities to fluorine have become available. A 19F coil,
interface and software extension were procured for the work of which this project is a
part, and as a relatively new setup, protocols are not well established.
The aim in this work is to investigate the capability of the 19F MRI setup, within
the limitations imposed by the research licence agreement with the manufacturer. As
a clinical scanner, options for pulse sequence development are limited, and this was not
feasible within the time constraints. Consequently, though there are a number of protocols
reported in the literature which give promising results, such as Rapid Acquisition with
Refocused Echoes (RARE) sequences at 11.7T [12, 204], or the steady state free precession
sequences at 1.5T [205], these were often not available to be replicated, or did not have
suitable parameters or options available, e.g. the number of averages or echo time. Fast
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low angle single shot (FLASH) sequences however have been used on clinical strength
scanners [206, 207], and were available for this work, so were focused on in this project.
The sensitivity of the coil with respect to the sample placement is important, and could
have considerable e ects on the results produced. Since a large portion of this project
involves the development of imaging agent systems, analysis of various model phantoms
demonstrated the concentration ranges that would be required.
1.7.4 Project aims: imaging agent development
Once a robust delivery system is found, the aim is to incorporate imaging agents,
while maintaining the design requirements discussed above, at a su cient concentration
for imaging.
Luminescence techniques for example have relatively high sensitivity, requiring con-
centrations in the nanomolar to micromolar range, depending on the quantum yield. MRI
on the other hand requires much higher concentrations due to its low inherent sensitivity.
The delivery systems developed are therefore investigated to verify that the luminescence
is bright enough for microscopy and flow cytometry applications. The relaxivity is also
measured for samples containing gadolinium, and fluorine MRI carried out for fluorine-
containing samples.
The relaxivity is dependent on the field strength of the scanner, and the MRI work in
this project has been carried out on a clinical strength 3 tesla scanner. This immediately
gives an indication of the clinical translatability of the system. This approach contrasts
with many studies, in which the development is carried out in a pre-clinical scanner of
higher field strength, thus giving a skewed impression of their translatability.
1.7.5 Project aims: Cellular interactions investigations
Comprehensive investigations of cellular uptake and viability of these systems are
beyond the scope of this project. This is due to the number of factors that would a ect
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the uptake: specific cell type, temperature, donor variability, culture conditions, etc..
The viability is also complex as it will depend partly on the cell type, uptake and culture
conditions, but would also be assessed di erently depending on the application of interest.
This project therefore aims to carry out preliminary studies to assess the feasibility
of labelling the cells, and the requirements for su cient labelling for the various imaging
modalities.
Peripheral blood mononuclear cells (PBMCs) are to be used, as they are relatively
rapid, easy and inexpensive to isolate, as compared for example to dendritic cell prepa-
rations. The PBMC blood fraction contains both monocytes and lymphocytes, which
are both of interest for immune cell therapies. The aim is therefore to observe the
concentration-dependent uptake into both cell types, where possible by flow cytometry
and fluorescence microscopy. MRI analysis will then indicate whether the labelled cells
show enhanced contrast, making them dual or tri-modal imaging agents.
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CHAPTER 2
GENERAL EXPERIMENTAL DETAILS AND
IMAGING CAPABILITIES
This chapter details materials and methods which are common to all of the following
chapters. The aim of this is to provide a central reference point and avoid repetition.
The chapter also explores the capabilities of the MRI imaging systems used in the rest
of the work. These experiments were carried out alongside the testing of the imaging
agent systems, but are presented separately here in order to demonstrate the challenges
involved, especially in fluorine MRI.
2.1 Materials
2.1.1 Common reagents and solvents
Tetraethyl orthosilicate (TEOS) (Acroseal) and 3-aminopropyl triethoxysilane (APTES)
were purchased from Sigma Aldrich. Ammonium hydroxide (28 - 30%) was purchased
from VWR. Ethanol was purchased from Fisher Scientific (UK).
2.1.2 Imaging agents
Fluorescein sodium salt, 1-bromo-heptadeca-fluorooctane (PFOB) and trifluoroethanol
were purchased from Sigma-Aldrich. Primovist (GdDTPA-EOB) was produced by Bayer.
45
Sodium tetrakis(3,5-bistrifluoromethylphenyl)borate was purchased from ABCR. Gadolin-
ium chloride hexahydrate was purchased from Alfa Aesar.
2.1.3 Other equipment
200 mesh copper transmission electron microscopy (TEM) grids were purchased from
Agar Scientific (UK) or Electron Microscopy Supplies (USA).
The centrifuge used in the nanoparticle preparation was a Gallenkamp fixed head
angle rotor or a Corning LSE Compact with a fixed angle rotor. The sonicator used here
was a Decon FS200b 35-45kHz ultrasonic cleaning system.
2.2 Instrumental details and methods
2.2.1 Preparation and analysis of samples by DLS
As-prepared nanoparticle samples were diluted until visibly clear with the stated sol-
vent – usually deionised water or ethanol. For dynamic light scattering (DLS) mea-
surements, sample suspensions were placed in 1 ml plastic disposable cuvettes (Sarstedt
polystyrene cuvettes) and analysed using a ZEN3600 Zetasizer Nano (Malvern, UK).
Samples were equilibrated to 25¶C for 2 minutes prior to measurements. Light was de-
tected at 173¶ backscattered. Each sample was measured 3 times, with each measurement
consisting of at least 10 runs.
For zeta potential analysis the same sample was used as for DLS. The suspension was
placed in a polystyrene folded capillary cell (Malvern, DTS1061), and analysed by the Ze-
tasizer Nano (Malvern, UK). Each sample was measured 3 times, with each measurement
having an automatic number of runs.
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2.2.2 Preparation and analysis of samples by TEM
8µl of as-prepared nanoparticles were dropped onto a Formvar coated 200 mesh copper
TEM grid held in opposable tweezers. The drop was left to settle for 1-2 minutes then
the excess was blotted by touching the droplet with filter paper. The grid was left to air
dry in the tweezers for a minimum of 30 minutes, and usually overnight.
The grids were analysed using a Jeol 1200EX transmission electron microscope with
an accelerating voltage of 80keV.
2.2.3 Density analysis of nanoparticles
All density measurements were carried out by Dr. R. Williams.
The true density of all samples was evaluated using an AccuPyc II 1340 (Micromeritics,
U.S.A) helium pycnometer; each sample was subject to ten purge and measurement cycles
with helium. Average density of the samples were calculated from measuring the mass
of a known volume of sample (typically 0.75 ml) in powder form. Relative density was
calculated as the average density divided by the true density. Porosity was then calculated
as 1 minus the relative density and multiplied by 100%.
2.2.4 Preparation of samples for ICP-MS analysis
Samples were analysed by inductively coupled plasma mass spectrometry (ICP-MS)
to find the gadolinium and ruthenium content, where relevant. The nanoparticles were
dissolved to release the ions prior to analysis. All samples were prepared and analysed in
triplicate.
350-400 mg of oven-dried silica nanoparticles were weighed accurately and placed in
a 100 ml PTFE beaker. 4 ml of hydrofluoric acid (47-51% trace analysis from Sigma
Aldrich) and 15 ml of nitric acid (67% trace metals from VWR) were added and the
suspension was stirred using a PTFE-coated stirrer bar at approximately 400 rpm for
3 hours at room temperature. The temperature was gradually raised (10¶C every 30
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minutes) to heat the samples at 50¶C for 24 hours and then to 75¶C for 24 hours, until
dry.
67% nitric acid was added then carefully diluted with distilled water to yield a 1:100
(w:v of original solid mass) solution in 2% nitric acid. For example, with 398 mg of silica
used initially, the solution was made up to 39.8 ml using 2% nitric acid, by adding 1.2
ml of 67% nitric acid then diluting with 38.6 ml of distilled water. Samples were stirred
for one hour then filtered through a 450 nm syringe filter (Minisart RC25, Sartorius) into
polypropylene centrifuge tubes. No particulates were visible prior to filtering; this step
was required by the ICP-MS operator as a precaution.
Samples were analysed by Dr. S. Baker, using an Agilent 7500ce inductively-coupled
plasma mass spectrometer with an Octopole reaction system (ORS) for the removal of
polyatomic interferences. A Miramist nebuliser was used for sample introduction. The
plasma was run with an RF power of 1500 W. Gd was analysed at mass 157 and Ru at
mass 101.
2.2.5 Preparation and analysis for luminescence measurements
As prepared nanoparticles were diluted to the stated concentration and placed in
quartz cuvettes. Excitation and emission analyses were performed using an FLSP920
Time Resolved Spectrometer (Edinburgh Instruments), using a xenon lamp and a visible
light photomultiplier tube (PMT).
2.2.6 Preparation and analysis for UV-visible spectroscopy
As-prepared nanoparticles were scanned in quartz cuvettes and, where necessary, di-
luted so as to obtain a maximum absorbance below 1. Measurements were carried out in
a Cary 5000 spectrometer.
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2.2.7 NMR characterisation
NMR characterisation of 1H and 19F nuclei was performed on an automated Avance
AVIII 300MHz spectrometer (Bruker). 1H analysis was with a standard 1D 30¶ pulse
sequence (denoted as zg30). 19F analysis was carried out by a standard inverse-gated
decoupled 1D 19F pulse sequence (zgig).
2.2.8 MR imaging
MRI was carried out on a 3 T Magnetom Verio (Siemens).
1H scans were carried out using a 16 channel birdcage head coil with a spoiled 2D
gradient recalled echo saturation recovery sequence. The samples were raised to the
middle of the coil and centred laterally. Falcon tubes of distilled water were also placed
in the coil to aid localisation and calibration. The slice thickness was 4.5 mm, and the
sequence had a repetition time (TR) of ranging from 235 - 9200 ms, echo time (TE) of
1.4 ms, a flip angle of 8¶, 100% sampling and 32 averages (NA) per slice.
19F scans were carried out using a flexible surface coil with 1H and 19F transmit and
receive capabilities. A proton localiser scan was carried out to locate the samples, then
the frequency was switched to approximately 115.957 Hz and centred on the peak of
interest. The pulse sequence was based on a 3D gradient echo FLASH programme, with
a slice thickness of 4 mm, a TR of 2.1 ms, a TE of 0.96 ms, 32 averages and an 8¶ flip
angle unless stated otherwise. Samples were placed directly on top of the upturned coil
and were grouped in the centre over the area which had been found to contain the coil
element by earlier measurements, as discussed in section 2.5.
The field of view for both sequences varied as necessary to provide the maximum signal
to noise ratio (SNR) while avoiding aliasing artefacts.
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2.3 Cell preparation and analysis
The following section describes the methods used in all chapters that include cell
treatments.
2.3.1 Peripheral blood mononuclear cell isolation and treatment
Peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood
of volunteer donors. Total blood was layered onto a Lymphoprep density gradient medium
and centrifuged at 700 x g for 20 minutes. The mononuclear layer was removed and placed
in phosphate bu ered saline (PBS). The pellet was washed three times by centrifugation
and resuspension in PBS, then the cells counted by haemocytometer, with Trypan blue
staining to verify viability. The PBMCs were incubated at 2 x 106 cells/ml in RPMI 1640
with gentamycin, penicillin and streptomycin, and 10% foetal calf serum, and any stated
treatments. Cell suspensions were placed in plastic well-plates and stored at 37°C in 5%
CO2.
2.3.2 Cell analysis by flow cytometry
The treated PBMCs were centrifuged (5 minutes at 650 x g) and resuspended in
PBS three times. The suspended cells were then placed in flow cytometry tubes at a
concentration of 2 x 106 per ml. Samples were reagitated by gentle vortex mixing prior
to analysis.
PBMCs were analysed on a CyAn ADP 9 colour flow cytometer (Beckman Coulter,
UK). The detection was gated so that only single cells were recorded.
Flow cytometry analyses cell populations by creating a laminar flow which passes
individual cells through a LASER light beam. The forward and side scattered light are
detected by photomultiplier tubes, and filters can be placed in the light path to gate out
wavelengths of interest.
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2.3.3 PBMC analysis by light microscopy
Various methods were attempted for preparing the PBMCs for microscopy. Being non-
adherent, the natural spherical morphology of the PBMCs exist only when in suspension.
Techniques which preserved this however, such as sealing the cell suspension in an imaging
chamber (Grace Biolabs) did not reliably lead to clear images being produced, as seen in
section 5.3.2. All other light microscopy images presented in this thesis were therefore
produced by the following method.
PBMCs were washed by centrifugation at 650 x g and re-suspension in PBS to a
concentration of 2 x 106 per ml. 200µl of the cell suspension was pipetted into the funnel
of a cytospin slide attachment, and then spun onto poly-L-lysine coated glass microscope
slides for 3 minutes at 300 rpm. The slides were air dried for 30 minutes.
The cells were fixed by immersion in methanol for 2 minutes and allowed to air dry.
The slides were then wrapped in aluminium foil and stored at -20°C.
For brightfield cell staining, a Kwik-Di  preparation (Fisher Scientific, UK) was carried
out. This stain combination consists of methanol as a fixative and permabiliser, eosin as
a red stain and methylene blue as a blue stain. The expected results, according to the
product insert, are that red blood cells should appear pink, lymphocytes should have a
clear blue cytoplasm, possibly with red-purple granules, and monocytes should have a
pink and blue cytoplasm, possibly with blue granules.
Slides were defrosted while wrapped, then stained according to the manufacturer in-
structions and rinsed under a gentle stream of deionised water. The samples were mounted
while still wet using Immu-Mount (Fisher Scientific, UK), and covered with cover-slips.
Slides were stored at 4°C until required. Microscopy was carried out within 3 days, but
usually within hours of mounting.
Imaging was carried out on an Zeiss Axioskop 40 microscope equipped with a mercury
arc lamp and a DAPI 420 nm long pass filter.
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2.3.4 Cell analysis by TEM
PBMCs were washed by centrifugation at 650 x g and re-suspension in PBS twice.
The cells were then washed into glutaraldehyde bu er (2% glutaraldehyde in PBS) and
stored at 6°C.
Embedding and sectioning was carried out by the Centre for Electron Microscopy at
the University of Birmingham.
Briefly, the fixed cells were centrifuged to form a pellet and embedded in resin. The
resin was microtomed to produce thin sections, stained with uranyl acetate, and placed
on copper TEM grids coated with holey carbon.
The cell sections were imaged on a Jeol 1200EX transmission electron microscope at
80 keV.
2.3.5 Cell analysis by MRI
The PBMCs settled in aqueous suspension, and therefore two methods were used in
this project for imaging cells by MRI.
Cells were initially suspended in 10% gelatin (w/v in PBS) at a known concentration
and placed either in polypropylene deep-well plates or in microcentrifuge tubes.
It was found however that, especially where a high concentration of imaging agent was
required, such as with the 19F MRI experiments, that this method produced no signal.
Cells were therefore pelleted in microcentrifuge tubes, before having 10% gelatin (w/v in
PBS) layered on top to prevent movement.
Samples were then placed in the centre of the MRI scanner coil, and imaged as de-
scribed above.
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2.4 1H MR capabilities
In exploring the capabilities of the equipment available, one aim was to establish how
much variation in the results occurred as a consequence of sample placement. For proton
imaging, this was tested both with the birdcage (head) coil, and the dual frequency surface
coil used also for the 19F MRI.
2.4.1 Imaging with the birdcage coil
The dependence of sample location within the coil was investigated by the variation
across a rack filled with microcentrifuge tubes containing deionised water. This mimicked
the set-up for sample imaging used during this project but on a larger scale as the whole
rack was filled.
The relaxation time of the water was measured from each of the tubes, and plotted on
a scale of distance across the rack, see Figure 2.1. The centre of the surface plot should
correspond to the centre of the head coil, which was placed in the centre of the scanner.
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Figure 2.1: Variation in relaxation time of distilled water measured horizontally through
the 16 channel 1H birdcage coil. Vertical distance indicates the direction from the top of
the head towards the neck. Horizontal distance indicated the direction from ear-to-ear.
The plot shows variation in the direction corresponding to the conventional z axis of
the scanner, labelled as vertical in Figure 2.1, which passes through the centre of the
bore. From roughly the centre of the coil to close to the top of the coil (0 mm on the
vertical distance axis), the relaxation times vary by 0.1 seconds in a gradual reduction
moving outwards. From the centre to the bottom of the coil the change is greater, with
the relaxation time falling by 0.35 seconds. This might be improved where a larger sample
area is necessary by also using a neck coil, though the sensitivity profile of the combined
coils would have to be checked too.
There appears to be less variation horizontally across the coil, with the highest values
appearing by the edge of the sampled area, though the centre only relaxing 0.07 seconds
slower than the outer samples. This can be explained by the shape of the coil, as the
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coils in the sides of the birdcage would be closer to the samples than the coils above the
central ones.
These results suggest that the measured relaxation times would be most consistent if
samples are placed within the central area of the coil, of roughly 5 cm x 5 cm. If they
cannot be within this area however the variation could be corrected using calibration
plots.
2.4.2 1H imaging with the 19F coil
The same rack of microcentrifuge tubes containing deionised water as were used for
the birdcage proton coil were scanned using the dual band 1H/19F coil.
The relaxation times are plotted in Figure 2.2.
Figure 2.2: Variation in relaxation time of distilled water measured across the 1H/19F
surface coil.
There is some variation across the coil, though it is only at the edges that there is
a large drop in the relaxation times by several hundred milliseconds. This is probably
simply due to the distance from the active part of the coil to the sample. There is not
however an obvious pattern to the variation in the middle 5 x 15 cm rectangle above this
coil, so proton measurements within this area can be expected to have an error of up to
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200 ms in measured relaxation times as a result of the location.
The other significant point to note is that the relaxation times of the water samples
are considerably lower than those measured using the head coil. With the head coil, the
measured T1 of water was roughly 2.9 - 3.1 seconds, whereas on the fluorine coil, the same
samples are showing T1s of 1.8 - 2.0 seconds.
2.5 19F MR capabilities
The capabilities of the 19F MRI system determine the requirements for a multimodal
probe. The fluorine coil used in this work is a dual-frequency transmit and receive surface
coil.
The detection capabilities of the coil were explored initially using an array of bottles
containing 1 M trifluoroethanol (data not shown). It was then explored further, both
in terms of lateral range and distance from the surface, by imaging a box containing a
solution of 0.3 M trifluoroethanol.
This study was then extended to find the signal-to-noise ratios with compounds con-
taining a range of equivalent fluorine substituent groups. This encompasses molecules
comparable to those of direct clinical relevance, such as tri-fluorinated drugs, to molecules
which would require special formulation due to their low solubility.
2.5.1 Fluorine imaging background
Fluorine MRI was first carried out by Holland in 1977 [208]. A glass tube containing
1.4 M sodium fluoride was imaged on a 0.7 T MRI scanner [110].
Since then field strengths have increased, and 19F imaging has been carried out on a
range of scanners. On the clinical strength end of the spectrum, samples were spectro-
scopically detected at 1.5T, with fluorinated drugs in the micromolar range and thousands
of averages [15, 209]. Similarly, a 10 mM concentration of trifluoroethanol was examined
at 3T, but again with 900 to 1800 averages [210]].
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On the research end of the spectrum, much development has been carried out on 11.7
T MRI scanners with perfluorocarbon emulsions in the low milimolar range, so requiring
fewer averages in general [211, 12, 204].
These experiments were all carried out on systems with varying scanners, coils and
pulse sequences. A significant problem with 19F MRI being used clinically is the insen-
sitivity of the technique. Many clinical studies to date have involved using high field
MRI pre-clinical scanners, which can demonstrate the principle, but can give an overly
optimistic view of what is currently possible clinically.
In the following section the capabilities of the available equipment for this project were
investigated. A 3 T clinical MRI scanner was used with a commercially available coil and
accompanying software extension. This provides a realistic picture of the challenges facing
19F MRI.
2.5.2 Coil capabilities
The equipment was set up as indicated in Figure 2.3. A box containing 0.3 M triflu-
oroethanol was placed directly on the surface of the fluorine coil so that it covered the
central area.
Figure 2.3: Arrangement of 19F surface coil for imaging of a box of 0.3 M trifluoroethanol
(TFE). The shape of the coil and its houseing relative to the sample are illustrated.
Slices were imaged through the box, parallel with the surface coil, with increasing flip
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angles. The closest slice to the coil is shown in figures 2.4a and 2.4b for high (40¶) and
low (3¶) flip angles respectively. The area of the sample showing signal varies from the
edge of the sample box (with high flip angle) to the location and shape of the coil in the
centre (for low flip angle).
(a) 0.3 M TFE measured
with high flip angle (40°)
(b) 0.3 M TFE measured
with low flip angle (3°)
Figure 2.4: Comparison of images produced by 19F MRI at high (a) and low (b) flip
angles.
A cross section vertically through the slices is illustrated in Figure 2.5 to show the
depth of the signal from the surface of the coil, which corresponds to the bottom of the
images. For the high flip angle case the images are noisy, with the signal largely and
most consistently coming from the area above the coil itself. The range of the signal is
approximately 50 mm above the surface of the coil. For the low flip angle case there is a
stronger signal from the area above the coil, but this is essentially lost within 30 mm of
the surface. False colours are added for clarity.
The SNR through the centre of this cross section was plotted with distance, as shown
in Figure 2.6. For the high flip angle case, the SNR remains roughly constant but is low,
starting at 3 and dropping to 2.5 within 60 mm. In the low flip angle case, the SNR has
dropped by 50% within 30 mm.
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(a) 0.3 M TFE measured with high flip
angle (40°)
(b) 0.3 M TFE measured with low flip
angle (3°)
Figure 2.5: Comparison of cross sections of image stacks produced by 19F MRI at high
(a) and low (b) flip angles. The bottom of the images are directly on top of the coil, while
the top of the images are 6 cm above.
Figure 2.6: Comparison of SNR changing with distance from the coil surface. The image
stacks were produced by 19F MRI of 0.3 M TFE at high (40°) and low (3°) flip angles.
This indicates the limited range both in terms of the lateral area over which the coil
can detect signal, and the distance from the coil the sample can be. This could potentially
cause problems for in vivo imaging, since in the body the 19F tracers could easily be more
than 50 mm away from the coil.
For practical purposes this means that the amount of fluorine incorporated into a
multimodal system must not only be high enough for detection with the most focused
sequences (which will image close to the coil), but also with higher flip angles, which will
allow a greater volume in which the fluorine can be detected.
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Since much of the previous work on 19F MRI has involved either high field strengths
or small surface coils fitted directly over a small animal, a systematic and consistent
investigation of the detection limits was undertaken for a range of fluorinated species.
The broad aim is to provide a reference point for future work on clinical field strength
19F MRI.
2.6 Detection limits of various molecules by 19F MRI
at 3 T
Before multimodal imaging agents can be created it is helpful to know the rough
concentrations of the various components that will be required. There are competing
e ects in the selection of a fluorine tracer; a higher number of fluorines per molecule
will produce a higher SNR but lower aqueous solubility or miscibility. Conversely lower
numbers of fluorine will be more soluble in water, so more suitable for cell culture, but
will have a reduced SNR.
The e ect of the number of fluorines per molecule on the SNR of 19F MR images was
therefore investigated to provide a reference point for the development of the multimodal
agents.
2.6.1 Molecules with 3 equivalent fluorines
The detection limit for molecules with three equivalent fluorines was measured by the
imaging of a range of concentrations of trifluoroethanol in water. The resulting image
and the plot of the calculated signal to noise ratio is displayed in Figure 2.7.
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(a) 19F image of TFE. Concentrations are indicated in white in mol/L.
(b) Plot of SNRs vs. concentration.
Figure 2.7: Trifluoroethanol (TFE) imaged by 19F MRI at a range of concentrations, and
the corresponding plot of the SNRs. The error bars represent the error due to noise and
variation across the region of interest.
In Figure 2.7 it can be seen that an SNR of at least 15 is preferable, as this gives a
distinct outline of the sample tube. This corresponds however to a molecular concentration
of 0.73M, which is an unfeasibly high concentration for cell tracking purposes.
The lower concentration samples can be distinguished with an SNR of 5, produced by
samples of 0.19 M. Such a high concentration is still unlikely to be possible in cell tracking
situations. Moreover, though the sample can be delineated from this image, the contrast
may still not be great enough for confident detection with unknown sample locations.
2.6.2 Molecules with 6 equivalent fluorines
1-iodo-3,5-bis(trifluoromethyl) benzene was used as a model for molecules with six
MR-equivalent fluorines. The highest SNR was observed with a flip angle of 4¶, so one of
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the acquired images is shown in Figure 2.8a, and the SNR was calculated from this. The
SNR is plotted against concentration in Figure 2.8b.
(a) 19F image of ITFM2Ar. Concentrations are indicated next to each sample.
(b) Plot of SNRs vs. concentration.
Figure 2.8: 1-iodo-3,5-bis(trifluoromethyl) benzene (ITFM2Ar) imaged by 19F MRI at a
range of concentrations, and the corresponding plot of the SNRs. The error bars represent
the error due to noise and variation across the region of interest.
For a SNR of 5, a concentration of 40 mM is required, whereas for an SNR of 15, a
141 mM solution is necessary.
2.6.3 Molecules with 9 equivalent fluorines
Europium tris[3-(trifluoromethylhydroxymethylene)-(D)-camphorate] (Eu(facam)3) has
3 equivalent fluorine nuclei on each of its ligands, so was investigated as a complex with
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9 equivalent fluorines. The SNR of the complex dissolved in methanol was examined at
a range of concentrations and flip angles. The highest SNR appeared with a flip angle of
4¶, and an image using this is shown in Figure 2.9 along with a plot of the SNR against
concentration.
!
!
100mM 
80mM 
60mM 
30mM 
10mM 
(a) 19F image of Eu(facam)3. Concentrations are indicated next to each
sample.
(b) Plot of SNRs vs. concentration.
Figure 2.9: Europium tris[3-(trifluoromethylhydroxymethylene)- (D)-camphorate]
(Eu(facam)3) imaged by 19F MRI at a range of concentrations, and the corresponding
plot of the SNRs.
For a SNR of 5, a concentration of 22 is needed in order to be able to detect the
sample. As can be seen however from the image, this will not be clearly delineated. For
a SNR of 15 a concentration of at least 77 mM is necessary.
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2.6.4 Molecules with 24 equivalent fluorines
The SNR of a molecule with twenty four equivalent fluorines was investigated. Tetrakis(3,5-
bis(trifluoromethyl)phenyl)borate, known as BArF, was dissolved in diethyl ether and
imaged at various flip angles. The SNR was highest using a flip angle of 8¶, so data using
this flip angle is presented.
A plot of the SNR varying with concentration is shown in Figure 2.10, along with an
image of the regions of interest. !
 
(mM)          (mM) 
     50          8 
          2 
     25          6 
         0  
     10          4 
(a) 19F image of BArF. Concentrations are indicated next to each sample.
(b) Plot of SNRs vs. concentration.
Figure 2.10: Tetrakis(3,5-bis(trifluoromethyl)phenyl)borate (BArF) imaged by 19F MRI
at a range of concentrations, and the corresponding plot of the SNRs.
For an SNR of 5, a concentration of 13 mM would be necessary, based on the fitted
line in Figure 2.10. Ideally a much higher concentration of between 25 and 50 mM would
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be present, since, as above, a clear signal should be visible for quantification, as can be
seen in the image.
2.6.5 Discussion
The above results are summarised in Figure 2.11 as a plot of the concentrations needed
to produce SNRs of 5 and 15, which correspond to distinguishable and clearly delineated
samples respectiely.
Figure 2.11: Plot of the required concentrations (in mM) to produce a given SNR (5 or
15) plotted against the number of fluorines per molecule.
It is interesting to note that the required concentrations do not correspond if con-
sidered in terms of fluorine concentrations, suggesting that there are other factors than
concentration a ecting the signal. These could include the viscosity of the sample, but
also coil loading, the reception field distribution, the T1 and Tú2 of the samples and the
tip angle [212].
All of these need therefore to be carefully considered in future work, especially involv-
ing quantitation, so that these are taken into account when comparing, for example, a
fluorine compound in tissue to a reference sample outside the body. These samples will
not only have very di erent environments, a ecting their viscosity, T1 and Tú2, but will
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also be in di erent locations in the coil, leading to variation from coil sensitivity, receptor
field distribution, and the tip angle experienced by the sample.
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CHAPTER 3
TRAPPING IMAGING AGENTS IN A
NANOPARTICLE MATRIX
Some nanoparticles consist of an extended network, such as a silica, in which other
small molecules can be trapped. This can be achieved chemically by covalently linking
the molecule to a monomeric component of the network, such as a silane [213, 214]. It
can also be achieved physically by selecting both the nanoparticle and the molecule for
their positive interaction. This chapter explores the physical trapping of imaging agents
inside silica matrices.
3.1 Background and design
Imaging agents often rely on their molecular structure for their physical and chemi-
cal properties. For example, the fluorescent properties of fluorophores often depend on
the presence of a planar aromatic system [215]. If imaging agents are incorporated into
nanoparticles, it is therefore usually preferable for the molecular structure to be undis-
turbed.
While covalent linking of an imaging agent into the structure will have the advantage
of more reliable entrapment and lower leakage levels (see examples in [216, 217]), it risks
changing the imaging agent’s structure by requiring a physical linker in some cases, and
hence its properties. For some agents the change may be an improvement, as with some
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fluorophores where an increase in the quantum e ciency is observed [218]. This limits
the available agents however to ones where a linker can be attached without disrupting
the agent’s capabilities.
Physical entrapment into the nanoparticle matrix can be highly e ective while main-
taining the structural integrity of the imaging agent. It is also highly versatile, since
to trap an alternative molecule only requires that they have similar physical properties,
rather than requiring a reaction with a monomer of the network.
The nanoparticle matrix should have suitable properties to accommodate the molecules
to be trapped. It should also be able to carry a high concentration of the imaging agents
with the structure remaining fit for purpose.
Silica networks, for example, are robust covalent structures which have been modified
extensively to tune their physical and chemical properties. Methods include the incorpo-
ration of silanes to modify the charge or hydrophobicity [219], to add fluorescence [214]
and to introduce porogens to create mesoporous networks [168]. In this chapter silica and
amine-modified silica have been used to electrostatically trap positively and negatively
charged molecules respectively.
In terms of the nanoparticles’ cargo, almost any small imaging agent could potentially
be incorporated into a larger structure such as a nanoparticle. The main limiting factors
are the interaction of the matrix with the molecules, the size of both structures, and the
permeability of the matrix, for the molecules where this is relevant.
In this chapter the encapsulation of two modality agents were attempted: fluorophores
for fluorescence techniques, and contrast agents for proton MRI. Where possible, clinically
approved molecules were used as they have been studied thoroughly and their e ects in
the body are generally known. This was the case for proton MRI contrast agents, where
Gd EOB-DTPA (marketed as Primovist by Bayer, UK) was used, and for fluorescein
which is used in opthalmic eye drops and angiography [220].
Initially ruthenium tris phenanthroline was trapped electrostatically inside a simple
silica matrix. This method has been previously reported [165], and provided a basis for
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early investigations. The versatility of silica nanoparticles however allows further surface
functionalization in order to also image them by other modalities, as explored in Chapter
4.
Many imaging agents of interest, such as gadolinium chelates for MRI and organic
fluorophores such as fluorescein, are negatively charged. These cannot be trapped elec-
trostatically in a negatively charged silica matrix and hence positively charged silica ma-
trices were explored in order to trap them. In this system, Gd DTPA-EOB and fluorescein
were trapped inside a silica nanoparticle which was created by co-condensation with an
aminated silane during the synthesis.
This idea was explored further in an attempt to create particles with no pH dependence
in their properties (unlike the primary amine functionalised particles), which could poten-
tially lead to a variable interaction with the imaging agents. The APTES was therefore
replaced by a quaternary aminated silane, trimethyl[3-(trimethoxysilyl)propyl]ammonium
chloride (Me3APTMS). The synthesis was otherwise replicated, except for the addition
of a base to catalyse the reaction. This was necessary since the reaction with APTES is
autocatalysed.
3.2 Experimental details
The experimental details described here are used specifically in this chapter. All
materials and experimental methods used in multiple chapters are described in the general
experimental details in Chapter 2 to avoid repetition.
3.2.1 Materials
Silanes
Silanes used in this chapter are: tetraethyl orthosilicate (Acroseal, Fisher Scientific);
(3-aminopropyl) triethoxysilane (98%, Alfa Aesar); trimethyl [3-(trimethoxysilyl)propyl]
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ammonium chloride (ca. 50% in methanol, TCI Europe).
3.2.2 Nanoparticle synthesis
The synthesis of silica nanoparticles consisting of negatively charged and positively
charged silica matrices are described here. Methods for doping these particles are also
provided here.
Negatively charged silica nanoparticles
53.5 ml EtOH, 3.2 ml NH4OH (28%), 1.6 ml TEOS and 1 ml [Ru(phen)3](PF6)2 (1
mg/ml in acetonitrile) were placed in a round-bottomed flask. The solution was stirred
for 24 hours, during which it became turbid.
The suspension was washed by centrifugation at 5000 rpm (approximately 3300 x g)
for 30 minutes and resuspension in clean solvent. The nanoparticles were washed twice
with ethanol and twice with water.
For storage the nanoparticles were resuspended in ethanol.
Primary aminated silica nanoparticles (ASiNPs)
Primary aminated silica nanoparticles (ASiNPs) were synthesised by a sonochemical
method described in [221].
2 ml of tetraethyl orthosilicate (TEOS) and 0.5 ml of (3-aminopropyl)triethoxysilane
were added to 15 ml of ethanol in a glass vial. The mixture was sonicated for 5 minutes,
then 0.5 ml of distilled water was added dropwise.
The mixture was sonicated for 3 hours, during which time the solution became turbid
and usually gelled.
The resulting gel or suspension was washed by centrifugation at 5000 rpm (approx-
imately 3400 x g) for 20 minutes and resuspension in clean solvent. The nanoparticles
were washed twice in ethanol and twice in distilled water.
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For storage nanoparticles were resuspended in ethanol.
Gadolinium doped ASiNPS Instead of 0.5 ml of water, 0.5 ml of 12.5 mM
GdEOB-DTPA was added dropwise to the silane mixture. The gadolinium solution was
clinical grade Primovist (at 0.25 M) diluted with distilled water.
Fluorescein doped ASiNPS 5mg of fluorescein sodium was added to the silane
mixture before the addition of the water.
Gadolinium and fluorescein doped ASiNPS 5mg of fluorescein sodium was
added to the initial silane mixture, and 0.5 ml of 12.5 mM Gd EOB-DTPA was added as
for the GdASiNPs.
Quaternary aminated silica nanoparticles (Me3ASiNPs)
Quaternary aminated silica nanoparticles (Me3ASiNPs) were synthesised by an anal-
ogous sonochemical method to the ASiNPs.
2 ml of tetraethyl orthosilicate (TEOS), 1.07 ml ethylamine and 1.2 ml of Me3APTMS
were added to 15 ml of ethanol in a glass vial. The mixture was sonicated for 5 minutes,
then 0.5 ml of distilled water was added dropwise.
The mixture was sonicated for 3 hours, during which time the solution became turbid
and usually gelled.
The resulting gel or suspension was washed by centrifugation at 5000 rpm (approx-
imately 3400 x g) for 20 minutes and resuspension in clean solvent. The nanoparticles
were washed twice in ethanol and twice in distilled water.
For storage nanoparticles were resuspended in ethanol.
The above synthesis was modified to incorporate various imaging agents.
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Gadolinium doped Me3ASiNPS Instead of 0.5 ml of water, 0.5 ml of 12.5 mM
Gd EOB-DTPA was added dropwise to the silane mixture. The gadolinium solution was
clinical grade Primovist (at 0.25 M) diluted with distilled water.
Fluorescein doped Me3ASiNPS 5mg of fluorescein sodium was added to the
silane mixture before the addition of the water.
Gadoliniumand fluorescein doped Me3ASiNPS 5mg of fluorescein sodium was
added to the initial silane mixture, and 0.5 ml of 12.5 mM Gd EOB-DTPA was added as
for the GdMe3ASiNPs.
3.2.3 Nanoparticle characterisation
Nanoparticles were characterised by DLS and TEM as described in Section 2.2.1 and
2.2.2.
Encapsulation e ciency
The amount of gadolinium trapped in the nanoparticles was measured by ICP-MS.
Samples were prepared according to Section 2.2.4.
MR contrast enhancement
Nanoparticle samples were diluted with ethanol to a range of concentrations as stated
and placed in glass vials or polyethylene microcentrifuge tubes. 1H MRI was carried out
on a 3T clinical scanner; details and pulse sequences are described in Section 2.2.8.
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3.3 Synthesis and characterisation results
Silica nanoparticles were created by the hydrolysis and condensation of silanes by two
di erent methods. They are capable of electrostatically trapping a range of molecules in
their matrix in order to deliver them into immune cells.
Positively charged species can be readily trapped in typical (negatively charge) silica
structures, which were formed in this case by a modification of the Stober synthesis
[163, 214]. This was carried out as a precursor to the dual-modal particle created in
Chapter 4.
Negatively charged species however require a positively charged silica matrix for elec-
trostatic trapping. Nanoparticles with positively charged networks were therefore created
by sonochemical co-condensation of the silanes tetraethyl orthosilicate (TEOS) and 3-
aminopropyl triethoxysilane (APTES), and doped with various negatively charged imag-
ing agents.
3.3.1 Negatively charged silica nanoparticles
Doping silica nanoparticles with positively charged metal complexes is a well estab-
lished technique [165]. Here ruthenium tris-phenanthroline-doped silica nanoparticles
(RuSiNPs) were created.
This work is described here for completeness but, since this project is application-
driven, the particles are characterised more fully in chapter 4 as the dual-modal system
of interest.
Light scattering (DLS)
RuSiNPs diameters were measured by dynamic light scattering (DLS). The results are
displayed in Table 3.1. Three repeat runs of the measurement were carried out, and the
distributions produced, as well as the closest Gaussian fit to the distribution, are displayed
in Figure 3.1.
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Figure 3.1: Histogram of RuSiNP radii measured by DLS analysis.
Diameter (nm)
(by intensity)
Diameter (nm)
(by number)
Zeta potential
(mV)
Mean 146 98 -55
Standard deviation 43 24 1
Table 3.1: DLS measurements of RuSiNPs
The number distribution was considered to indicate the more accurate diameter, mak-
ing these particles 98 nm in hydrodynamic diameter with a standard deviation of 24 nm
corresponding to a hydrodynamic radius of 49 nm, with a standard deviation of 12 nm.
Electron microscopy (TEM)
The size of the nanoparticles was also measured by electron microscopy. Images were
analysed using the automated TEM analysis algorithm described in Section 7.1. Briefly,
the magnitude and direction of changes in the image intensity were used to determine
the edge locations, and then a heuristic circle detection method was used to find circular
shapes matching the edges. These shapes, constrained by the direction of the intensity
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changes, approximate the nanoparticle perimeters, and hence provide a diameter for each
individual nanoparticle.
The mean radius of the RuSiNPs measured from 401 nanoparticles in such images was
found by the above method to be 43 nm ± 6 nm. Characteristic images are shown in
Figure 3.2.The plotted histogram of radii is shown in Figure 3.3.
Figure 3.2: TEM images of ruthenium doped silica nanoparticles (RuSiNPs).
75
Figure 3.3: Histogram of RuSiNP radii measured from TEM images by automated seg-
mentation.
As would be expected, the radius as measured by TEM, 43 nm, is slightly smaller than
that measured by DLS, i.e. 49 nm. This could be due to TEM measuring only the dense
core of the silica rather than the particle plus its hydration spheres, as with DLS [222].
It could also be an e ect of TEM measuring only a microscopic sample, as opposed to
the bulk measured with DLS, since these values are both within the standard deviation
of each other.
Luminescence and luminescence lifetimes
The luminescence excitation and emission spectra are shown in Figure 3.4. Excitation
scans were monitored at 590 nm and emission scans were excited at 480 nm.
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Figure 3.4: Excitation and emission spectra of RuSiNPs and [Ru(phen)3][(PF6)2] in water
and acetonitrile respectively. ⁄ex = 480 nm; ⁄em = 590 nm.
The ruthenium luminescence emission is not significantly a ected by the trapping pro-
cess, whereas the excitation spectrum appears to have broadened slightly. This might how-
ever be attributed to scattering by the particles. The emission spectrum has broadened
very slightly upon trapping, but the maximum remains at 590 nm upon encapsulation.
The spectra are comparable to those reported in the literature [122, 165].
The luminescence lifetimes for these nanoparticles are presented in Table 3.2. These
are discussed in detail in Section 4.3.1, but are comparable with literature values.
Sample t1 (ns) t1 (%) B1 t2 (ns) t2 (%) B2 t A ‰2
RuSiNP 547 13 280 1836 87 557 1405 7.7 1.03
Table 3.2: Luminescence lifetime measurements of the RuSiNPs
3.3.2 Primary aminated silica nanoparticles
Aminated silanes have frequently been conjugated to molecules of interest in order to
functionalise silica nanoparticles; examples include references [223, 224, 225].
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They have rarely been used to modify the entire structure of the nanoparticle at greater
than dopant concentrations. Such nanoparticles have been described in the context of ce-
ramics [221], but were not developed for biomedical ends. Mesoporous silica nanoparticles
have been created also using a co-condensation method combining TEOS and a quater-
nary aminated silane [170], though here they claimed that due to the di erent hydrolysis
rates of the silanes the amine groups are mainly localised on the surfaces. Consequently
they claimed to trap indocyanine green into the pores by multiple interactions, and hence
have not necessarily demonstrated trapping into the silica matrix.
The aminated particles developed for ceramics in reference [221] were therefore created
by sonochemical co-condensation of TEOS and APTES in the presence of fluorescein
and GdDTPA-EOB (Primovist). These are referred to as FlASiNPs, GdASiNPs and
FlGdASiNPs for particles doped with fluorescein, GdDTPA-EOB and both compounds,
respectively. Although the FlGdASiNPs are really the dual-modal system of interest,
where relevant the separately doped ones were analysed in some cases to clarify the origin
of a given e ect.
Light scattering (DLS)
The FlGdASiNPs were analysed by DLS in various solvents. The results are displayed
in Figure 3.5 and Table 3.3.
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Figure 3.5: Distributions by number of diameters of FlGdASiNPs, measured by DLS.
The FlGdASiNPs were suspended in a range of solvents to assess their level of aggre-
gation. (N.B. In RPMI the samples were too unstable in suspension to obtain reliable
measurements.)
Mean diameters (nm) per peak EtOH Water PBS RPMI + FCS DMSO
Peak 1 373 729 1734 2192 986
Peak 2 1516
Peak 3 2989
Table 3.3: Peak means of the FlGdASiNPs’ diameters, as measured by DLS and shown
in Figure 3.5.
The FlGdASiNPs showed a concerning level of polydispersity. Given the particles’
morphologies in the electron microscopy images (see Section 3.3.2), this could be a conse-
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quence of aggregation. This is evident even in the ethanol dispersion, though this solvent
produced the fewest aggregates greater than a micron in diameter.
Dispersion in aqueous salt-containing media, i.e. PBS and cell culture medium (RPMI
1640, both with and without 10% FCS), appears to cause the greatest level of aggregation.
The e ect of the peptides and salts in the RPMI itself could be disrupting the FlGdAS-
iNPs’ stability, since their presence has been shown to cause aggregation in variety of
silica nanoparticles [226]. The distribution in the serum-containing medium however is
consistent with reports of a protein corona, which occurs when proteins deposit on the
nanoparticle surface [227]. This could be stabilising the particles enough to allow disper-
sion in the RPMI, though still creating aggregates.
The dispersion in water appeared to be aggregating during the experiment, as seen by
the shifting in the distributions, which is also consistent with studies of aminated silica
nanoparticles [226]. Dispersion in DMSO appears to result in significant aggregation,
producing micron sized clusters, but which were stable, at least in the short term.
These results could be a ected by the solvent polarity, but the calculations involved
in obtaining them also rely on given solvent properties, which will be slightly di erent
for each solvent. While this data was included where possible, some approximations were
necessary. For example, the FCS containing RPMI would have had a higher viscosity
than that with RPMI only. The RPMI was also coloured with an indicator, which would
change the optical properties of the solution somewhat. Therefore, although the aqueous
suspensions were treated as having similar colloidal properties, this may have skewed the
results.
These results do suggest however that the nanoparticles have a low colloidal stability.
The stability will be a ected by a number of factors, including the surface charge of the
particles, the density of the particles, the solvent and any excipients in the solvent (such
as salts or peptides). These are discussed further below.
The zeta potential measurement of the FlGdASiNPs produced more reproducible re-
sults. Samples were measured in deionised water, and the obtained values are presented
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in Table 3.4.
NP sample Zeta potential (mV) Standard deviation
FlGdASiNPs 30 0.2
Table 3.4: The mean zeta potential of FlGdASiNPs and the standard deviation from the
mean.
The standard deviation of the three measurements is small, suggesting that the surface
charge is overall stable. The positive charge is expected due to the presence of the amine
groups in the particles, and more promising than reports of the amine groups folding
back in to interact with the negatively charged silane network, e ectively neutralising the
charge [228].
The low stability of the suspension indicated by the sizing experiment is somewhat
explained by the relatively low surface charge; the colloidal stability should be improved
by greater positive charge.
Electron microscopy (TEM)
The FlGdASiNPs were analysed by transmission electron microscopy. Typical images
of the nanoparticles doped with fluorescein (FlASiNPs), gadolinium-DTPA-EOB (GdAS-
iNPs) and both agents (FlGdASiNPs) are displayed in Figure 3.6.
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(a) FlASiNPs (b) Histogram of FlASiNP radii (nm)
(c) GdASiNPs (d) Histogram of GdASiNP radii (nm)
(e) FlGdASiNPs (f) Histogram of FlGdASiNP radii (nm)
Figure 3.6: TEM images of doped ASiNPs containing (a) fluorescein, (b) gadolinium
DTPA-EOB and (c) fluorescein and the gadolinium complex.
The radii were measured using the custom-written TEM analysis algorithm described
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in Section 7.1, and are summarised in table 3.5.
ASiNP sample Mean radius (nm) Standard deviation No. NPs measured
FlASiNPs 42 12 395
GdASiNPs 34 10 618
FlGdASiNPs 44 13 195
Table 3.5: Radii of ASiNPs as measured by TEM.
The dual modal fluorescein and gadolinium labelled nanoparticles are 44 nm in radius
by TEM. This is considerably smaller than the sizes measured by DLS, though this can
be explained by the aggregates that are visible in the TEM images, which would be all
the DLS would detect if they existed as such in suspension as well as when dry.
The morphology is consistent with other silica gels, which have been reported to form
fractal-like aggregates in some cases [229, 230]. These structures and their properties
would need to be investigated thoroughly if these particles were found to be of interest
for this project or future work.
The other point to note is that the particles labelled with gadolinium were consistently
smaller than those which incorporated fluorescein. The reason for this is unclear since
the mechanism of formation of these particles has not been explored. This does not a ect
the dual modal system investigated here, but is a consideration for further development
of this system to include other imaging agents.
Encapsulated concentration
The gadolinium content of the dual modal fluorescein gadolinium nanoparticles was
measured by ICP-MS, as described in Section 2.2.4.
A 10 mg/ml solution of FlGdASiNPs was found to contain an average of 5.16 µg of
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gadolinium per ml (standard deviation of 0.22 µg (Gd) / ml). Therefore the nanoparticles
contained 0.516 µg(Gd) per mg of nanoparticles.
The fluorescein concentration could not be calculated accurately by absorption because
the quantum yield would have been changed by interaction with the nanoparticle matrix,
as suggested by the lifetimes, presented below in Section 3.3.2. As indicated by the same
luminescence results however and by the cell study experiments below (Section 3.4), the
combination of the concentration of fluorescein and the remaining fluorescence is readily
su cient for cell labelling purposes.
Luminescence
The luminescence of the fluorescein labelled ASiNPs were measured and compared to
free fluorescein in solution.
The fluorescence spectrum of the FlGdASiNPs, see Figure 3.7 is not shifted signif-
icantly, with the excitation wavelength maximum remaining at 492 nm when free and
trapped alone, but rising to 499 nm when trapped with the gadolinium complex. The
emission maximum changes slightly, with the free fluorescein at 518 nm, the FlASiNPs
shifting to 516 nm and the FlGdASiNPs at 517.5 nm. The peak width for both the
excitation and emission appears to have narrowed upon trapping.
It is worth noting however that the fluorescence spectrum of fluorescein is quite variable
in these small ways depending on the protonation state and solvent [231, 232]. It indicates
however that the fluorophore has not been significantly disrupted.
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Sample t1 (ns) t1 (%) B1 t2 (ns) t2 (%) B2 t A ‰2
FlASiNPs 1.737 24.4 0.062 3.87 75.5 0.086 2.98 106.05 1.189
FlGdASiNPs 3.448 79.5 0.06 5.48 20.5 0.01 3.74 55.85 1.06
Table 3.6: Luminescence lifetime measurements of the FlGdASiNs and FlASiNPs.
Figure 3.7: Excitation and emission spectra of FlGdASiNPs, FlASiNPs and fluorescein,
all in distilled water. Excitation scans were monitored at 520 nm and emission scans were
excited at 490 nm.
Luminescence lifetime data for the fluorescent ASiNPs is presented in table 3.6.
The fluorescence of free fluorescein in solution varies with pH, but can be considered
to be in the region of 4.3 ns - 4.6 ns at pHs above 6.35, and shorter for lower pHs [233].
Longer lifetimes have however been observed when the molecular motion is hindered by
a silica structure [234].
Neither of the fitted lifetimes of these nanoparticle formulations match the value for
free fluorescein, suggesting that the fluorescein molecules are interacting with the matrix,
and that there is little or no detectable free fluorescein present.
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The fitted lifetimes for the FlASiNPs, (1.74 ns (24%) and 3.87 ns (76%) are similar
to those reported for FITC-doped silica nanoparticles in reference [235], that is 1.6 (32%)
and 3.79 (68%), though the calculated total lifetime di ers due to the relative percentages.
For the FlGdASiNPs the lifetimes are considerably di erent, though there is still a
lifetime of 3.45 ns for the majority of the emission. The second lifetime fit of 5.5 ns is
similar to that seen for fluorescein doped into SBA-15 nanoparticles [234].
It should be noted however that reports are varied for the lifetimes of fluorescein in
trapped and untrapped states, and these are highly dependent on the protonation state
and the environment [233, 231, 235, 232]. Comparisons to literature values are therefore
made with some caution, but suggest that the fluorescein is trapped in the matrix.
MRI contrast enhancement
A MR image of the FlASiNPs, GdASiNPs and FlGdASiNPs in solution is displayed
in Figure 3.8, and the corresponding relaxivities are shown in Table 3.7 and Figure 3.9.
Figure 3.8: 1H MR image of ASiNPs containing fluorescein, gadolinium and both imaging
agents together.
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Figure 3.9: MR relaxivities ASiNPs containing fluorescein, gadolinium and both imaging
agents together. Values were calculated (a) per nanoparticle and (b) per gadolinium.
ASiNP sample Relaxivity s≠1mM≠1 Relaxivity s≠1(mg/ml)≠1(NP)
FlGdASiNPs 43 0.14
FlASiNPs (15) 0.05
GdASiNPs (54) 0.18
Water (0.78) 0.003
Table 3.7: MR relaxivities of FlGdASiNPs, FlASiNPs and GdASiNPs, calculated per
gadolinium ion and per nanoparticle. N.B., numbers in parenthesis are not true measured
values but are provided for comparative purposes, as discussed in the main text.
Overall the GdASiNPs, labelled only with gadolinium, show the greatest concentration-
dependent change in relaxation rate. The e ect is slightly reduced for the FlGdASiNPs
as fluorescein is expected to displace some of the gadolinium chelates in the dual-modal
particles. The FlASiNPs show the least concentration-dependent change in relaxation
rate, as would be expected considering the lack of gadolinium.
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The relaxivity of the FlGdASiNPs is 43 s≠1mM≠1(Gd), and can be calculated accu-
rately in relation to the number of gadolinium ions since the number of gadolinium ions
present in a typical sample was measured by ICP-MS. The other values plotted in Fig-
ure 3.9 and table 3.7 are calculated as if the samples had the same Gd content as the
FlGdASiNPs, and are therefore inaccurate, but are provided for control purposes.
Only the Gd content of the FlGdASiNPs was measured to minimise unnecessary han-
dling of hydrofluoric acid, which was necessary for the sample preparation for ICP-MS.
The relaxivity of the water sample, 0.8 s≠1mM≠1(Gd), gives an indication of the error
involved, since these samples contain no nanoparticles or gadolinium. The relaxivity of
the FlGdASiNPs is well outside this range, suggesting that there is contrast enhancement
occurring. The magnitude of the relaxivity value has been observed in mesoporous silica
nanoparticles [169, 236], and could be attributed to a geometrical confinement e ect [237].
The FlASiNPs however show an unexpectedly high relaxivity of 15 s≠1, which suggests
that some of the relaxation e ect is also due to the nanoparticles themselves rather than
the gadolinium. The presence of the nanoparticles would increase the viscosity of the
solution [238], so some concentration-dependent change in the relaxation rate is expected.
3.3.3 Quaternary aminated nanoparticles
In an extension from Section 3.3.2, there was an attempt to remove the inherent pH
dependence of the system through the incorporation of quaternary amines instead of
primary amines.
The synthesis was replicated, with the substitution of the relevant amines. One ob-
stacle however was that the synthesis of the primary amines was auto-catalysed. With
no basic amines present, extra base was required to initiate the hydrolysis of the silanes.
Various bases were tried, including ammonium hydroxide, ethylamine and triethylamine,
with added volumes controlled so the pH of the solution matched the starting conditions
of the ASiNP reaction.
Fluorescein and gadolinium were incorporated as above, with the results referred to as
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FlMe3ASiNPs, GdMe3ASiNPs and FlGdMe3ASiNPs. The resulting gels were dispersed
and characterized by DLS and TEM, as shown below.
Light scattering (DLS)
The suspensions of the Fl, Gd and FlGdMe3ASiNPs were analysed by dynamic light
scattering (DLS). The consequent distributions were fitted to Gaussian distributions, as
presented in Figure 3.10. The mean diameters and standard deviations stated are those
of the fitted curves.
Figure 3.10: Distributions by number and intensity of diameters of FlGdMe3ASiNPs,
measured by DLS.
FlGdASiNP Diameter (nm)
(by intensity)
Diameter (nm)
(by number)
Zeta potential
(mV)
Mean 1085 1076 27.9
Standard deviation 332 298 6.37
Table 3.8: Mean diameter of FlGdMe3ASiNPs as measured by DLS. N.B., only the number
distribution means are shown since the intensity distributions, shown in Figure [subfig ref]
were too polydisperse to provide an accurate fit.
The size distributions obtained by DLS indicate that nanoparticles did not form from
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this method. The fluorescein doped silica preparation shows some particles in the tens of
nanometres size range, though the variation between the three experimental runs shows
that the samples are not stable. This variation and low stability is also observed for the
GdMe3ASiNPs and the FlGdMe3ASiNPs, though this is less obvious due to the plots being
presented on a logarithmic scale. Both of the preparations which contain gadolinium also
have size distributions in the micron range, suggesting that they would not be suitable
for labelling cells.
The surface charge of these particles is positive for all three dopant formulations. This
should encourage interactions with the cell membrane, and hence improve cell uptake.
The values are however unexpectedly lower than that seen for the ASiNPs, which could
be due to the incomplete or unsuccessful formation of the nanoparticles. This is explored
further in light of the electron microscopy results below.
Electron microscopy (TEM)
The TEM samples of the FlMe3ASiNPs were prepared according to the standard
method described in Section 2.2.2. The other Me3ASiNPs were also similarly prepared,
but no structures could be found on the grids when analysed, and since only micron-sized
structures could be seen by DLS, these systems were pursued no further.
There were no discrete particle-like structures observed for the FlMe3ASiNPs. Instead,
a broad range of shapes were seen as a varying continuum across a large section of the grid.
Snapshots of these are shown in Figure 3.11. It should be noted that the circular shapes
in some of these snapshots could not be focused through in the same way as spherical
particles, and can therefore be considered to be flat object
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Figure 3.11: TEM images of quaternary aminated silica nanoparticles labelled with fluo-
rescein.
One suggestion to explain these patterns is that the gel, instead of consisting of discrete
particles as for typical nanoparticles, is more homogenous, and has dried flat on to the
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grid. Based on the DLS results (Section 3.3.3), there may have been spherical structures
prior to dehydration. Further investigations would be necessary to characterise the gel if
this system were pursued.
Luminescence
The luminescence spectra of the aminated silica gels were measured in order to deter-
mine whether the gels could be used as fluorescent markers. The spectra are displayed in
Figure 3.12.
Figure 3.12: Excitation and emission spectra of FlMe3ASiNP gels and fluorescein.
The spectra are similar to fluorescein fluorescence spectra, with some broadening in
the excitation spectrum, possibly due to scattering, and a small increase in the Stokes
shift.
Given the DLS and TEM results, these gels were considered to fall outside the speci-
fications of this project so further work was halted in favour of other systems.
92
3.4 Cell treatment results
The interaction of developed nanoparticle systems with cells is essential to determining
whether they could be a useful tool for immune cell therapies. The aim of these experi-
ments was therefore to observe which cell types, if any, would take up the most promising
nanoparticles and, if so, any significant e ect on the cell morphology or viability.
Particles similar to the RuSiNPs have shown good uptake into cell types other than
immune cells [236, 239]. Since the dual modality aspect is of the most interest, however,
cell tests were only carried out on the particles which had been further functionalised to
incorporate gadolinium. These results are presented in Section 4.4.1.
The FlGdASiNPs were carried forward due to their dual-modality. Their uptake into
cells might be expected to be greater than the RuGdSiNPs since they have a positive
surface charge [9]. There have however been reports of toxicity concerns with aminated
silica particles, attributed at least partly to disruption of the cell membrane [240], which
would need to be thoroughly investigated if the FlGdASiNPs were to be pursued further.
PBMCs include a range of white blood cells which could potentially be of interest in
immune cell therapies, especially monocytes and lymphocytes. PBMCs were therefore
treated with FlASiNPs, GdASiNPs and FlGdASiNPs, and observed by flow cytometry,
fluorescence microscopy and 1H MRI.
3.4.1 Flow cytometry results
The e ect of the nanoparticle treatment on the cells was investigated by measuring
the forward scatter and side scatter of a laser passing perpendicularly through a stream of
individual cells. The forward scattered light indicates the size of the cell, since the larger
the cell the more it will slightly deflect the beam. The side scatter, which is measured at
a much higher angle, shows the granularity of the cell, since high granularity will deflect
the beam more.
These two properties of each individual cell are plotted on a forward scatter vs. side
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scatter plot to give an overview of the size and granularity of the cell population. Since
di erent cell types will intrinsically have di erent such properties they will tend to cluster
together, which are referred to as clouds.
The forward vs. side scatter plots for PBMCs with no nanoparticles, 0.1 mg/ml of
FlGdASiNPs and 0.5 mg/ml are shown in Figure 3.13 as the extremes of the treatment
results. These plots have an ellipse marking the monocyte cloud. The lymphocyte cloud
is the high intensity area below and slightly to the left of the monocyte cloud.
Another rough but useful measure can be the amount the cloud of a given cell type
moves with treatment. This was measured here by the percentage of the whole cell popula-
tion remaining in the selected gate with increasing nanoparticle concentration treatments,
and is presented in Figure 3.14 for treatments with FlGdASiNPs and FlASiNPs.
As can be seen from Figure 3.14, there is a significant reduction in the cells within the
original gate at 0.5mg/ml, suggesting that the cells have undergone significant changes.
From the corresponding scatter plot it is clear that the cell size is reduced, since the
cloud has moved to the left. It also appears to have spread in terms of granularity, with
some cells higher in the plot, so more granular, and therefore possibly containing large
nanoparticle aggregates, and some cells much less granular, so either shrunk or completely
disrupted.
This trend is apparent in the lower nanoparticle concentration plot, with the trend
increasing with treatments.
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(a) Control (0 mg/ml NP) (b) 0.1 mg/ml NP (c) 0.5 mg/ml NP
Figure 3.13: Forward scatter (FS) vs, side scatter (SS) plots for di erent nanoparticle
treatment concentrations, showing the changes in size and granularity of the cells. The
monocyte gate is highlighted by the black ellipse.
Figure 3.14: Plot showing percentage of cells (monocytes and lymphocytes) remaining
within original gate with increasing nanoparticle concentration (FlASiNP and FlGdAS-
iNP) treatments.
A bandpass filter was simultaneously used so as to be able to detect the fluorescein
content in the cells. After the autofluorescence was gated out, the fluorescence brightness
displayed by each cell was measured on a histogram. The percentage of cells showing
fluorescence above the autofluorescent range, and the median of the histogram peak,
were measured both within the monocyte and lymphocyte gates. This therefore suggests
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both what proportion of the cell type have taken up nanoparticles, and how much they
have taken up. These values are presented in Figure 3.15, both for treatments with
FlGdASiNPs and FlASiNPs.
As can be seen, at lower concentrations, only a small percentage of the cells have
taken up any nanoparticles to a detectable concentration, with only a small shift in the
histogram. By 0.25 mg/ml of nanoparticles the labelling has increased to 50% for both
cell types with FlGdASiNPs. Curiously for both cell types the uptake of the FlASiNPs is
lower, though this could have been experimental error due to treatments with very small
quantities of nanoparticles, which showed some aggregation.
The brightness of the cells, i.e. the median fluorescence, is roughly proportional to the
percentage of labelled cells at the lower concentrations. At the higher concentrations, the
cells remaining within the size and granularity gate are clearly showing a high degree of
fluorescence. In the monocytes there is a much greater shift in the FlGdASiNP brightness
than in the FlASiNPs at the highest concentration.
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(a) Monocytes
(b) Lymphocytes
Figure 3.15: Plot showing the percentage of monocytes (a) and lymphocytes(b) contain-
ing fluorescent nanoparticles and the median degree of fluorescence, plotted against the
concentration of ASiNPs (either FlASiNPs or FlGdASiNPs) the cells were treated with.
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3.4.2 Microscopy
The uptake in the cell was further investigated by fluorescence microscopy.
PBMCs incubated with 0.25 mg/ml FlGdASiNPs were prepared for microscopy in the
same way as for the RuGdSiNPs. Unfortunately no recognisable cells could be detected.
Although the flow cytometry results above suggest that there are some potentially viable
cells which have been labelled with the FlGdASiNPs, the nanoparticles can be seen to be
significantly aggregated, and are therefore likely to have destroyed any viable cells during
the cytospin process.
For comparison purposes the FlGdASiNPs with PBMCs preparation was imaged, and
is displayed in Figure 3.16. Some purple stained shapes are visible in the bright-field image
which may be remnants of cells, but this cannot be readily confirmed. The bright areas in
the fluorescence image co-localise with red areas on the bright-field image, suggesting that
the eosin is binding to the nanoparticles, and staining them red. This should be noted if
this protocol were developed in future work as it could produce misleading counterstaining
of the cells.
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Figure 3.16: Micropscopy images showing the stained cells by brightfield microscopy (top
left), the corresponding fluorescence image (top right) and an overlaid combined image
(below).
As an alternative gentler method, cells were labelled as above but were stained only
with DRAQ5, and placed in an imaging chamber (Grace Biolabs) sealed with a coverslip.
This avoided the cytospinning step, which could have caused a significant amount of
damage to the cells in view of the nanoparticle aggregates spun with them.
A microscopy image of the FlGdASiNP labelled cells is shown in Figure 3.17. The
green FlGdASiNPs are clearly seen clustered around the DRAQ5-stained nuclei, suggest-
ing uptake into the cytoplasm of the cells. There are clusters of FlGdASiNPs visible which
are not localised around nuclei, which were attributed to nanoparticle aggregates. This
demonstrates that the FlGdASiNPs can act as fluorescent cell labels, though purification
to remove aggregates and extracellular nanoparticles would be necessary to false positive
identification of cells.
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Figure 3.17: Micropscopy image showing stained PBMC nuclei (red), and FlGdASiNPs
(green). Images were acquired per channel and overlaid with false colours.
These microscopy experiments were however not pursued further in view of the MRI
results below.
3.4.3 MR imaging
PBMCs were incubated with 0.25 mg/ml of FlGdASiNPs, washed and resuspended in
1ml of 10% gelatin at concentrations ranging from 10 x 106 to 50 x 106. The samples were
then imaged by MRI in order to measure any contrast enhancement, by measuring the
relaxation rate, with gadolinium (Primovist) samples alongside them as controls. One of
the images produced and the associated relaxivity plots are shown in Figures 3.18, 3.19
and 3.20
The suspension of FlGdASiNP-labelled PBMCs showed no increase in relaxation rate
with concentration. This suggests that the gadolinium concentration inside the cells is
too low for detection by MRI. This result indicates that these nanoparticles, while novel
and having interesting other potential applications, are not suitable for cell tracking by
MRI.
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Figure 3.18: MR image of (top row) GdDTPA-EOB dissolved in 10% gelatin at a range
of concentrations, and (bottom row) a range of concentrations of PBMCs treated with
0.25 mg/ml FlGdASiNPs, also in 10% gelatin.
Figure 3.19: Plot of the relaxivity values calculated from GdDTPA-EOB dissolved in 10%
gelatin.
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Figure 3.20: Plot of the relaxivity calculated from PBMCs treated with FlGdASiNPs,
suspended in 10% gelatin.
3.5 Conclusions
Both positively and negatively charged silica matrices have been found to be e ec-
tive in trapping imaging agents. This method of electrostatically trapping agents in a
nanoparticles matrix has therefore been found to be a useful tool for nanotechnology.
The standard negatively charged silica particles have the disadvantage that there are
few positively charged imaging agents of interest. Their synthesis is well understood
however, and the particles can be readily formed with regular morphologies. In order to
increase the potential of these particles, they are further developed in chapter 4 by surface
functionalization.
This novel use of positively charged aminated silica matrix is more versatile in what
can be electrostatically trapped, since there are many negatively charged imaging agents.
The non-uniform morphology and high tendency towards aggregation of these particles
are of some concern in this system. These particles might be stabilised in suspension
by the deposition of an alternative layer of material, either silane, metal or polymer. In
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order for this to occur however the particles would first need to be separated, otherwise
the deposition with occur only on the surface of the aggregates.
While an analogous aminated silica matrix with a permanent positive charge was
attempted, this route proved too problematic in the available time. This would be an
interesting option in future work if stable particles could be formed with the quaternary
amine throughout the matrix, perhaps by a Stober process involving co-condensation of
the silanes. One factor to consider in this would be the relative hydrolysis times of the
component silanes, which can a ect their distribution through the matrix [170]. In order
to maximise the positive charge throughout the matrix and so maximise loading capacity,
the volume and addition time of the co-silane could be optimised in the same way as the
distribution of dopant can be controlled [241].
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CHAPTER 4
BINDING IMAGING AGENTS TO A
NANOPARTICLE SURFACE
Nanoparticles, due to their small size, provide large surface areas for modification
with molecules of interest. The binding of imaging agents to nanoparticle surfaces, are
explored in this chapter, specifically focusing on both silica nanoparticles, as discussed in
Chapter 3, and gold nanoparticles, which can reliably be formed at much smaller sizes,
thus providing larger surface areas.
4.1 Background and introduction
One frequently employed method of delivering a molecule into cells is to attach it to
a vehicle with good uptake properties. This ideally delivers a discrete, known and high
concentration of the molecule in a well characterised and stable format. Multiple agents
can similarly be bound to one surface, with the same advantages.
Nanoparticles are suitable vehicles for this purpose due to their small size, easily
modifiable surfaces and readily characterisable morphology.
4.1.1 Gold nanoparticles
Gold nanoparticles are particularly of interest due to their small diameter, and hence
their high surface area to volume ratio.
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Modification can be carried out with any thiol-bearing imaging agents, giving them
considerable versatility. They have previously been functionalised with a range of imag-
ing agents, from luminescent lanthanide or transition metal dyes [242, 243] to gadolinium
based contrast agents [244, 245]. The disadvantage is that the metal ligands usually
require custom synthesis to include at least one thiol moiety, as in the four studies refer-
enced.
AuNPs have been synthesised by a number of methods, with various reducing agents
and stabilising molecules.
The Turkevich method [179] involves the reduction of heated gold salts (chloroauric
acid) and stabilisation of the resulting particles, both by citrate ions. This is the sim-
plest method, and produces citrate-stabilised gold nanoparticles between 10 - 20 nm in
diameter, [178], though the size has subsequently been varied to a much wider range [246].
In the Brust method [247], the reducing agent is sodium borohydride, and tetraoctyl
ammonium bromide is used to stabilise the particles in an organic phase. This allows
the nanoparticles to be formed and funcitonalised in an organic solvent, allowing more
options for surface modification. The particles are however smaller than the Turkevich
method, falling between 2 and 5 nm in diameter.
The Martin method [248] also uses sodium borohydride as the reducing agent, and
produces either non-stabilised or dodecanethiol-stabilised particles of between 3.2 and
5.2 nm. The non-stabilised particles require tight control of the reagent ratios, and the
dodecanethiol AuNPs are soluble in solvents such as hexane.
In this work AuNPs were synthesised by the Turkevich method, then surface- func-
tionalised to add two imaging agents; a luminescent iridium complex and a gadolinium
complex for MRI contrast enhancement.
4.1.2 Silica nanoparticles
Silica nanoparticles are similarly versatile in that they can be modified, through the
condensation onto the surface of alkyl silanes, with a wider range of surface groups than
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gold. There are many functionalised silanes commercially available which add amine,
thiol, carboxylate or phosphonate groups, to name but a few. The importance of modified
silica surfaces are highlighted by noting that several other nanoparticles, including gold
nanoparticles, SPIOs and quantum dots have all been coated with silica, either to improve
solubility or stability, or to enable further functionalisation [249, 250, 251, 252, 253].
In terms of multimodal vehicle design, trapping in the core can provide greater pro-
tection from the environment. Conversely some imaging agents need to be on the surface,
either for access to the solvent, as for T1 MRI agents [254, 236], or for ready chelation of
radionuclide labels [175, 255].
The synthesis of solid SiNPs typically proceeds either via a Stober synthesis or a
microemulsion synthesis.
In the Stober synthesis [163], tetraethyl orthosilicate is hydrolysed by a base (usually
ammonium hydroxide) and condensed in an alcoholic solution. This is a simple one-pot
synthesis and uncomplicated purification. The size of the particles is controlled by the
ratios of the silane, base and solvent (or solvents), from roughly 60 nm to 800 nm in
diameter [165], or as low as 15 nm with seeded growth mechanisms [256].
Microemulsion syntheses involve the use of surfactants to form nano-sized reaction
vessels [257, 258]. The hydrolysis and condensation occur inside the emulsion droplets,
thus controlling the particle sizes by limiting water concentrations [258]. This method
can produce smaller and more monodisperse particles than the Stober synthesis [259], but
requires complete removal of the surfactant, which is often not addressed.
In order to limit the risk of contamination from residual surfactant species, and to
be able to incorporate organic imaging agents, thus excluding calcination, the Stober
synthesis was used in this project.
4.1.3 Other nanoparticles
As mentioned above SPIOs can have their surfaces functionalised through a silica
layer, but they also have the added advantage that the core itself is an imaging agent.
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Dendrimers are highly controlled and can have a range of terminal imaging agents on
the surface, but they can have complex syntheses and purifications. Other nanostruc-
tures (such as hydroxyapatite, polymeric nanoparticles, silver nanoparticles, and carbon
nanotubes) could also be of interest for alternative solutions for this project’s goal, but
they require either more complex functionalisation processes or have associated toxicity
concerns.
4.1.4 Project plan
In this work luminescent RuSiNPs, as discussed in Chapter 3, were surface function-
alised with gadolinium DTPA-based ligands to form RuGdSiNPs, as illustrated in Figure
4.1. The ligand was based on a modification of a gadolinium ligand presented by Rieter
et al. [236].
Figure 4.1: Ruthenium tris-phenanthroline labelled silica nanoparticle with gadolinium
ligands bound to the surface (RuGdSiNP).
The ligand was based on a modification of a gadolinium ligand presented by Rieter et
al. [236], and is formed by reaction of the DTPA dianhydride with an aminated silane,
APTES, as shown in Figure 4.2.
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Figure 4.2: Illustration of the reaction between APTES and DTPA dianhydride to form
the 3-amidopropyltriethoxysilane-diethylenetriaminetetraacetic acid (APTES DTTA).
Gold nanoparticles were coated with the neutral gadolinium DTPA-based ligands as
illustrated in Figure 4.3, which displaced the citrate molecules but stabilised the particles
su ciently to allow addition of positively charged iridium bipyridyl complexes, shown in
Figure 4.4. The particles are illustrated in Figure 4.5. They were characterised, tested in
immune cells for cell uptake and assessed as a dual modal imaging agent.
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Figure 4.3: Structure of the GdQSH ligand used to functionalise the IrGdAuNPs.
Figure 4.4: Structure of the IrBpySAc used to functionalise the IrGdAuNPs.
Figure 4.5: Gold nanoparticle with gadolinium ligands and iridium bipyridyl ligands
bound to the surface (IrGdAuNP).
Both particles were synthesised, characterised, and tested in immune cells for cell
uptake and assessed as a dual modal imaging agent.
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4.2 Experimental details
The experimental details here are specific to this chapter. All materials and methods
used in multiple chapter are provided in Chapter 2 to avoid repetition.
4.2.1 Materials
Gadolinium(III) chloride hexahydrate and diethylenetriaminepentaacetic dianhydride
(98%) were purchased from Sigma Aldrich. Anhydrous pyridine (Acroseal over molecular
sieves) was purchased from Fisher Scientific. Ru(phen)3(PF6)2 was synthesised by S.
Adams in the group of Prof. Z. Pikramenou,
AuNP synthesis
Chloroauric acid was purchased from Alfa Aesar. Trisodium citrate was purchased
from Sigma Aldrich. IrBpySAc was prepared by Dr. N.J. Rogers, GdQSH was prepared
by Dr. D.J. Lewis, all of whom were in the group of Prof. Z. Pikramenou.
4.2.2 APTES-DTPA conjugation
500 mg (1.4 mmol) of DTPA dianhydride was placed under an argon atmosphere in
a 50 ml round bottomed flask and dissolved in 10 ml of anhydrous pyridine. 350 µl (1.5
mmol) of APTES was added and the mixture was stirred with a magnetic stirrer bar for
24 hours at 800 rpm.
The DTPA-APTES was purified by precipitation with approximately 50 ml of hexane
followed by separation by centrifugation. This process was repeated a further two times
before drying by rotary evaporation and under high vacuum, producing 752 mg (1.25
mmol) of white powder (yield 90%).
1H NMR of the silanetriol (300MHz, D2O + NaOH) ” 3.10 - 2.96 (12H, m, 8H
CH2COO– + 2H CH2C(O)N + 2H CH2NC(O)), 2.55 - 2.45 (8H, s, NCH2CH2N), 1.45
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(2H, m, SiCH2CH2), 0.37 - 0.31 (2H, m, SiCH2).
13C NMR (400MHz,PENDANT, DMSO) ” 173 (4C, COOH), 169 (1C, s, C(O)NH), 55
(10C, 4C CH2(CO(NH)) + 1C CH2(COOH) + 3C Si(OCH2CH3) + 2C C(O)NCH2CH2),
52 (4C, s, NCH2CH2N), 50 (4C, s, CH2Si(OCH2CH3)).
ESI-MS (TOF -ve ion) of the partially hydrolyzed and deuterated silane m/z 597.8
([M≠H]– 28%) 537.7 ([M≠H≠2OEt+ 2OH]– 9%).
FTIR (solid) 1755 (med, C=O, COOH), 1640 (s, C=O, amide), 1400 (s, C-O-H bend-
ing), 1250 (med, C-O, COOH), 1075 (s, N-C), 915 (Si-CH2).
4.2.3 Nanoparticle syntheses
Silica nanoparticles were synthesised according to an adapted Stober synthesis [163],
then modified with functionalised silanes. Gold nanoparticles were synthesised according
to the Turkevich method and then modified with functionalised thiols.
Silica nanoparticles (RuGdSiNPs)
53.5 ml EtOH, 3.2 ml NH4OH (28%), 1.6 ml TEOS and 1 ml Ru(phen)3(PF6)2 (1
mg/ml in acetonitrile) were placed in a round bottomed flask. The solution was stirred
for 24 hours, during which it became turbid.
Separately, 88 mg (22µmol) of APTES-DTPA was dissolved for 30 minutes in 180 µl
of 1M NaOH. 18.6 mg (50µmol) of GdCl3 ·6H2O was added and allowed to dissolve for 30
minutes. The ligand solution was then added to the nanoparticle suspension and stirred
over night.
The suspension was washed by centrifugation at 5000 rpm (approximately 3300 x g)
for 30 minutes and resuspension in clean solvent. The nanoparticles were washed twice
with ethanol and twice with water.
For storage the nanoparticles were resuspended in ethanol.
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Gold nanoparticles (IrGdAuNPs)
19.8 mg of chloroauric acid was placed in a round-bottomed flask in the dark and
dissolved in 50 ml of deionised water. The solution was heated to reflux and stirred
vigorously. 57.2 mg of trisodium citrate was dissolved in 5 ml of deionised water, and the
solution was quickly added to the vortex.
The solution turned dark red and was heated at reflux for a further 10 minutes, then
allowed to cool to room temperature with stirring.
For coating the AuNPs, the 1 mM GdQSH solution was freshly prepared in methanol.
IrBpySH solution was prepared by dissolving IrBpySAc in acetonitrile to 7 mM, then
freshly diluting to 3.5 mM with 30% NH4OH before each preparation.
The SPR band was verified by UV/visible spectroscopy before and during coating. A
characteristic band with ⁄max at 520 nm was required initially.
5 aliquots of 20 µl of GdQSH solution (100 µl in total) were added to 1 ml of AuNPs (9
nM), causing a shift in the SPR to 526 nm. 3 aliquots of 2 µl of the IrBpySH solution (6
µl in total) were then added to the AuNPs, leading to a shift in the SPR to approximately
527 nm.
The IrGdAuNPs were then washed at least twice by centrifugation at 12100 x g, and
resuspended in deionised water.
To create GdAuNPs, the synthesis was identical except the addition of the iridium
was omitted.
4.3 Synthesis and characterisation results
Dual modal silica and gold nanoparticles were created by a modified Stober synthesis
and the Turkevich method respectively, followed by surface functionalisation with custom-
made imaging agent complexes. Both were designed to exhibit luminescent properties and
proton MRI contrast enhancement.
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4.3.1 Silica nanoparticles
One advantage of silica is that it allows the combination of trapping fluorophores in
its matrix and surface functionalisation. This maximises the available surface area for
the ligands which require solvent access, while also giving a high loading of those imaging
agents which do not.
Here silica nanoparticles were created by a modified Stober synthesis and the surface
was functionalised with gadolinium chelates. Ruthenium tris-phenanthroline was trapped
in the matrix of the nanoparticle, as discussed in Chapter 3, creating in principle a dual
modal system.
Light scattering (DLS)
Dynamic light scattering (DLS) measurements were carried out on the gadolinium-
functionalises RuSiNPs (RuGdSiNPs). The sizes are presented in Table 4.1, along with
those from Section 3.3.1 for comparison. A histogram of the radii is shown in Figure 4.6.
Sample
Diameter mean (nm)
(by intensity) ±
standard deviation
Diameter mean (nm)
(by number) ±
standard deviation
Zeta potential (mV)
± standard
deviation
RuGdSiNPs 164 ± 47 115 ± 29 -30 ± 1
RuSiNPs 146 ± 43 98 ± 24 -55 ± 1
Table 4.1: Diameters and zeta potentials of the RuSiNPs and RuGdSiNPs as measured
by DLS
The hydrodynamic diameter of the RuGdSiNPs is found to be 115 nm with a standard
deviation of 29 nm, corresponding to a radius of 57.5 nm with a standard deviation of
14.5 nm.
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By light scattering the size of the particles appears to increase upon functionalisation,
and although this is to be expected, there seems to be a considerable di erence in the size
between the Gd-functionalised and non-Gd-functionalised RuSiNPs.
Various aspects of the RuGdSiNPs are non-ideal for DLS measurement. The pres-
ence of the [Ru(phen)3]2+ could lead to luminescence in the sample which would disrupt
the measurements. The density of these particles, although approximated by that of
amorphous silica, will not be totally accurate due to the doping with the [Ru(phen)3]2+.
Therefore, since the two distribution means fall within the standard deviations of each
other, both by number and intensity, these can be taken as an approximation to the size
of the particles in the bulk solution to support the more reliable TEM data.
Figure 4.6: Histograms of RuGdSiNP diameters measured by DLS analysis.
Electron microscopy (TEM)
Transmission electron microscopy images were taken of the RuGdSiNPs. A character-
istic image is shown in Figure 4.7, and the histogram of the measured radii is shown in
Figure 4.7.
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Figure 4.7: TEM images of ruthenium doped silica nanoparticles with gadolinium conju-
gated to the surface (RuGdSiNPs).
Figure 4.8: Histogram of RuGdSiNP radii measured from TEM images by automated
segmentation.
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The radius of the RuGdSiNPs was 37 nm ± 4 nm (based on 368 measured NPs).
These particles are therefore smaller than the RuSiNPs described in Section 3.3.1,
which were 43 nm in radius. While the synthesis consistently produced particles with a
suitably spherical morphology, the particle radius varied between approximately 35 and 45
nm. While consistency was maintained where possible, factors such as the concentration
of the ammonium hydroxide (which varied slightly between reagent bottles and decreased
with use) were found to be significant.
The radius of the RuGdSiNPs as measured by DLS, 57.5 nm, is considerably larger
than that measured by TEM, 37 nm. This could be due to the hydrodynamic diameters of
the nanoparticles being considerably larger than the dense cores visible by TEM. It could
also however be due to the microscopic number of particles being analysed by TEM, rather
than the bulk quantities measured by DLS. Nevertheless, for the reasons discussed above,
given the number of particles analysed by TEM, this size will be taken as representative
of the particle cores.
Binding e ciency
Nanoparticle samples were diluted to a concentration of 1:100 for ICP-MS analysis.
The ruthenium concentration was found to be 1.67 mg/l ± 0.2 mg/l. This corresponds
to a molar concentration of 17 µM. This is considerably lower than expected since very
little appeared to wash out, and a maximum of 40 mg/l could be expected based on the
amount added.
The sample was however dissolved and stored in nitric acid, in which ruthenium can
react when heated to form the volatile ruthenium tetroxide leading to loss of the metal
[260], though it is unlikely that this would have had such a significant e ect given the
gentle heating of the sample in this case.
The gadolinium concentration was found to be 59.3 mg/l ± 2.2. This corresponds to
a molar concentration of 378 µM. This is also smaller than expected since the maximum
value, based on the Gd added is 300 mg (Gd)/L. Since the ligand solution is colourless
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however, a large proportion could have washed o , so this is not of major concern at this
stage.
Luminescence profile and lifetimes
Figure 4.9: Excitation and emission spectra of RuGdSiNPs and [Ru(phen)3][(PF6)2]. Ex-
citation scans were monitored at 590 nm and emission scans were excited at 480 nm.
The luminescence spectra of the RuGdSiNPs compared to free [Ru(phen)3][(PF6)2] in
solution are displayed in Figure 4.9. The emission spectra appear to be almost identical,
with the maximum only shifting by 3 nm from 590 nm for the free complex to 593 nm for
the trapped complex, and the peak shape being slightly broadened. This shift is the same
as found for the RuSiNPs in Section 3.3.1, which is as expected considering the surface
modification should not alter the core structure.
The lifetime data for the RuGdSiNPs are presented in Table 4.2. The lifetimes are
similar to those of the RuSiNPs, also as would be expected since the surface modification
should not a ect the core. The changes that are observed could be a consequence of a
changed permeability with the extra coating, or could be within experimental error of the
fitting.
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Sample t1 (ns) t1 (%) B1 t2 (ns) t2 (%) B2 t A ‰2
RuGdSiNP 590 15 367 1762 85 672 1348 3.8 1.01
RuSiNP 547 13 280 1836 87 557 1405 7.7 1.03
Table 4.2: Luminescence lifetime measurements of RuGdSiNPs, along with the RuSiNP
measurements from Section 3.3.1 for reference.
In broader terms, however, the values are similar to those reported for similar particles
[165], i.e. 530 ns for the free dye and 1357 ns for [Ru(phen)3]2+-doped Stober silica
nanoparticles. This suggests either that there was some dye free in the solution, despite
the particles being thoroughly washed and none being visible under UV light, or that
some of the dye is trapped in such a way as to allow enough movement and oxygen access
to simulate a free environment.
MR contrast enhancement
RuGdSiNPs were imaged by 1H MR at a range of concentrations between 0 and 20
mg/ml. The images were analysed by the automated MR analysis tools described in
Section 7.2 to find the relaxivity of the samples. The relaxivity plots are shown in Figure
4.10, with the slope of the fitted line giving the relaxivity.
The relaxivity of the RuGdSiNPs was found to be 3.3 s≠1mM≠1 (i.e. mM of gadolinium
ions). This is the same order of magnitude as currently available clinical contrast agents,
though a little lower than expected given the similarity between the complexes. For
example Primovist, measured simultaneously as a reference standard, was found to have
a relaxivity of 5.7 s≠1mM≠1. This di erence was disappointing but the system was pursued
given a clear trend showing contrast enhancement and the other potential benefits of the
dual modality.
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Figure 4.10: MR relaxivity plots of RuGdSiNPs imaging agents together. Values were
calculated per gadolinium.
4.3.2 Gold nanoparticles
The AuNPs were prepared by the Turkevich method [178], which produced 13 - 15
nm gold nanoparticles. In order to add proton MRI contrast enhancement the citrate
was replaced by the GdQSH complexes, which were not charged but helped stabilise
the nanoparticles by their steric bulk. Positively charged thiolated iridium bipyridyl
complexes (hydrolysed IrBpySAc from reference [261]) were then substituted in to produce
dual modal IrGdAuNPs.
The synthesis was robust and reproducible when carried out under UV-visible spec-
troscopic observation to verify the shifts in SPR bands. The particles exhibited su -
cient stability for cell treatment, but aggregated upon longer term storage, requiring the
nanoparticles to be prepared freshly for each experiment.
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Light scattering (DLS)
The diameters of the AuNPs and IrGdAuNPs are 14 nm and 18 nm respectively,
as measured by dynamic light scattering (DLS), corresponding to radii of 7 and 9 nm
respectively. The full data is shown in Table 4.3.
Sample
Diameter mean (nm)
(by intensity) ±
standard deviation
Diameter mean (nm)
(by number) ±
standard deviation
Zeta potential (mV)
± standard deviation
AuNPs 26 ± 0.5 14 ± 0.5 -41 ± 1
IrGdAuNPs 28 ± 0.5 18 ± 0.5 47 ± 0.2
Table 4.3: Diameters and zeta potentials of IrGdAuNPs and AuNPs as measured by DLS.
There is an increase in the diameter with the addition of the iridium and gadolinium
complexes, as expected given the steric bulk the imaging agents would provide.
Figure 4.11: Histograms of IrGdAuNP diameter dispersions measured by DLS.
The change in the zeta potential from the functionalisation step reflects the revers-
ing of the surface charge by the replacement of the negatively charged citrate molecules
with the bulky, neutral gadolinium complexes. The positive charge then comes from the
functionalisation with the iridium complexes, indicating successful functionalisation.
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The zeta potential for the IrGdAuNPs does however suggest that the particles should
be colloidally stable. The limited shelf life of the particles is therefore not explained by
the surface charge.
A possible alternative explanation could be that the surface of the IrGdAuNPs will
be covered in aromatic and alkyl ligands, so presenting a hydrophobic and largely aprotic
surface. This may lead to gradual flocculation and eventually aggregation of the particles
when in aqueous media. The shelf life would ideally be addressed in further work if these
particles were to be pursued, but the stability was considered su cient for reliable further
testing in this project.
Electron microscopy (TEM)
Figure 4.12: TEM image of gold nanoparticles (AuNPs).
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Figure 4.13: Histogram of AuNPs radii measured from TEM images by automated seg-
mentation.
The unlabelled AuNPs were analysed by TEM. The radius was found to be 7.5 nm
with a standard deviation of 1 nm based on the measurement of 493 NPs. A representative
image is shown in Figure 4.12, and the histogram of the measured radii in Figure 4.13.
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Figure 4.14: TEM images of gold nanoparticles coated with iridium and gadolinium com-
plexes (IrGdAuNPs).
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Figure 4.15: Histogram of IrGdAuNPs radii measured from TEM images by automated
segmentation.
The mean radius of the IrGdAuNPs by TEM is 8 nm with a standard deviation of 1
nm, based on the measurement of 179 NPs by the method described in Section 7.1. A
representative image is shown in Figure 4.14, and a histogram plot of the measured sizes
is shown in Figure 4.15.
Given the microscopic nature of analysis by TEM and the standard deviations of these
two measurements there appears to be no significant change between the citrate-coated
and the functionalised AuNPs. This is to be expected considering the low contrast that
would be produced by the organic ligands in TEM. The iridium and gadolinium, though
heavy atoms, would have concentrations too low for them to contribute significantly to
the nanoparticle contrast. Based on the images, the functionalisation does not appear to
have had a detrimental e ect on the nanoparticles’ morphology or dispersion.
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There is also no significant di erence between the TEM and DLS size for these parti-
cles.
Luminescence
The excitation and emission spectra of the IrBpySH complex was measured by S.
King, and is shown in Figure 4.16. The emission maximum is at 580 nm, with excitation
at 380 nm. The excitation spectrum is characteristic of similar iridium bipyridyl-based
complexes [262, 263, 264]. A non-maximal excitation was used in order to more closely
match the instrumentation capabilities for analysis of cells (flow cytometry, microscopy
etc.), which rely on using visible wavelength light.
Figure 4.16: Excitation and emission spectra of the iridium bipyridyl-based ligand (20
µM) in methanol. Excitation scans were monitored at 578 nm and emission scans were
excited at 380 nm.
The photochemical properties of the IrGdAuNPs were analysed and discussed by Dr.
N.J. Rogers [132]. Briefly, the particles showed similar excitation and emission spectra,
with the emission maximum unchanged at 580 nm.
This profile makes the particles suitable for microscopy or fluorescence techniques using
a 355 nm LASER, and possibly feasible using a mercury or xenon arc lamp [265, 266].
Wavelengths lower than this should be avoided however as there is a risk of oxidative
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DNA damage [267].
MR contrast enhancement
The relaxivity of the free gadolinium complex was found to be 5.1 s≠1mM≠1, which is
comparable to commercially available contrast agents [139]. A corresponding MR image
is shown in Figure 4.17, along with the plot used to calculate the relaxivity in Figure 4.18.
Figure 4.17: MR image of the GdQSH complex.
Figure 4.18: Plot of the relaxation rate against the gadolinium concentration for the
GdQSH complex.
The IrGdAuNPs and GdAuNPs showed a contrast enhancing e ect, as can be seen in
characteristic images of a range of concentrations of both particles in Figure 4.19. This
is quantified through the relaxivity, calculated from a plot of the inverse relaxation time
plotted against concentration, shown in Figure 4.20.
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Figure 4.19: MR image of IrGdAuNPs (bottom row) and GdAuNPs (left column of
samples).
Figure 4.20: Plot used to calculate the relaxivities of the IrGdAuNPs
The particles showed relaxivities of 7.1 s≠1mM≠1 for the GdAuNPs, and 8.4 s≠1mM≠1
for the IrGdAuNPs. These are both considerable increases compared to the gadolinium
complex alone, as would be expected from an increase in the rotational correlation time.
It would however also be expected that the GdAuNPs would have higher relaxation
rates than those where some of the gadolinium complexes have been displaced by irid-
ium complexes. This does not appear to be the case though possibly due to the higher
gadolinium loading on the IrGdAuNPs compared to the GdAuNPs (1306 Gd per NP as
opposed to 1043 respectively, as measured by ICP-OES by Dr. N.J.Rogers [132]).
These results demonstrate the e ective gadolinium functionalisation of the AuNPs,
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and that they show a greater relaxation rate than current clinical contrast agents. When
combined with the luminescence results, they show the functionalisation of the AuNPs
for both luminescence and MRI, making them promising dual modal agents.
4.4 Cell treatment results
Both of the nanoparticle systems developed in this chapter showed dual-modal imag-
ing capabilities and were readily characterisable. They were therefore incubated with
immune cells to observe any uptake into the various cell types, with particular focus on
the monocytes and lymphocytes.
4.4.1 Silica nanoparticles
One promising nanoparticle system was the RuGdSiNPs. They were readily charac-
terised, showing clear and regular morphologies, with good long term stability in solution,
and showing dual modal imaging capabilities for 1H MRI and fluorescence techniques.
One particular aspect of interest was how the RuGdSiNPs would interact with DCs.
These cells naturally endocytose in order to process antigens, so some uptake would be
expected. A preliminary study was carried out to observe the labelling of the DCs by
flow cytometry.
DCs were derived from PBMCs, which were isolated by a gradient density column,
and the CD14 positive cells were selected by magnetic filtering. The monocytes were
cultured to mature DCs over 5 days, and RuGdSiNPs were added on the third day; the
cell uptake was assessed by flow cytometry.
The other aspect of extra interest was how the flow cytometry values varied between ex-
periments with di erent donors. PBMCs from five donors were treated with RuGdSiNPs
and incubated for 24 hours, then the fluorescence was measured by flow cytometry. Sam-
ples were also analysed by light microscopy and MRI to assess whether the RuGdSiNPs
labelled the cells su ciently for detection by both modalities with realistic numbers of
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cells. Although meaningful quantitative viability tests were beyond the scope of this
project, an indication of the cell viability was obtained from the flow cytometry data in
combination with the microscopy data.
Flow cytometry of RuGdSiNPs in dendritic cells
Flow cytometry was carried out on DCs loaded with the RuGdSiNPs, though aggre-
gates in the sample caused some problems with the instrument. Forward scatter/side
scatter plots are shown in Figure 4.21, indicating the change in the size and morphology
of the cells with varying nanoparticle treatments.
The change in the percentage of labelled cells, and the degree of labelling (i.e. the
median channel fluorescence) is plotted in Figure 4.22. There is some uptake by the
dendritic cells at the lowest concentration of 0.19 mg(NP)/ml, with 39% of the DCs
being labelled and a median channel fluorescence from those cells of 24.0. This increases
to 45% with treatment at 0.375 mg(NP)/ml and a median channel fluorescence of 27.7,
but at higher concentrations fewer cells are labelled and those that are, are less bright.
This could be due to the aggregation of the nanoparticles being most severe above this
concentration, and hence the nanoparticles not being available for uptake. It could also
be due to a natural limit to the amount dendritic cells will take up.
(a) 0 mg/ml NP (b) 0.375 mg/ml NP
Figure 4.21: Forward scatter vs, side scatter plots for (a) DCs and (b) DCs treated with
0.375 mg/ml RuGdSiNPs, showing the changes in size and granularity of the cells. The
DC gate is highlighted by the black ellipse.
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Figure 4.22: Plot showing the percentage of DCs containing RuGdSiNPs and the median
degree of fluorescence, plotted against the concentration of RuGdSiNPs the cells were
treated with.
Flow cytometry of RuGdSiNPs in PBMCs
PBMCs were treated with RuGdSiNPs at a range of concentration for 24 hours, then
analysed by flow cytometry. The results are displayed in Figure 4.23, with the an example
of the forward scatter/side scatter plots at di erent treatment concentrations shown in
Figure 4.24. No significant uptake was observed in the lymphocytes in these experiments
so only the monocyte data is presented.
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Figure 4.23: Plot showing the percentage of monocytes containing RuGdSiNPs and the
median degree of fluorescence, plotted against the concentration of RuGdSiNPs the cells
were treated with.
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(a) 0.05 mg/ml NP
(b) 0.15 mg/ml NP
(c) 0.25 mg/ml NP
Figure 4.24: Forward scatter vs, side scatter plots for PBMCs treated with increasing
concentrations of RuGdSiNPs, showing the changes in size and granularity of the cells.
The monocyte gate is highlighted by the black ellipse. The histograms of the channel
fluorescence are also shown for each concentration.
The uptake of the RuGdSiNPs is analysed both in terms of the number of cells which
contain the label, denoted by the percentage of positive cells, and the amount of the label
taken up into the labelled cells, denoted by the median channel fluorescence.
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In this case the experiment was repeated with five di erent donors, over two days,
to show the variability that can arise. The error bars show the standard deviation of
the labelled cell percentage over the five experiments. There was an average 67% of
monocytes labelled across all nanoparticle treatment concentrations. The median chan-
nel fluorescence on the other hand rises to a peak at a 0.15 mg/ml RuGdSiNP treatment
concentration, with a plateau afterwards, suggesting that there is no benefit from increas-
ing the concentration beyond this. A compromise must therefore be found for future
work between the maximum positive labelling, the maximum label uptake, and the cell
viability.
A preliminary measure of the cell viability at the di erent RuGdSiNP treatment con-
centrations is the proportion of cells remaining within the monocyte gate, which is deter-
mined on a control sample. This indicates whether there is a significant change in size
or morphology within the monocyte population with increasing cell concentrations. The
mean percentage of the whole cell population falling within the monocyte gate is plotted
against treatment concentration in Figure 4.25.
Figure 4.25: Plot showing the percentage of the whole cell population falling within the
monocyte gate, plotted against the concentration of RuGdSiNPs the cells were treated
with. The ’Cells only’ data was a control sample with no nanoparticle treatments, while
the ’DMSO’ sample was a vehicle control at the highest treatment concentration, but
without the nanoparticles. The error bars indicate the standard deviation over 5 donors.
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There is a clear drop in the percentage of cells falling within the monocyte gate with
increasing treatment concentrations. The RuGdSiNPs appear to be a ecting the cells
at all concentrations, but in a concentration-dependent manner. The DMSO (vehicle)
control, which involved the same volume as for the 25 mg/ml RuGdSiNP treatment, may
be having a small e ect but a much smaller one than the nanoparticles themselves.
It should be noted that the flow cytometer used does not give any indication of the
volume required to examine a given number of cells. There is therefore no measure of
the number of cells which have died and disintegrated during the treatment. This high-
lights the need for extensive viability testing for any system that emerges as a potential
multimodal imaging agent.
Microscopy of RuGdSiNPs in PBMCs
Labelling was carried out at a range of RuGdSiNP concentrations to observe the e ect
of the nanoparticles on the cell morphologies, which were indicated by the flow cytometry
results above.
At a RuGdSiNP concentration of 0.05 mg/ml, the cells show recognisable morpholo-
gies, with nanoparticles mostly appearing to be in the cytoplasm of the cells, see the
microscopy image in Figure 4.26. The fluorescence appears to be punctate, suggesting
that the nanoparticles have been taken up into the cells in vesicles. The types of vesicle
could be investigated further as part of future work by using vesicle specific fluorescent
counterstains such as Lysotracker.
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Figure 4.26: Micropscopy images showing the stained cells by brightfield microscopy (top
left), the corresponding fluorescence image indicating the RuGdSiNP locations (top right)
and an overlaid combined image (below).
At a higher nanoparticle concentration of 0.15 mg/ml, the nanoparticles can also be
seen as punctate fluorescence which is co-localised with the cells, see Figure 4.27. The
cells however look less recognisable as healthy cells, with large-lobed anuclear structures
seeming to contain clusters of nanoparticles. These could be clusters of dying or dead
cells. They could also be giant cells, formed to process the high concentration of foreign
matter, i.e. the RuGdSiNPs. These could be the larger structures seen developing with
the loss of the monocyte cloud in the flow cytometry results.
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Figure 4.27: Micropscopy images showing the stained cells by brightfield microscopy (top
left), the corresponding fluorescence image indicating the RuGdSiNP locations (top right)
and an overlaid combined image (below).
MRI of RuGdSiNPs in PBMCs
50 x 106 PBMCs were labelled with 0.15 mg/ml of RuGdSiNPs to provide the maxi-
mum labelling, as seen by flow cytometry. Although there may be some loss of viability
at this concentration, as suggested by the microscopy results, maximum labelling was
considered preferable for this experiment. The RuGdSiNP labelled cells, suspended in
gelatin, had a relaxation rate of 0.52 s≠1, while the control sample, containing gelatin,
showed a rate of 0.49 s≠1.
The labelled cells showed a small di erence from the control sample of gelatin based
on the relaxivities (see Figure 4.28). This was not obvious in the corresponding images,
however, as shown in Figure 4.29, indicating that the cells would not be readily localisable
in vivo and that therefore there is insu cient uptake of nanoparticles at this concentra-
tion. This is not surprising considering the relatively low uptake of the nanoparticles (see
flow cytometry results). It does suggest however that these would not be suitable for
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multimodal cell tracking unless the uptake could be improved, as this high concentration
of cells would be undetectable.
Figure 4.28: Plot of the relaxation rates against gadolinium concentration, calculated
from GdDTPA-EOB and from 50x106 PBMCs which were labelled with 0.25 mg/ml
RuGdSiNPs, washed, then suspended in 10% gelatin.
Figure 4.29: MR image of the RuGdSiNP-labelled PBMCs (top centre), a control samples
of 10% gelatin, water samples around these and gadolinium (Primovist) samples (bottom
row) at a range of concentrations.
4.4.2 Gold nanoparticles
Gold nanoparticles labelled with gadolinium and iridium (IrGdAUNPs) were incubated
with PBMCs in order to observe any uptake by the cells. The luminescence excitation
spectrum of the iridium, with absorption mainly below 400 nm, makes these particles
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unsuitable for analysis by many standard biological methods. The flow cytometer carried
no lasers below 405 nm in wavelength, resulting in the nanoparticles not being detectable
by this method (see appendix A for flow cytometry of cells at 405 nm).
The microscopy in this project was carried out on a system with a mercury lamp which
leads to some excitation in the UV range [265]. This coupled with a DAPI and FITC
filter set should allow some imaging of any nanoparticles loaded into PBMCs.
Transmission electron microscopy (TEM) has also been used to observe the uptake of
the IrGdAuNPs by the PBMCs. The gold nanoparticle cores provide high contrast in the
images, and with a low energy electron beam the cellular structures can simultaneously
be seen.
Microscopy of IrGdAuNPs in PBMCs
Initial microscopy on the IrGduNPs aimed to retain the native cell morphologies.
The IrGdAuNP labelled cell suspension was labelled with a red nuclear stain, DRAQ5,
according to the manufacturers instructions and placed in an imaging chamber (Grace
Biolabs), which was sealed with a glass coverslip. The cells were imaged immediately
through the glass coverslip. A typical microscopy image is shown in Figure 4.30.
Figure 4.30: Multi-channel micropscopy image showing PBMCs nuclei labelled in red and
the IrGdAuNPs in yellow. (Images were acquired per channel and overlaid with false
colour.)
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There are IrGdAuNPs are clearly clustered around the nuclei suggesting uptake into
the cytoplasm. For most of the cells there does not appear to be any uptake into the
nucleus, which is reassuring as interaction with the DNA could risk damage to the cells.
There are however also clusters of nanoparticles with no nucleus, which could be due to
uptake by anuclear cells, excessive uptake leading to apoptosis and so local labelled cell
debris, or out-of-focus cells, or free nanoparticles. It is not clear without further staining
which of these is the case.
Since out-of-focus cells were problematic for the imaging, the micropscopy preparation
was revised to produce cells in a monolayer with extra staining. The disadvantage is that
the non-adherent cells must be layered on to the surface by cytospinning, where the cells
are e ectively centrifuged on to a slide surface. Kwik-Di  staining was then used to stain
the entire cell and help di erentiate between cell types.
Figure 4.31 shows an example of IrGdAuNP-treated PBMCs which appear to be
healthy, with a range of cell types present. There is however no observable uptake of
the IrGdAuNPs by this method, as no significant level of fluorescence co-localises with
the cells in the bright-field image.
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Figure 4.31: Micropscopy images showing the labelled cells by brightfield microscopy (top
left), the corresponding fluorescence image (top right) and an overlaid combined image
(below).
This was unexpected given the nanoparticle luminescence observed by imaging in the
chamber (Figure 4.30), so was considered to be possibly a result of the cell staining
process, either due to reaction of the nanoparticles with the dyes or loss of the particles
during the permeabilisation step.
The microscopy of the IrGdAuNPs has therefore proved to be challenging, though a
range of other stains may be preferable for these nanoparticles. For example a membrane
stain or actin stain would indicate the extent of the cell, and combined with the nuclear
stain and cytospinning, would provide more information on the cellular localisation of the
IrGdAuNPs.
These microscopy experiments were not pursued in this work in view of the MRI
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results presented below. It is anticipated however based on these preliminary results
that IrGdAuNPs could be an e ective cell label for luminescence-based techniques with
suitable optimisation.
Electron microscopy of IrGdAuNPs in PBMCs
Gold nanoparticles can be readily discerned by TEM due to their high electron density.
When taken up into cells, which are subsequently embedded in resin and sectioned, the
nanoparticles can still be distinguished from the background when the cells are lightly
stained.
Figure 4.32: TEM images, at increasing magnifications from left to right, of PBMCs
containing IrGdAuNPs.
In both cells shown in Figure 4.32 the nanoparticles are collected into clusters.
In the top image the IrGdAuNPs appear to be membrane-bound. This could be a
consequence of the cell type. The large lobed nucleus suggests that the cell could be
a granulocyte, which are often phagocytic, and would be expected to take up foreign
particles in vesicles.
The second cell shown above appears to have taken the nanoparticles up into the
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cytoplasm, as no surrounding structure is visible. While this could be an artefact from
the staining process, the nucleus is much smaller and more regularly shaped, suggesting
a di erent cell type; it could possibly be a B cell.
It should be noted however that there were many cells present on the grids which
did not appear to contain any nanoparticles. Sectioning the cells necessarily will exclude
much of the cell material, which might have contained nanoparticles. Nevertheless, the
conclusion must be that though nanoparticles do appear to have been taken up into a
variety of cell types, there is only a low level of cell labelling.
MR of IrGdAuNPs in PBMCs
50x106 PBMCs were labelled with IrGdAuNPs at a concentration of 0.9nM (NPs),
washed and suspended in 1 ml of 10% gelatin. The cell suspension was imaged by 1H
MRI to determine whether the labels caused any contrast enhancement. A characteristic
image is shown in Figure 4.34. The relaxation rate was calculated by the algorithm
described in Section 7.2, and is plotted along with gadolinium controls in Figure 4.33.
A relaxation rate of 0.52 s≠1mM≠1 was observed. This is comparable to the signal
produced by the RuGdSiNPs labelling PBMCs, which also had a relaxation rate of 0.52
s≠1mM≠1, As for the RuGdSiNPs this would not be considered a great enough change in
contrast to localise the cells in vivo, so would similarly require improved uptake in order
to be an e ective tool for cell tracking.
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Figure 4.33: Plot of the relaxation rates against gadolinium concentration, calculated from
GdDTPA-EOB and from 50x106 PBMCs which were labelled with 0.9nM IrGdAuNPs,
washed, then suspended in 10% gelatin.
Figure 4.34: MR image of the IrGdAuNP-labelled PBMCs (bottom left), alongside sam-
ples of gelatin containing 2.5 mg/ml RuPFOBGdHSNPs (bottom centre) and RuPFOB
HSNPS (bottom right). The top row shows water samples.
4.5 Summary and conclusions
4.5.1 Silica nanoparticles
RuGdSiNPs of 70 - 80 nm in diameter were synthesised and characterised. The lu-
minescence spectra were similar to those of the free dye, and the lifetime was similar
to comparable reported RuSiNPs. [Ru(phen)3]2+, as for the RuSiNPs is therefore con-
sidered to be trapped in the matrix with no significant disruption due to the surface
functionalisation.
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The gadolinium complex conjugation meanwhile resulted in MRI contrast enhance-
ment comparable to current clinical contrast agents. This is disappointing considering
the increase in the relaxivity reported due to the greater rotational correlation caused
by the slower tumbling of the nanoparticles [268, 269]. The rates observed however were
considered to be su cient to continue with cell treatments.
Both monocytes and lymphocytes were found to take up the RuGdSiNPs by flow
cytometry. Punctate fluorescence attributable to the RuGdSiNPs was observed by fluo-
rescence microscopy, confirming uptake with little change to the PBMCs’ appearance with
a treatment concentration of 0.05 mg/ml of RuGdSiNPs. Higher concentrations showed
changes in the cell morphology, suggesting a limit the particles leading to healthy labelled
cells.
The RuGdSiNPs were therefore considered to be useful for luminescence techniques,
but requiring further work before they could be useful as MRI labels.
4.5.2 Gold nanoparticles
The IrGdAuNPs, of 16 - 18 nm in diameter, were tested as dual-modal contrast agents.
The luminescence spectra were similar to the unbound complex, while MRI showed con-
trast enhancement greater than currently available clinical contrast agents.
When used as cell labels for PBMCs, however, while there was a suggestion of uptake
seen by microscopy and TEM, MRI indicated that improved uptake would be necessary
in order for the cells to be visible in vivo.
Binding to the nanoparticle surfaces can consequently be considered to be an additional
tool for adding further functionality, but, as implemented here, only had limited abilities
for cell tracking.
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4.5.3 Cell treatments
Future work for cell treatments would include examining the e ects of the nanoparti-
cles on the cells. The first analysis would look at viability, in order to check how cytotoxic
the nanoparticles are. Various assays could accomplish this, such as MTT, which gives
an indication of mitochondrial function, or Sytox green, which permeates only into dead
cells and can be analysed by flow cytometry. Other factors of interest would be to verify
if the monocytes, once labelled, can still di erentiate into dendritic cells, and whether
either of these cell types still have phagocytotic capacity. The next stage would then be
to examine the ability of the relevant cells to migrate, as the derived DCs would need to
be able to travel to the lymph nodes post injection.
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CHAPTER 5
MULTIPLE IMAGING AGENT CAPABILITIES IN
MOLECULAR STRUCTURES
This chapter explores ways of reliably delivering multimodal agents for immune cell
tracking which are alternatives to nanotechnology by using covalent structures which
incorporate multiple functionalities. A commercially available fluorinated fluorescent dye
is therefore investigated for its cell tracking potential.
5.1 Background and introduction
While nanotechnology can theoretically provide many of the solutions necessary for the
delivery and retention of imaging agents, there are also significant disadvantages. Unless
the distribution of the nanoparticle sizes is very small, there is a chance of di erent sizes
having varying e ects on biological systems [198]. Moreover, due simply to their size,
some particles will often be tra cked through the cell in vesicular systems, via various
uptake pathways [270].
Having relatively simple molecules that are intrinsically multimodal is therefore at-
tractive. If the components are covalently linked, the proportions of the imaging agents
will be maintained, with no question of di erential leakage from a vehicle or cell unless
the molecule is degraded. The size of a small molecule means that it could potentially
pass through the cell membrane, as with many drugs and fluorescent dyes, possibly thus
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reducing problems of vesicular segregation and tra cking.
Dendrimers could provide an interesting avenue of research since they have sizes de-
fined by their ’generation’ and are therefore monodisperse when pure. Their synthesis
and purification are however complex, and therefore not as readily translatable to the
clinic as is desired for this project. More accessible molecules have been considered here.
Systems such as a GdDTPA complex conjugated to a fluorinated coumarin dye [271],
which would be technically trimodal by 1H MRI, 19F MRI and fluorescence, were con-
sidered. One fundamental problem however is that gadolinium moieties covalently linked
to fluorine groups, even by long chains, have a significant relaxation enhancing e ect on
the fluorine [272]. This would dampen or remove the 19F MRI signal without UTE pulse
sequences. While such a system would therefore be of interest if other MRI equipment
were available, it would not be suitable for this work.
A simple commercially available molecule, 7-amino-4-trifluoromethyl coumarin (AFC),
see Figure 5.1, was investigated. This is a coumarin dye which also has a trifluoromethyl
functionalisation that could be used for 19F magnetic resonance.
Figure 5.1: Molecular structure of 7-amino-4-trifluoromethyl coumarin (AFC).
AFC has previously been used as a marker for caspase activity [272]. The fluorophore
is conjugated to a peptide (usually Ac-DEVD or Ac-LEHD), and fluoresces when the
peptide is cleaved by caspase, a biomarker for apoptosis [273, 274]. It is similarly sold in
plasmin assay kits attached to a plasmin substrate peptide, e.g. SensoLyte AFC Plasmin
Activity Assay Kit.
AFC has also been used as a 19F NMR probe for glutathione transferase [275], with the
aim of eventually developing a probe to measure the enzymatic activity. The change in
chemical shift of the singlet 19F peak upon cleavage from the ‘masking’ group, indicated
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the presence of glutathione transferase. This could potentially be of interest for work
such as this as it indicates that the frequency of the 19F peak will shift if the molecule
is conjugated via the amine group. Hence if this molecule were further functionalised by
conjugation, the bond subsequently breaking would be detectable by MRI.
The dual-modal imaging agent capability of AFC was examined. It was then incubated
with PBMCs, and the uptake observed by flow cytometry, microscopy and MRI. The aim
was to assess whether it is taken up at su cient levels to be useful for cell tracking.
5.2 Characterisation results
7-amino-4-trifluoromethyl coumarin (AFC) was purchased from Sigma Aldrich, and
was used as provided. The dual-modal capabilities of AFC and its PBMC labelling are
assessed for cell imaging by fluorescence techniques and 19F MRI.
5.2.1 Luminescence
The fluorescence excitation and emission spectra of 7 amino-4-trifluoromethyl coumarin
(AFC) were measured, and are plotted in Figure 5.2. The excitation and emission maxima
are 440 nm and 487 nm respectively.
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Figure 5.2: The luminescence excitation and emission spectra of 7-amino-4-trifluoromethyl
coumarin in methanol. Excitation scans were monitored at 520 nm and emission scans
were excited at 445 nm.
The fluorescence profile of AFC is suitable for fluorescence using visible light excitation
sources. The emission is su ciently shifted to allow filtering to distinguish it from the
excitation light.
5.2.2 MRI signal
The 19F MRI signal from solutions of AFC in DMSO was measured for a range of
concentrations, and the resulting image is displayed in Figures 5.3 and 5.4.
Figure 5.3: 1H MR image of AFC at a range of concentrations, as annotated.
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The samples showed a low signal-to-noise ratio, as plotted in Figure 5.4. This is
comparable to the SNR obtained for trifluoroethanol (see Section 2.6.1), a molecule which
also has three MR-equivalent fluorines.
Figure 5.4: SNR of AFC samples in the 1H MR image (see Figure 5.3).
The low SNR of the AFC indicates that, as expected from the experiments in Section
2.6.1, it would need to be taken up and retained in cells at very high concentrations in
order to be of use in in vivo cell tracking by 19F MRI.
5.3 Cell treatment results
AFC was incubated with PBMCs to test their interaction with immune cells. In
particular, cellular uptake was noted, as well as the ability of the dye to label the cells
for multimodal imaging. The dyes was incubated with isolated PBMCs for 24 hours and
observed by flow cytometry, microscopy and 19F MRI.
5.3.1 Flow cytometry
Flow cytometry showed that the uptake of the AFC into monocytes occurs readily, see
Figure 5.5. 86% of the monocyte cloud were labelled with fluorescent material on average
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over the four treatment concentrations (with standard deviation 1%). There was also
an increase in the median brightness of the labelled cells with increasing concentration,
indicating a concentration dependent labelling.
86% of the lymphocyte cloud were also labelled with AFC (standard deviation 1%).
The median channel fluorescence was however much lower than for the monocytes, with a
maximum of 150 (arbitrary scale) for the lymphocytes compared to 670 for the monocytes,
indicating that there is concentration dependent labelling, but to a more moderate level.
Typical forward scatter/side scatter plots at various AFC concentrations are shown in
Figure 5.6. One point to note is that there is much less debris present than in the other
flow cytometry plots in this work, due to the lack of nanoparticle aggregates. This makes
the analysis more reliable as the smaller granular points are more likely to correspond to
dead or dying cells.
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(a) Monocytes
(b) Lymphocytes
Figure 5.5: Plots showing the concentration-dependent uptake of AFC into (a) monocytes
and (b) lymphocytes by flow cytometry. The blue bars indicate the percentage of the cell
type which are labelled, while the red line indicates the median brightness of the labelled
cells.
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(a) DMSO control ([AFC] = 0)
(b) 10 µM AFC
(c) 100 µM AFC
Figure 5.6: Forward scatter/side scatter plots of PBMCs labelled with increasing AFC
concentrations, and the corresponding fluorescence histograms.
The other point to note is that, as can be seen in Figure 5.7, fewer of monocytes and
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lymphocytes are found in the cell clouds with increasing concentration of the dye. The
percentages of the total cell population that fall within the gates of their control cloud
decreases with concentration, most notably above 10 µM AFC. This could be due to the
dye disrupting the membrane at higher concentrations, leading to increased cytotoxicity.
Figure 5.7: Plot of the decreasing percentage of each cell type (monocytes and lym-
phocytes) which remain within the same size and granularity gate (from the forward
scatter/side scatter plots). Values indicate the percentage of the total cell population
falling within these gates, depending on the AFC labelling concentration.
10 µM AFC would therefore be a reasonable concentration for future viability based
testing, as it is expected that at this concentration the majority of the cells will be healthy.
5.3.2 Fluorescence microscopy
The AFC is unfortunately not compatible with immunohistochemistry processes such
as staining with Kwik-Di , possible due to the methanol permeabilisation step allowing
the dye to leak out. Therefore though the cells were visible by brightfield microscopy,
appearing similar to the stained control cells, no fluorescence was detected.
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5.3.3 MRI detection
PBMCs were treated for 24 hours with 10 µM AFC, corresponding to the highest dose
that showed little change in cell size or morphology by flow cytometry.
PBMCs were pelleted at 50x106 and 20x106 cells and imaged by MRI. No signal was
detectable above the level of the noise. The 50 x106 cells pellet was then lysed by son-
ication, re-suspended in D2O and analysed by fluorine NMR. No signal was detectable
spectroscopically either, suggesting that the AFC is not present at a high enough concen-
tration in the cells to be useful for cell tracking by 19F MR.
5.4 Conclusions
Simple molecules are easier to work with than nanoparticles, and can bear multiple
functionalities. AFC, an intrinsically dual modal agent, produced a single 19F MR peak,
so did avoid problems of chemical shift artefacts. It also produced a fluorescence signal
involving excitation and emission well within the visible range of the spectrum and a large
enough Stokes’ shift to allow filtering if necessary.
AFC was readily taken up into PBMCs and detected by flow cytometry. Uptake de-
pended on concentration, and the levels of uptake di ered between monocytes, which
became fluorescent at low concentrations around 3 µM, and lymphocytes, which required
higher concentrations in the 100 µM range in order to shift the median channel fluo-
rescence. Cytotoxicity at these high concentrations is a concern however, as the flow
cytometry indicated a considerable change in the size and shape of the cells. There was
however no 19F MRI peak detectable on a clinical scanner from a cell pellet, suggesting
that the local concentration of dye in the cells is not high enough to generate a signal.
AFC is therefore not a suitable dual modal agent for cell tracking used alone.
The signal could potentially be boosted if the number of fluorines per molecule could
be increased. For example, the molecule could be attached to a central structure such
as 3,3-bis(carboxymethyl)glutaric acid to produce 4 equivalent trifluoromethyl groups per
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molecule, so boosting the signal by 5. Three potential problems with this are that the
solubility of the highly fluorinated molecule may be low in solvents that can be used in cell
culture, that the purification of the fully conjugated structure from the partially reacted
structures may be di cult, and the fluorescence excitation may be shifted into the UV.
If a suitable compound were designed and these problems were resolved however the use
of molecular structures could be an interesting way to label the cells for dual modal cell
tracking.
As mentioned above, trimodal cell tracking by fluorescence, 1H and 19F MRI would
be more challenging since the gadolinium for the 1H contrast will exert a relaxation-
enhancing e ect on the fluorine groups [272, 276], making them more di cult to detect
with standard MR protocols. There are ultrashort echo time (UTE) sequences [277] which
might resolve this problem, and that could be of interest in future work.
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CHAPTER 6
TRAPPING IMAGING AGENTS IN A
NANOPARTICLE CORE
In this chapter, hollow nanoparticles were created with the aim of encapsulating imag-
ing agents inside the cavity. A range of syntheses were explored for forming the shells,
and the most promising was developed into a trimodal imaging agent for luminescence
techniques, 1H MRI and 19F MRI.
6.1 Introduction
Having explored various other avenues through this work, it was found that a high
loading of fluorine would be necessary in order to detect particles by 19F MRI. There
has been much research on porous structures, such as mesoporous silica nanoparticles,
for trapping imaging agents [169, 278]. It follows however that a larger cavity, such as in
hollow nanoparticles, would be beneficial in order to obtain maximum fluorine loading.
A hollow structure such as this could be modified further with other agents for lumi-
nescence or 1H MRI contrast. This might then prove to be an e ective way of delivering
reliably high concentrations of multiple agents into cells.
Hollow liposomal and polymeric systems have been investigated extensively [279, 16,
146, 150, 147]. While these have advantages such as high biocompatibility and translata-
bility, they tend to be larger and less robust than silica particles due to e ects such as
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Ostwald ripening. A smaller alternative system was therefore sought, as discussed below.
6.2 Overview and system design
The creation of hollow shells were investigated focusing on silica, a robust biocompat-
ible material [280, 281]. There are reports of the permeability of silica, possibly making
the inclusion of mesopores unnecessary for some agents, but the synthesis of both solid
and mesoporous shell structures were explored here, thus potentially allowing for the
introduction of a greater range of imaging agents.
There are many reported techniques for producing these hollow shells, ranging from
homogeneous templating [282], where a solid silica particle is created then the core is
degraded, to heterogeneous templating [283], where an alternative material is used for the
core, which is subsequently removed. The following techniques for synthesising hollow
silica nanoparticles were attempted in this project.
Method 1: Dissolution and regrowth
292 nm hollow particles were reported to be made by dissolving 400 nm solid silica
particles in a borate solution, and their spontaneous regrowth on the surface [284]. The
solid spheres are created by a rapid Stober process which produced highly monodisperse
nanoparticles. A polymer (polyvinyl pyrrolidone) is deposited on the surface and the
nanoparticles are reacted with sodium borohydride in water. The borohydride forms a
borate salt, which aids in the dissolution of the nanoparticles. The dissolved silicates
then redeposit on the surface, regrowing the nanoparticle shell, as illustrated in Figure
6.1. The roughness of the shells is then reportedly controlled by the temperature to which
this solution is heated.
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Figure 6.1: Illustration of the formation of hollow nanoparticles by simultaneous disso-
lution and regrowth. A silica nanoparticle is coated in polymer, the particle is dissolved
and the shell spontaneously reforms.
The aim in this project was to replicate this method but with smaller nanoparticles,
so forming hollow shells of approximately 100 nm.
Method 2a: Latex templating in acid
Silica shells can also be created by a heterogeneous templating method, making the
subsequent removal of the core easier. Silica coated latex beads can be hollowed either
by dissolution of the core in a solvent, or by calcination at a temperature, 550¶C, which
will remove the organic matter and leave the silica intact. This method was therefore
attempted with modifications of reference [285], as illustrated in Figure 6.2.
Amine-modified beads had poly-L-lysine deposited on their surface. Freshly hydrol-
ysed silicate species were then added in acidic solution, which crosslinked to form a silica
shell, catalysed by the poly-L-lysine. The core was removed by stirring with toluene or
dichloromethane. It is worth noting that the poly-L-lysine may still be present in the
silica shell unless the particles are calcined, which may or may not be desirable. This
could be verified in a hollow particle suspension by zeta potential measurements.
The starting silane was varied from the tetraethyl orthosilicate to the tetramethyl
orthosilicate as it was thought that the di erent hydrolysis rates might a ect the shell
formation so reduce the amount of debris.
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Figure 6.2: Illustration of the formation of hollow nanoparticles templated by a latex
sphere. A polystyrene latex bead is coated in polymer, coated in silicic acid. The core
and polymer are then calcined or dissolved away.
Method 2b: Latex templating in base
Amine-modified latex beads may also be coated with silica in basic solution according
to reference [286]. The latex beads are dispersed in an ammonia alcohol solution and the
silica precursor added in the same manner as a Stober synthesis. The latex core can then
be removed as above, by calcining or solvent extraction.
Method 3: Selective etching
Hollow particles can also be created by the selective etching of silica nanoparticles
in a heated basic solution [282]. Solid spheres are created according to a Stober type
synthesis then coated with a shell incorporating C18 chains as porogens. After washing,
particles are etched in base, washed and calcined to remove the C18 chains. This process
is illustrated in Figure 6.3.
Figure 6.3: Illustration of the selective etching of silica nanoparticles. A silica nanoparticle
is coated with organically modified silanes, the core is etched away, and the particle is
calcined leaving a hollow porous shell.
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Loading of imaging agents
The first step in adding imaging functionality to the hollow particles was coating the
surface with gadolinium complexes, producing gadolinium-functionalised hollow nanopar-
ticles (GdHSNPs), In this case the gadolinium complex was the same GdDTPA-APTES
silane that was used in Chapter 4. This would add proton MRI contrast enhancement,
while leaving the core of the GdHSNPs to be filled with other agents.
Loading of imaging agents into the core was then attempted with the most promising
silica shells, as indicated in Figure 6.4. The imaging agents used for the filling must be:
smaller in diameter than the nanoparticle; capable of either being trapped during the
synthesis or being introduced afterwards (e.g. through pores in the shell). They must
also not require interaction with the bulk of the solvent, since they would be limited in
interaction to the contents of the shell.
In this work, PFOB was used as a 19F MRI tracer which is immiscible with water and
has previously been clinically approved. The immiscibility should reduce leakage from the
nanoparticle into aqueous media, and the previous clinical approval is an indication of the
capability for it to be manufactured to GMP standards, and of its bio-inert properties.
Figure 6.4: Illustration of the loading of hollow nanoparticles with imaging agents.
Other design considerations
Using a removable heterogeneous template to form hollow silica nanoparticles has been
investigated in the literature with magnetic [285], calcium carbonate [287] and carbon
[288] nanoparticle templates. These hollow particles tend to be anywhere between 10-200
nm in diameter, depending strongly on the size of the template, with rough surfaces, as
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frequently seen by electron microscopy.
In order to minimise the surface area to volume ratio, hence increasing the volume of
cargo the particle can contain (see Figure 6.5), it is desirable to use larger hollow particles.
This is limited however by the size of particles that cells can internalise readily, and the
associated cytotoxicities, as discussed in Section 1.5.
Figure 6.5: Plot showing the relation between surface area to volume ratio and the core
volume for a range of sphere radii.
Large hollow nanoparticles or microparticles (in the range of 200 nm to micrometers
in diameter) have also been reported [289, 290]. These are often created around latex
bead templates, the polydispersity of which determine the polydispersity of the hollow
structures. At these sizes, the surfaces seem to be more readily controlled, providing the
possibility of smooth solid surfaces or rougher more porous shells as required.
Particles in the range of 100-150 nm in diameter would be interesting vehicles, and
a range of the reported methods were investigated. They have a relatively low surface
area to volume ratio, but may still be readily internalised by the cells. The aim at first
was therefore to create nanoparticles in this size range, and although the final trimodal
particles in this work are larger, the eventual goal would be to reduce the size back to
this range if the loading of fluorinated species were su cient for MRI.
Other design considerations are that the shells should allow the imaging agents to
enter or be trapped, but in this case must also minimise leakage. Design features to allow
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this could include:
• Favourable interactions (hydrophobicity, electrostatic or covalent) to hold the agents
inside;
• Capping of the nanoparticle surface once the agents are trapped;
• Incorporating the agents in a liquid medium that subsequently gels or solidifies,
thus reducing their di usion rate, though this would probably require UTE pulse
sequences for the fluorine MRI.
The first option was used in this work in that a hydrophobic fluorous solvent filled
the shells which were suspended in aqueous solvents, though the other methods could be
interesting avenues for future work depending on the imaging agents of interest.
6.3 Experimental details
Experimental information included here is specific to this chapter. All other details
can be found in the general experimental details section in Chapter 2.
6.3.1 Materials
Octadecyltrimethoxysilane (C18TMS) (90%) was purchased from Sigma-Aldrich (UK)
and warmed to 25¶C prior to use if necessary to ensure the product was fully liquid.
Sodium carbonate (Na2CO3, purum) was purchased from Fisher Scientific (UK).
Polyvinyl pyrrolidone (average molecular weight 58 kDa) was purchased from VWR.
Sodium borohydride (98%), tetramethyl orthosilicate (98%) and poly-L-lysine hydrobro-
mide powder (70-150 kDa) were purchased from Sigma Aldrich.
Aliphatic amine latex beads (0.1 µm, 2% w/v) were purchased from Life Technologies.
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6.3.2 Hollow silica nanoparticle syntheses
The synthetic methods for creating hollow silica nanoparticles are described in this sec-
tion. Various syntheses were attempted by a range of methods: dissolution and regrowth,
heterogeneous templating by latex beads, and selective etching.
Synthesis by dissolution and regrowth
Silica nanoparticles were formed by a modification of the Stober synthesis.
A solution of 2.8 ml of NH4OH (28-32%), 30.6 ml distilled water and 16.6 ml of ethanol
was rapidly mixed with a solution of 4.5 ml of TEOS and 45.5 ml of ethanol. The mixture
was stirred for 6 hours at 800 rpm, but became turbid within minutes.
The nanoparticles were washed by centrifugation and resuspension in ethanol twice
and water twice. The nanoparticles were concentrated to 30 mg/ml by centrifugation and
resuspension. This suspension was split into 10 ml aliquots to test di erent methods of
forming the shell.
One 10 ml aliquot of the nanoparticle suspension was placed in a plastic centrifuge
tube and 600 mg of NaBH4 was added. The suspension was left for 10 days with occasional
shaking to resuspend the nanoparticles.
Another 10 ml aliquot of the 30 mg/ml nanoparticle suspension was used for a more
rapid reaction. The nanoparticles were centrifuged and resuspended in a 2.9% polyvinyl
pyrrolidone solution (291 mg PVP, 58 kDa, in 10 ml of distilled water). 600 mg of NaBH4
was added. A gas evolved rapidly causing foaming. The suspension was transferred to
a 500 ml round bottomed flask and stirred while heating to 50¶C. It was held at this
temperature for 6 hours then washed in water three times.
Synthesis by latex templating in acid
1 M silicic acid was prepared from TEOS by stirring 230 µl of TEOS in 0.01 M HCl
for 20 minutes.
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625 µl of aliphatic amine latex spheres (0.1 µm) were mixed with 10 ml of PBS and 2
ml of 0.1% poly-L-lysine (70-150kDa) in PBS and sonicated briefly. 250 µl of 1 M silicic
acid was then added, and the mixture was stirred for at least 10 minutes. The particles
were washed with water then re-suspended in toluene. The toluene suspension was stirred
for 24 hours, washed into fresh toluene and stirred for a further 24 hours. The particles
were then washed with ethanol three times and water three times, and dried in a glass
vial in an oven.
Surface modification of the HSNPs latex-templated in acid
The HSNPs were prepared as for the plain HSNPs, then resuspended at 10 mg/ml in
ethanol.
Meanwhile 177 mg (295µmol) of APTES-DTPA was dissolved for 30 minutes in 600 µl
of 1 M NaOH. 400µl (200µmol) of 0.5 M GdCl3 in distilled water was added and allowed
to dissolve for two hours. The 250µl (50µmol of Gd) of the ligand solution was then added
to the nanoparticle suspension and stirred over night.
The resulting particles were washed by centrifugation and resuspension in ethanol
three times and water three times.
Synthesis by latex templating in base
1.3 ml of aliphatic amine polystyrene beads, 6.7 ml of water and 40 ml of 2-propanol
were placed in a round-bottomed flask. 1 ml of NH4OH was added, and the pH was
verified as being between 11 and 12. 219 µl of TEOS was added and the suspension was
stirred at 800 rpm for 3 hours. The particles were washed with propanol, then resuspended
in toluene and stirred for 24 hours.
The particles were purified by centrifugation and resuspension in ethanol three times
then water three times.
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Synthesis 1 by selective etching
36 ml of ethanol, 5 ml of deionised water and 1.6 ml of ammonium hydroxide (NH4OH
28-32%) were stirred in a 250 ml round-bottomed flask for 30 minutes. 3 ml of TEOS
were added and the solution was stirred for a further 1 hour, during which it became
turbid.
1 ml of C18TMS and 2.5 ml of TEOS were mixed and added to the suspension, then
stirring continued for a further 1 hour.
The nanoparticles were then washed three times by centrifugation, decantation of the
supernatant and resuspension to the same volume in ethanol. They were finally washed
and resuspended in approximately 100 ml of 0.6 M Na2CO3 and transferred to a 500 ml
round-bottomed flask.
The basic nanoparticle suspension was heated to 80¶C while stirring, and maintained
at that temperature for 30 minutes.
The particles were then again washed in distilled water three times before drying in a
glass petri dish at room temperature or vial in a drying oven.
The dried nanoparticles were calcined for 6 hours at 550¶C in air (ramp rate 5¶C/min)
and allowed to cool to room temperature overnight.
Synthesis 2 by selective etching
The solid and coated silica particles were created as for synthesis 1.
The nanoparticles were then washed three times by centrifugation, decantation of the
supernatant and resuspension to the same volume in ethanol. They were finally washed
and resuspended in approximately 200 ml of 0.6 M Na2CO3 and transferred to a 500 ml
round-bottomed flask.
The basic nanoparticle suspension was heated to 80¶C while stirring, and maintained
at that temperature for 4 hours.
The particles were washed, dried and calcined as for synthesis 1.
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Surface functionalisation of HSNPs produced by selective etching (synthesis
2) with gadolinium
APTES-DTPA was synthesised as in Section 4.2.
88 mg (22 µmol) of APTES-DTPA was dissolved for 30 minutes in 180 µl of 1 M
NaOH. 18.6 mg (50 µmol) of GdCl3 · 6H2O was added and allowed to dissolve for 30
minutes. The ligand solution was then added to a HSNP suspension of 300 mg in 30 ml of
ethanol. The particles were stirred over night at 800 rpm, then washed twice with ethanol
and twice with water by centrifugation at 4000 x g, decantation of the supernatant and
resuspension.
Filling the cores of HSNPs produced by selective etching (synthesis 2) with
ruthenium tris-phenanthroline and PFOB
0.5 mg of [Ru(phen)3](PF6)2 was suspended in 0.5 ml of PFOB by sonication. 225µl
of this suspension was added, in aliquots of 25µl with sonication for roughly ten seconds
after each addition, to 10 mg of dried HSNPs or GdHSNPs in a glass vial. The liquid
appeared to be absorbed by the solid after each addition, with the final addition seeming
to reach the saturation point, thus creating RuPFOBHSNPs or RuPFOBGdHSNPs.
The particles were then suspended in 1 ml of PBS with minimal agitation or sonication.
6.3.3 Hollow nanoparticle characterisation
Light scattering (DLS)
Hollow nanoparticles are not reliably characterisable by DLS, since the calculations
involved rely on the density and optical properties of the sphere, which will be di erent
for nanoparticles of varying shell thickness and composition.
Zeta potential measurements were nevertheless carried out for the sake of comparison
between the charges of the functionalised and non-functionalised surfaces. These were
carried out as detailed in Section 2.2.1.
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Electron microscopy (TEM and SEM)
TEM samples were prepared as in other chapters, as detailed in Section 2.2.2.
For scanning electron microscopy (SEM), samples were placed on an adhesive carbon
pad on a sample stub. The surface was sputter coated under vacuum with gold at 25mA
(Emscope SC500). The preparation was then imaged in a Philips XL30 ESEM-FEG.
Density, luminescence spectroscopy and ICP-MS
The density of samples was measured by helium pycnometry as described in Section
2.2.3. All of the density measurements were carried out by Dr. R. Williams.
Luminescence spectra were recorded as for the other chapters, as described in Section
2.2.5
ICP-MS samples were prepared and analysed as in other chapters according to Section
2.2.4
6.4 Synthesis and characterisation results
Method 1 is a modification of a reported process of dissolving nanoparticles for the
silicate species to redeposit on the surface thus creating shells [284]. The solid nanopar-
ticles were first created with a deliberately low density silica matrix by a rapid form of
the Stober synthesis. The silane molecules are given less time to hydrolyse before being
incorporated, so making the matrix in the core weaker and more susceptible to hydrolysis.
After coating with a stabilising polymer and addition of borohydride, the rehydrolysed
silicate species reportedly deposit on the surface of the particle, thus regrowing the silica
matrix [284]. The method was mainly developed and reported for larger particles. Here
the aim was to modify this method for roughly 100 nm nanoparticles. No hollow particles
were visibly produced however, see Section 6.4.1, so further techniques were explored.
Next hetergeneous templating was tried in order to form the silica shells. Aminated
polystyrene latex beads were coated with silica, structured around poly-L-lysine deposited
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on the latex surface, with the coating step occurring in either an acidic or basic solution.
Using an acidic solution has the advantage of maintaining the stability of the latex spheres,
but requires the shells to be in a basic solution for further functionalisation with metal
complexes. Using a basic solution has the opposite benefits and disadvantages. This
did produce hollow particles, but debris mixed with the particles makes purification dif-
ficult. Modifications to the surface made this problem worse, as shown in Section 6.4.2,
suggesting that the technique would need considerable optimisation to make it feasible.
Hollow nanoparticles were also created according to a selective etching protocol [282].
In a similar way to method 1, a particle is formed with a silica core, but in this case the
surface layer is interspersed with lipophilic areas formed from a silane with an 18-carbon
chain, C18TMS. The less well-condensed core is more susceptible to base catalysed hydrol-
ysis than the surface, allowing the selective removal of the core, followed by calcination
of the C18 chains. This method showed more promising results, so these were developed
as a basis for creating trimodal imaging agents. The particles were surface-functionalised
with gadolinium complexes, and filled with a perfluorocarbon fluorophore suspension.
The synthesis and characterisation of this trimodal imaging agent is described in Section
6.4.3.
6.4.1 Hollow particle synthesis by dissolution-regrowth
Nanoparticles were initially created by a rapid version of the Stober process. According
to reports in [284] they could then be etched by reaction with sodium borohydride, either
at ambient temperature over 10 days or at a higher temperature within an hour.
This is an attractive method because it appears to produce highly regular particles
with a highly controllable shell thickness and core size.
Unfortunately however the results reported in [284] could not be reproduced for par-
ticles with roughly 100-200 nm diameters. The sodium borohydride appeared to have no
e ect, either at ambient temperature, or at higher temperature.
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Light scattering (DLS and zeta potential measurements)
The nanoparticles before the dissolving process had a mean diameter of 160 nm ±
40 nm (by number distribution), or 190 nm ± 44 nm (by intensity distribution), with a
polydispersity index of 0.023. These particles therefore have a corresponding radius 80
nm ± 20 nm. This would be a suitable size to allow for the reduction in diameter seen
during dissolution process in the original article.
The zeta potential was -5 ± 2 mV, which is surprisingly low for a silica nanoparticle,
and possibly due to terminal OEt groups on the surface where the silane was not fully
hydrolysed.
Figure 6.6: DLS intensity (left) and number (right) distributions for the silica nanoparti-
cles prior to the borohydride treatment.
Electron microsopy (TEM and SEM)
Characterisation was principally carried out by TEM to assess the e ectiveness of the
synthesis as this gives a clear outline of the particle and an indication of its morphology.
The particles used as the base structures varied in size, but had a clear solid mor-
phology, as shown in Figure 6.7 with the measured size distribution plotted in Figure 6.8.
The mean radius was 76 nm ± 9 nm based on 398 particles detected in the TEM images,
analysed by the method described in Section 7.1.
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Figure 6.7: TEM image of silica nanoparticles used as the initial particles for the synthesis
of hollow silica nanoparticles by dissolution and regrowth.
Figure 6.8: Histogram of SiNPs’ radii measured from TEM images by automated segmen-
tation. The red line shows the fitted Gaussian distribution.
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These SiNPs were considerably smaller than those in the original article, but formed
by a similar method. Their composition was therefore expected to be similar, so subject
to the same reactions.
After the dissolution-regrowth treatment step the particles contained more debris and
had less well defined morphology, suggesting that a reaction with the silica was occurring.
They did not however appear to contain any cavities, as shown in Figure 6.9.
Figure 6.9: TEM images of silica nanoparticles after the dissolution-regrowth treatment
intended to create hollow SiNPs.
Conclusions
The results reported in [284] could not be reproduced for nanoparticles of roughly 160
nm diameters. The sodium borohydride appeared to have no hollowing e ect, either at
ambient temperature, or at higher temperature. This synthesis was therefore not pursued.
6.4.2 Hollow particle synthesis by latex templating
Polystyrene latex nanoparticles, with poly-L-lysine first deposited on the surface, were
coated with silanes to produce a silica shell. The poly-L-lysine would provide extra
positively charged amine groups for the deposition of the silicate species. The latex core
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was then dissolved away using organic solvents, leaving a hollow silica shell.
The benefit of this method is that the latex templates are available in highly monodis-
perse suspensions, thus creating silica shells with very readily controlled sizes. The tem-
plate can also be readily removed, either by calcination or by dissolution in organic solvent.
While calcination can be more e ective at removing the core than solvents [285], it was
found that, with the quantities handled during these experiments, less of the sample was
lost by the solvent extraction method. If a similar synthesis were scaled up in future work
calcination would be an important route to explore in order to maximise the cavity’s
volume.
Coating in acidic solution: electron microsopy (TEM)
The synthesis was explored using both TEOS and tetramethyl orthosilicate (TMOS) as
silane precursors, pre-hydrolysed in acidic solution for 30 minutes. Characterisation was
carried out by TEM to assess the e ectiveness of the synthesis. The electron microscopy
images of the resultant silica shells after dissolution of the cores are shown in Figures 6.10
(TEOS) and 6.11 (TMOS).
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Figure 6.10: TEM images of HSNPs created by latex templating from TEOS in acidic
solution.
The TEOS HSNPs were found to have a mean radius of 59 nm ± 3 nm. They appeared
to have poorly defined silica shells, making shell thickness determination di cult. There
is also a significant amount of debris present which could not be readily separated from the
nanoparticles during purification. Though this could simply be nanoparticle aggregates,
so potentially capable of trapping PFCs in their core, this would be problematic for cell
uptake. One point to note is that there were no obvious secondary solid particles observed.
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Figure 6.11: TEM images of HSNPs created by latex templating from TMOS in acidic
solution.
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Figure 6.12: Histogram of inner and outer radii of HSNPs created by acidic latex tem-
plating using TMOS, as measured from TEM images.
The TMOS HSNPs were found to have a mean radius of 59 nm ± 3 nm, with a
shell thickness of 15 nm ± 2 nm. The HSNPs made using TMOS have better-defined
shells than above, possibly due to the slower hydrolysis rate of TEOS leading to a lower
concentration of silicic acid than with TMOS. There are also solid silica nanoparticles
visible which would be di cult to separate from the HSNPs. The formation of silica
particles in acidic solution have been reported in other work [291], showing it can be a
common problem with this method and adding considerable challenges to the production
of pure shells.
This synthetic route did reliably produced monodisperse nanoparticles with a relatively
thin shell, with di erent potential options for development through the variation of the
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silanes. If the synthesis could be modified to improve the purity of the nanoparticles for
the TMOS nanoparticles, or to produce smoother shells for the TEOS nanoparticles, this
would be a promising method for producing silica shells. This may be solved by carrying
out the hydrolysis in the presence of the templates, allowing the silicate species to deposit
on the surface immediately and reduce the concentration available for forming secondary
particles. A low concentration layer-by-layer approach may also be e ective.
It is also worth noting that these reactions were carried out on a small scale, and the
scale up of this synthesis could be costly due to the need for monodisperse polystyrene
particles as the template.
Light scattering (zeta potential measurements)
Although dynamic light scattering is a flawed method for analysing hollow nanoparti-
cles so the results should be approached with some caution, zeta potential measurements
were carried out in order to examine the surface charge of the HSNPs created by acidic
latex templating.
The particles were found to have a surface charge of 36 ± 0.4 mV. This positive surface
charge is to be expected due to the poly-L-lysine embedded in the shell, and would be
potentially beneficial for uptake of the HSNPs by cells. One consideration for future work
is that this advantage might be removed by calcination if it were used instead of solvent
extraction to remove the core.
Surface modification of latex-templated HSNPs: electron microscopy (TEM)
As the most robust in appearance of the latex-templated particles, the TMOS-coated
HSNPs were selected for treatment with GdDTPA-APTES in order to add proton MRI
contrast enhancement.
As can be seen in Figure 6.13, functionalising the surface of the latex templated HSNPs
with further silanes has, in this case, degraded the morphology of the particles. While
hollow structures are still clearly visible, the edges appear to be much rougher, with some
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possibly fused together.
Figure 6.13: TEM images of HSNPs created by latex templating from TMOS in acidic
solution, then functionalised with gadolinium functionalised silanes.
This synthesis was therefore not pursued, though it could have been an interesting
alternative avenue.
Coating in basic solution: electron microscopy (TEM)
This synthesis was attempted as an alternative route to the acidic latex templating
method described above. Shells here are also templated by the latex beads, but with the
reaction solution basic, and similar in composition to the Stober synthesis.
The electron microscopy images are displayed in Figure 6.14.
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Figure 6.14: TEM images of HSNPs created by latex templating in basic solution.
The nanoparticles produced by this method distinctly resembled standard Stober silica
nanoparticles rather than Hollow nanoparticles. No other structures such as collapsed
silica shells were found. Modification of the image intensities revealed no further structures
either.
The latex beads used did recommend maintaining a neutral to low pH medium for
the particle suspension, so the templates may have collapsed before the silica could be
deposited. This synthesis was not pursued further.
Conclusions
HSNPs were readily formed when templated in acidic solution, although the method
has some disadvantages. One in particular is that the synthesis of a gadolinium function-
alised version could not be performed without washing the particles, since the gadolinium
will be released from the complex at low pHs. This adds considerable time and material
costs since there is often a loss of material during the washing steps. Another disadvan-
tage is the cost of the latex beads, which limits the scale of the reaction and which are
unrecoverable.
These methods would be of interest for further work however if various problems
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could be overcome. The main challenges are the purification from debris, or minimising
the aggregation of the particles, as well as the optimisation of the particle coating process,
which would ideally lead to discrete and smooth particles. In view of this other syntheses
were explored.
6.4.3 Hollow particle synthesis by selective etching
Silica nanoparticles as sacrificial templates were created by the Stober method, then
coated with a co-condensed mixture of silanes, thus incorporating porogenic C18 chains.
The core was etched away in 0.6 M Na2CO3 for 30 minutes at 80¶C leaving a silica
shell, with hydrophobic regions on the surface. The C18 chains were then removed by
calcination, leaving hollow porous silica shells.
This method is attractive because it uses only silanes to form the shell, avoiding the
need for additional surfactants, polymers or a heterogeneous core. Hollow nanoparti-
cles were formed using this synthesis which were further developed into proof-of-concept
trimodal imaging agents for fluorescence, 1H MRI and 19F MRI.
Synthesis 1: electron microsopy (TEM)
Characterisation was carried out by TEM to assess the e ectiveness of the syntheses.
Hollow nanoparticles were produced, though with a varying size distribution, see Figure
6.15.
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Figure 6.15: TEM image of HSNPS created by selective etching by synthesis 1.
It was however unreliable in producing these results reproducibly. An example of the
incomplete etching is illustrated in Figure 6.16. A range of etching results, from solid
particles and rattle-type particles to hollow nanoparticles, can be seen. There is also a
significant amount of debris present. This would be unacceptable for progress towards
clinical use, and would lead to ine cient loading of imaging agents.
Figure 6.16: TEM image of HSNPS created by incomplete selective etching by synthesis
1.
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Synthesis 2: electron micropscopy (TEM and SEM)
Another article [292] by some of the same authors as for synthesis 1 [282] details a
slightly modified version of the selective etching synthesis used above. The most significant
di erence was a longer etching time being used and a stated etchant volume, and two
concentrations of etchant were investigated.
The particles were also formed with greater diameters in order to verify the method
according to the original procedure. The electron microscopy images from these parti-
cles before and after calcination are presented in Figures 6.17 and 6.19 respectively (for
particles hollowed in 0.6 M etchant). The contrast in all these figures has been altered
for clarity, causing noticeably reduced background noise. This has been necessary due to
the size of the silica shells leading to a higher volume of silica being present, and hence a
greater attenuation of the electron beam.
Figure 6.17: TEM image of HSNPS created by selective etching by synthesis 2 before
calcination.
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Figure 6.18: Histograms of the inner and outer radii of the HSNP shells, based on 127
particles.
The uncalcined particles have well defined morphology and a limited amount of debris
present. The outer mean radius was 315 nm ± 18 nm, and the inner radius was 235 nm
± 43 nm, giving a shell thickness of 80 nm.
There are some solid 81 nm ± 19 nm (based on 28 NPs) secondary particles present,
though these were not as obviously widespread as in the following modifications to the
particles. This could be due to the solid particles being trapped in aggregates; this is
discussed further below.
There are dark areas visible in the image, and the presence of debris in these areas
cannot be ruled out. Examining some of the dark areas did however show that at least
some of these are composed of hollow silica nanoparticle aggregates, since the same pat-
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terns of overlaid circles could be seen with extreme alteration of the contrast. Aggregates
could be expected in this uncalcined sample since the particles have hydrophobic surfaces,
and are suspended in water for the TEM sample preparation.
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Figure 6.19: TEM image of HSNPs created by selective etching by synthesis 2 after
calcination.
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After calcination fewer large aggregates were visible, see Figure 6.19, and the HSNPs
tended to be in small generally flat clusters, as shown in the top images. The smaller
clusters allow closer analysis of the debris present, which mostly consists of small solid
particles. Some of these appear to be closely associated with the surface of hollow particles,
where they might have been seeded. This is indicated partly by the multiple small dark
areas on the particles visible at the bottom of the fifth image, and the ‘raspberry-like’
e ect on the particle in the second image.
The radius of these particles has reduced somewhat during the calcination process,
measuring 258 nm ± 11 nm with a shell thickness of 87 nm ± 14 nm (based on 85
HSNPs) after calcination.
These particles were also analysed by scanning electron microscopy (SEM). The aims
were to confirm their hollow character, examine the surface morphology, and to determine
the nature of the aggregates visible by TEM.
The hollow nature of the particles can be seen by examining broken particles, as shown
in Figure 6.20, where a clear cavity is visible inside the broken shells.
Figure 6.20: SEM image of HSNPs showing the hollow cavity in broken particles.
The surface morphology can be seen in Figure 6.21, which shows a more representative
proportion of broken to non-broken particles (the majority appeared to have whole shells).
There is some roughness on the surface, as would be expected for a porous surface with an
etched core, though some of this could also be due to the sputter coating. The roughness
is similar to that observed in SEM images from the original article [282].
186
Figure 6.21: SEM image of HSNPs showing the rough surface morphology.
The aggregates visible only as dark areas by TEM are seen by SEM to be aggregates
of spherical particles, as seen in Figure 6.22. Though the largest aggregates could not be
imaged due to charge build-up causing local image noise, the aggregates shown here would
not have been characterisable by TEM. It is worth noting that none of the large particles
observed by TEM were solid, suggesting that the vast majority of the large spheres seen
in Figure 6.22 will be hollow particles.
Figure 6.22: SEM image of HSNPs showing the surface morphology of the clusters of
particles.
Another point to note is that small particles, often located on the surface of the large
hollow particles, are visible in these images as in the TEM images. Though they are less
prevalent than the large particles, they could a ect the bioactivity of the system, and
thus would need to be purified if possible, or ideally eliminated through optimisation of
the synthesis. This would be a crucial point to be addressed in future work.
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A long etching time of 3 hours and a higher concentration of etchant (1.2 M NaHCO3)
was also explored. This produced particles which were clearly hollow from the TEM
images, though some smaller particles are still visible, see Figure 6.23.
Figure 6.23: TEM image of HSNPs created by selective etching using synthesis 1 but with
a higher concentration etchant (1.2 M).
There is little obvious di erence between the HSNPs produced by the di erent con-
centrations of etchant, though further characterisation would help clarify the di erences
if it became of interest. For example SEM would help determine the surface morphology,
and nitrogen absorption or helium pycnometry would indicate the density of the shell
walls. For the purposes of this work however the HSNPs hollowed with 0.6 M etchant
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were investigated further as they appeared to be similar while less debris (in the form of
secondary particles) was visible when compared to the 1.2 M etched HSNPs.
Surface modification of the HSNPs: electron microscopy (TEM and SEM)
The HSNPs created by synthesis 2 with 0.6 M etchant were coated with GdDTPA-
APTES, a gadolinum functionalised silane. The resulting GdHSNPs were examined by
TEM and SEM.
After the gadolinium modification the particles are still spherical and hollow, with an
outer radius of 266 nm ± 16 nm and a shell thickness of 92 nm ± 18 nm, as would be
expected from the extra silanation step. They do however have a greater predominance of
debris visible. The particles also seem to be thicker in terms of the beam attenuation since
a change in the contrast was necessary for showing the hollow character of the particles
(rather than preferable for clarity as above). Characteristic images are shown in Figure
6.24, and the corresponding histograms are in Figure 6.25. The lower images show the
original image on the left, where the debris is seen to be solid spherical particles, and the
contrast-adjusted images are on the right showing the hollowness of the large particles.
One of the HSNPs in the bottom images appears to have a hole in the surface, where
there is an area of higher intensity, supporting the assertion that these are hollow spherical
particles.
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Figure 6.24: TEM images of GdHSNPs. The original images are shown on the left, while
the contrast enhanced version showing the hollow cores are on the right.
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Figure 6.25: Histograms of the GdHSNP inner and outer radii as measured from TEM
images.
These particles were also analysed by SEM after the gadolinium functionalisation
step. The aim was to observe any consequent changes in the particles and their surface
morphology. Figure 6.26 shows characteristic SEM images of the GdHSNPs. The spheres
are still clearly distinct from each other with a spherical morphology. Some are broken
but most have no visible holes.
The surface modification appears to have made the surface rougher, with more promi-
nent bumps, as shown in Figure 6.26. These could be nucleation sites for further particle
growth.
Some of the breaks in the nanoparticle shells have more irregular morphologies than
the non-functionalised particles. These could be an indication of the holes being closed by
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further functionalisation. This is particularly of interest as further work on these particles
could consist of capping the particles in order to minimise leakage of loaded imaging
agents. An interesting computational aspect of future work would also be to automate
quantifying the holes in the particles, though this would not be a trivial challenge.
Figure 6.26: SEM images of GdHSNPs.
Light scattering (zeta potential measurements)
Light scattering measurements were of limited use for the hollow nanoparticles since
the calculation of the size distribution depends upon the particle being a homogenous
material with a known refractive index and dielectric constant. With hollow nanoparticles
the scattering of the shell and the core will be di erent, producing overall unreliable
results.
Zeta potential measurements are also flawed for the same reasons as sizing calculations.
Measurements were nevertheless carried out for the HSNPs and GdHSNPs created by
selective etching (synthesis 2 with 0.6 M etchant). Values are provided for comparison
purposes as the change in the zeta potential, see Table 6.1, gives an indication of the
successful surface coating.
NPs Mean zeta potential (mV) Standard deviation
HSNPs -35.1 0.833
GdHSNPs -5.07 0.52
Table 6.1: Zeta potential measurements for HSNPs and GdHSNPs.
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These numbers are as expected considering the more neutral layer presented by the
GdDTPA complexes than by the terminal silanol groups. The reduction in zeta potential
does however suggest that the GdHSNPs should be considerably less stable in suspension
than the HSNPs since a higher surface charge enables colloidal stability. A further devel-
opment of these particles would therefore involve finding a balance of functionalisation to
tune the surface charge while maintaining water access to the gadolinium ions.
Density
The density of the shell walls of the HSNPs and GdHSNPs, both created by selec-
tive etching (synthesis 2 with 0.6 M etchant), were measured by helium pycnometry as
described in Section 2.2.3.
The HSNPs had a shell wall density of 2.9 g/ml, with a standard deviation of 1.2
g/cm3. The GdHSNPs had a lower density of 1.46 g/cm3, with a standard deviation
of 0.003 g/ml. Both of these values fall outside typical ranges for silica nanoparticles,
which are reported in the range of 1.9 - 2.2 g/cm3 [293, 72]. Some drop in density due
to the surface modification would not be surprising since the incomplete hydrolysis of
silanes during a Stober-like process would lead to a less well ordered matrix. The extent
of this reduction is however unexpected, and suggests a very low density addition to
the composition of the particles, or a structural change in the shells during the surface
modification.
Binding of gadolinium
The concentration of gadolinium in dissolved GdHSNP samples created by selective
etching (synthesis 2 with 0.6 M etchant) was measured by ICP-MS. An average of 59,3
mg (Gd)/l, with a standard deviation of 43.13 mg/l was found from triplicates of each
samples. This corresponds to a mean of 0.38 mM gadolinium, with a standard deviation
of 0.27 mM.
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Luminescence
The HSNPs created by selective etching (synthesis 2 with 0.6 M etchant) were infused
by sonication with [Ru(phen)3]+2 suspended in PFOB. These RuPFOBHSNPs were then
suspended in PBS for further analysis.
The luminescence excitation and emission spectra of the RuPFOBHSNPs are presented
in Figure 6.27, along with the spectra of [Ru(phen)3]+2 for comparison.
Figure 6.27: Luminescence excitation and emission spectra of RuPFOBHSNPs and
[Ru(phen)3]+2 for comparison.
The excitation spectrum of the RuPFOBHSNPs shows greater than 95% excitation
between 415-455 nm. The [Ru(phen)3]+2 excitation spectrum has two more distinct peaks,
with maxima at 369 and 468 nm.
The RuPFOBHSNPs have a broad excitation range, making them suitable for excita-
tion by 405 nm or 458 nm light sources.
The emission spectra show broadening on the [Ru(phen)3]+2 being suspended in PFOB,
with the emission maximum shifting from 590 nm for the free dye to 609 nm for the trapped
dye.
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1H MRI contrast enhancement
MRI was carried out on aqueous suspensions of GdHSNPs alongside water and gadolin-
ium complex (Primovist) controls in order to determine the sample relaxation rates. An
image and diagram describing sample placement is shown in Figure 6.28.
Figure 6.28: (Left) MRI image of GdHSNPs alongside gadolinium controls and water
controls. (Right) Diagram showing the corresponding placement and concentration of
samples, with water samples down both sides, gadolinium controls of decreasing concen-
tration down the central left column, and GdHSNPs of decreasing concentration down
the central right column.
It might be noted that the image above only shows clear contrast from the gadolinium
controls. The relaxivities obtained from the series of images however indicate that there
is concentration-dependent contrast enhancement from the GdHSNPs.
Direct comparison of the relaxation rates suggests that the gadolinium concentration
of the GdHSNPs at 10 mg/ml is roughly 0.3 mM. This agrees with the ICP-MS data
which indicates that it is 0.38 mM.
The relaxivity plots are shown in Figure 6.29. The slopes of the fitted lines indicate a
relaxivity of 7.64 mM≠1s≠1 for the Primovist controls and 5.04 mM≠1s≠1 for the GdHSNP
samples.
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Figure 6.29: Plot of the relaxation rate against the gadolinium concentration in the
GdHSNP and gadolinium control samples. the water is plotted as if it had the same Gd
concentrations for comparison. The slopes of the lines give the corresponding relaxivities.
The relaxivity of the GdHSNPs is therefore in the same range as the clinically available
contrast agents. Given the similar structure of the complex, this is not surprising, though
there appears to be no significant increase due to the slowed tumbling, as could be hoped.
The tumbling rate however is likely to vary once the nanoparticles are filled and in a
stable suspension, so this may vary as the particles develop.
Both HSNPs and GdHSNPs were filled with a [Ru(phen)3]+2 PFOB suspension by
sonication of the dry particles with the suspension, and the relaxation times measured.
Unfortunately however the particles were insu ciently stable when suspended in PBS to
allow reliable imaging. The particles were therefore suspended in gelatin as an initial
indication of what the contrast enhancement would be if they could be stabilised. The
relaxivity is illustrated in Figure 6.30.
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Figure 6.30: Plot of the relaxation rate against the gadolinium concentration in the RuP-
FOBGdHSNPs. The RuPFOBHSNPs, which contained the same weight of nanoparticles
before filling, are plotted as if they had equivalent Gd concentrations for comparison, The
slopes of the lines give the corresponding relaxivities. Two trendlines are shown for the
RuPFOBHSNPs data, one excluding the lowest concentration point (see main text for
reasoning).
The slopes in Figure 6.30 indicate a relaxivity of 0.20 mM≠1s≠1 for the RuPFOBHSNPs
and 2.91 mM≠1s≠1 for the gadolinium functionalised RuPFOBGdHSNPs. The di erence
between them is to be expected due to the presence of the gadolinium in the latter. The
data does not fit well with the trend line for the RuPFOBGdHSNPs. This was a prelimi-
nary experiment however, and there may have been an inhomogeneous distribution of the
nanoparticles in the gelatin for the lowest concentration sample resulting the relaxation
rate similar to those with no Gd. If this sample result is excluded therefore a relaxivity
of 1.09 mM≠1s≠1 is obtained.
While either of the relaxivities for the RuPFOBGdHSNPs are unexpectedly low com-
pared to the unfilled nanoparticle, with a reduction in the relaxivity from 5.04 to 1.09
mM≠1s≠1 (in the worse case), some important points should be noted.
There are multiple sources of possible error: the surfaces of the particles may not be
uniformly coated as suggested by the variation in the ICP-MS results (see Section 6.4.3)
the sample may not have been uniformly distributed in the gelatin, as noted above from
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the seemingly anomalous result for the lowest concentration RuPFOBGdHSNP sample;
there may be partial volume e ects in the MRI measurements if small air bubbles were
present in the gelatin. No bubbles were clearly visible, but this should be taken into
consideration.
The relaxivity for the RuPFOBGdHSNPs is of the same order of magnitude as clin-
ically approved gadolinium agents, but is distinctly lower than the particles’ unfilled
equivalents, as measured above. This could be due to the need to suspend the particles in
gelatin when filled, which could a ect the movement of the particles. It could also be due
to the limited colloidal stability of the particles which may result in them clustering and
hence not tumbling as readily. The unfilled GdHSNPs also has a low surface charge as
found by zeta potential in Section 6.4.3. There could therefore by a wetting e ect, with
the PFOB covering the outside surface of the particles as well as filling the cores. This
would explain the low colloidal stability, which is more severe than that seen with the
unfilled GdHSNPs. It would also result in reduced water access to gadolinium complexes,
which would explain the lower relaxivity.
There is nevertheless a clear di erence in the relaxation rates between the Gd function-
alised RuPFOBGdHSNPs and the non-functionalised RuPFOBHSNPs. While this should
be reproduced in future work, this lays the groundwork for a promising and versatile 1H
MRI contrast agent.
19F MRI signal in dual modal nanoparticles
Having created these trimodal particles, RuPFOBGdHSNPs, the aim was to assess
whether they could be imaged by both 1H and 19F MRI, and to identify any challenges
facing this process. 10 mg of GdHSNPs and 10 mg of HSNPs were therefore again filled
with the perfluorocarbon PFOB followed by suspension in PBS. Gelatin was added again
at 10% w/v to maintain the suspension. The [Ru(phen)3]+2 was excluded here however
to avoid any e ects it may have, though none are anticipated. These PFOBGdHSNPs
and the corresponding particles with no gadolinium bound to the surface, PFOBHSNPs,
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were imaged by two modes of MRI: 1H MRI and 19F MRI.
The sample images are presented in Figure 6.31 with the HSNP samples indicated
with arrows. The surrounding samples are control samples containing gadolinium (the
small samples on the right) and trifluoroethanol (the smaller samples on the left). The
large circles are tubes of water added to aid in localisation in the scanner.
The gadolinium samples were not all clearly visible in the same slice as the HSNPs
due to the sample containers being of di erent heights. This slice shown in on the left
of Figure 6.31 was selected to illustrate the clear di erence between the PFOBGdHSNPs
and the PFOBHSNPs in the 1H MR image.
Figure 6.31: 1H and 19F MR images of PFOBHSNPs and RuPFOBGdHSNPs; the samples
are indicated with green arrows.
The location of the TFE samples on the left of the slice shows the relative location of
the PFOBHSNP samples. The HSNP samples themselves are slightly overlapping due to
chemical shift artefacts, which PFOB is susceptible to producing. A simple SNR analysis
of the 19F image however shows a clear di erence in mean intensity between the two HSNP
samples. A plot of the SNRs of the TFE samples is shown in Figure 6.32, and the HSNP
SNRs were mapped onto this line to back calculate an estimate of the concentration.
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Figure 6.32: Plot of the mean intensity of the trifluoroethanol samples against the sample
concentration (blue diamonds), and the calculated concentrations of the PFOB in the
PFOBHSNP samples.
The PFOBHSNPs theoretically contain 0.87 mM PFOB based on the volume of PFOB
added. Back calculation estimates a concentration of 0.86 mM, and incomplete trapping
of the PFOB or low levels of leakage can readily explain the di erence between the two
values. The PFOBGdHSNPs however showed a much lower SNR, despite having been
loaded with the same volume and concentration as the others.
A number of factors could be involved in this observation. The gadolinium on the
surface may be exerting a paramagnetic relaxation e ect on the fluorine. Since the echo
times used in this sequence are too long to detect rapidly relaxing fluorine, these atoms
would appear to be quenched, leading to a loss of signal. This theory is supported by
a similar system, which was reported during the preparation of this thesis: a complete
signal quenching of a perfluorocarbon nanoparticles was claimed to be due to gadolinium
relaxation enhancement [294].
There is a further consideration in this project, which is that the gadolinium func-
tionalisation may be shrinking the nanoparticle surface pores, and therefore allow lower
PFOB uptake in some particles. This could be tested in future work by the removal of
the gadolinium ions in acidic solution after initial imaging to observe any restoration of
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the signal.
This proof-of-concept experiment indicates that this dual modal imaging can be carried
out with these nanoparticles.
This experiment also highlighted various challenges. The slice size and thickness could
not be copied between the 1H and 19F MRI protocols used here. If this were possible,
perhaps by careful selection of the sequences and various parameters involved, the process
of co-registering the images would be trivial. On the other hand if, as may be more likely,
this is a systematic problem, there would need to be robust co-registration algorithms
in place before this technique could be considered clinically. This problem is made more
di cult by the ‘hotspot’ nature of the technique, which would mean that suitable fiducial
markers would need to be included in both scans for co-registration to succeed. With a
surface coil of limited depth penetration this could be challenging to overcome, since any
inclusion of extra vials, for example, would necessarily entail a lower penetration to areas
in the body of interest, and therefore lower sensitivity of an already insensitive technique.
6.5 Conclusions
Hollow silica nanoparticles have been shown to form an excellent vehicle for multiple
imaging agents. The surface functionalisation combined with the inner cavity can sep-
arate agents that have negative interactions while simultaneously forming a multimodal
nanoparticle. They are moreover highly versatile in that the imaging agents could be
swapped for suitable alternatives.
Di erent syntheses were attempted to create the hollow shells. The most e ective was
found to be the method of selectively etching the silane core from a porous shell. It was
noted however that careful control of the conditions was necessary, especially in terms of
the base etchant volume to nanoparticle ratio.
Other syntheses resulted in considerable amounts of amorphous material and some-
times no hollow shapes could be found. The method of using a latex bead as a template,
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while expensive due to the cost of the latex beads, provided highly uniform sizes of shells.
These may be preferable for clinical development than the selective etching particles, since
the Stober synthesis of the templates naturally results in some polydispersity. In this work
however the amorphous material was not readily separable from the nanoparticles, and
therefore was considered too problematic too pursue. If this could be resolved by modi-
fication of the conditions or suitable purification in future work then this method would
be very attractive.
Trapping in nanoparticle cores can therefore be considered a valuable tool for the
delivery of imaging agents. The hydrophobicity of the perfluorocarbon was used in this
case to maintain the trapping. There is no reason however why other hydrophobic liquids
and suspensions should not replace the perfluorocarbon in further work, thus increasing
the range of agents or drugs that could be transported in the core. Similarly, the sur-
face functionalisation of these hollow particles was used to create proton MRI contrast.
They could however be modified to carry luminescent complexes to provide multicolour
luminescence.
Another aspect that would be of interest in future work would be to consider capping
the nanoparticles, either with more silane, or possibly with a heterogeneous layer of gold,
for example. Using a metal or a hydrophobic material could be beneficial as it would
create a less permeable barrier to leakage, though in this case a further hydrophilic layer
would be necessary to allow cell treatment. Similar work has been carried out with
solid particles [295, 296], and the techniques from layer-by-layer assembly [297] mean this
process could be finely controlled.
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CHAPTER 7
IMAGE ANALYSIS METHODS
This chapter describes the image analysis that has been carried out on the TEM and
MRI data during this project. The processes and algorithms involved are discussed.
7.1 Automated particle sizing from TEM images
In order to extract meaningful information from transmission electron microscopy
(TEM), many particles must be imaged, ideally from di erent locations on the sample
grid. According to the National Institute of Standards and Technology at least “200 dis-
crete particles should be measured from each of at least two widely separated regions of
the sample.” [298]. The analysis of these images could be carried out by hand. That is, if
investigating the size of nanoparticles, each circular shape could be delineated manually
and the diameter measured. This can however be a lengthy task considering the number
of nanoparticle measurements necessary, so the automation of detection of the nanopar-
ticles’ edges, and hence their size, is a useful tool. As well as the time benefits, it also
adds consistency and removes bias, depending only on the images themselves rather than
experimenter’s perception.
This problem usually breaks down into two components; edge detection in order to
threshold a greyscale image, thus delineating the nanoparticles, and circle detection in
the binary image in order to model and recognise the shape of the nanoparticles, thus
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finding their sizes.
Two methods were implemented in this project. Particular challenges arose from
overlapping nanoparticles, where there is not a whole circle to be detected, only an arc,
and hollow nanoparticles, which made both the edge detection and circle detection more
complex.
7.1.1 Background and overview
In TEM images where there is high contrast between the nanoparticles and the back-
ground, simple thresholding is often su cient to segment out the ROIs. From a binary
image, tools such as ImageJ’s Analyse Particles function can often be su cient to extract
information on the particle sizes and circularities. Alternatively, particles can be manu-
ally delineated, and the size of the selections analysed. These are simple methods, though
time consuming in the latter case. Their perception of being trivial may help to explain
why very few papers state the method used for their TEM image analysis.
It was found during this project however that particles were sometimes not readily
segmented by simple thresholding, either due to low contrast, rough edges, varying back-
ground (though this was generaly rectified at the imaging stage), or hollow structures.
Since manual delineation of the particles would be time consuming and subject to user
bias, more complex algorithms were explored in order to move towards automation of the
measurement.
The first method used was rapid circle detection (RCD), as described in reference
[299]. The second, referred to as compass gradients edge detection (CGED) involves more
sophisticated edge detection, using the vertical, horizontal and diagonal gradients of the
image.
The RCD method is a heuristic which has considerable advantages over methods such
as the circular Hough transforms in terms of processing power and memory e ciency
[299]. This primarily addresses the circle detection problem, and was initially combined
with simple Sobel edge detection, as implemented in Matlab.
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The second method developed improved the edge detection part of the process. Sobel
edge detection is based on convolution with vertical and horizontal gradient kernels, so
detects vertical and horizontal lines readily, but is less suited to circular shapes. In order
to cover more of the circle perimeter, eight points of the compass were used, adding the
diagonals to the analysis.
It was noted that information on the direction of the gradient, as well as its magnitude,
would be of use, since the gradients would converge on the centre of the circle. A Robinson
compass type kernel [300] was therefore used as a basis for the image analysis.
Both algorithms aided in the detection of the nanoparticles, and were therefore com-
bined for the analysis of the TEM images presented in the previous chapters.
The methods are discussed in detail below.
7.1.2 Algorithm I: Rapid circle detection (RCD)
Rapid circle detection (RCD) uses basic edge detection to distinguish the edges of the
circle. Random points selected from the edges are then tested for co-circularity. If the
points then meet certain other criteria, the circle is counted as a distinct nanoparticle.
This approach has the advantage that arcs can also be detected, so overlapping
nanoparticles should therefore not be problematic. It is also relatively rapid to run,
as the calculation is running based on four coordinates rather than a whole image.
Algorithm
The images are smoothed using a Gaussian filter. A threshold level is calculated by
Otsu’s method [301], and the intensity threshold used to segment out the nanoparticles.
The edges of the nanoparticles are then detected using a Sobel operator.
Circles in the image of the edges are then distinguished by a modification of the
method proposed in reference [299]. An edge pixel, v1, is randomly selected, and the set
of other edge pixels within a threshold distance calculated. Two other pixels, v2 and v3,
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are randomly selected from the subset, and the centre of the circle formed by these three
pixels is calculated. A fourth pixel, v4, is also randomly selected from the subset, and
tested for co-circularity, as illustrated in Figure 7.1.
Figure 7.1: Image illustrating the algorithm requirements of co-circularity for circle de-
tection.
If v4 does not fall on the perimeter of the circle the subset is re-tested a certain number
of times, proportionally to the number of edge pixels contained in it.
If v1-4 all fall on the perimeter of a circle, the number of other edge pixels approxi-
mately close to the perimeter of the circle is determined. This number is compared to the
number of pixels expected to lie there in order to ensure the presence of at least an arc.
Circles are accepted if they satisfy the following criteria:
• All 4 pixels are on or close to the edge of the circle;
• The radius is above a minimum threshold;
• There is a high proportion of the expected number of perimeter pixels present;
• The centre of the circle is within the image.
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If any further circles are selected which have a centre close to one that has already been
accepted, the one with the higher proportion of expected edge pixels present is retained.
This process is repeated until failure thresholds are met; these consist of a certain
number of failed attempts at finding circles, or too few edge pixels being left in the
subset.
The sizes of the detected circles from all the images are aggregated, presented as a
histogram, and the mean and standard deviation of the values are returned.
Some user bias can be removed by setting the threshold distance for the subset of edge
pixels around v1 to a very high value. Using a lower threshold can however speed up the
algorithm as there are fewer edge pixels to test with, and those in the subset are mire
likely to be relevant.
Testing
With real data where the nanoparticles are well contrasted with the background and
well defined, this analysis detects 89% of the nanoparticles when run on single images
(tested 3 times each on 4 images), and 86% when run on a stack of 10 images (run 3 times).
Nanoparticles were considered to be detected if, by inspection, the same centre would have
been selected if the process were carried out manually. The details are summarised in
table 7.1. An example of a typical image with the detected circles and the resulting
histogram is shown in Figures 7.2 and 7.3.
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Figure 7.2: Image illustrating stages of the algorithm being used on real data: the
smoothed image (left),the binary image (centre), and the results of the RCD detection
(right).
Images analysed
per run
Time taken
NP detection
sensitivity
False positives
1 7.52s 89.03% 2
10 71.90s 86.20% 3
Table 7.1: Results of testing the RCD algorithm on real data. The values for 1 image (top
row) are a mean of the results from three runs, each carried out on 4 di erent images.
The values for 10 images are a mean of the results from three runs using a stack of 10
images.
With su cient nanoparticles visible in the TEM images, reliably detecting 86% of the
particles would give a reasonably accurate representation of the size distribution.
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Figure 7.3: Typical image with the centres of the detected circles overlaid as blue crosses.
Figure 7.4: Histogram of the detected circles’ radii.
This algorithm does however have some flaws, as illustrated in Figure 7.5.
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(a) Detecting empty areas. (b) Not detecting overlapping areas.
(c) Detecting two circles as one.
Figure 7.5: Illustrations of problems with the RCD algorithm.
1. False positives can arise when nanoparticles are arranged so that there is a similarly
sized gap between them (see Figure 7.5a). This could be minimised by selection of a higher
minimum radius threshold, but this risks losing true positive smaller particles, so biasing
the distribution. It could also be solved by increasing the threshold for the proportion
of expected pixels present. This however risks the non-detection of overlapping or non-
spherical particles.
2. Overlapping particles are sometimes however still not detected, especially when
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they fall in a row, as in Figure 7.5b with significant overlap. This is attributable to the
edge detection, which does not detect the edges of the overlap.
3. False positives can also occur when multiple particles fall within the range of allowed
radii (which should be large to avoid bias). This occurs especially when there are other
suitably placed nanoparticles that can provide extra edge pixels, as seen in Figure 7.5c.
In conclusion, this method can provide e ective circle detection provided with suit-
able images and parameter selection. It could be improved with extra information being
extracted from the image. This is addressed by the following algorithm, which examines
the intensity gradients.
7.1.3 Algorithm 2: Compass gradients edge detection (CGED)
Standard edge detection using gradients often only uses the horizontal and vertical
intensity gradients of the image. For circular structure detection however more complex
analysis is desirable to allow for more rounded structures [300]. This method also has
the advantage that the gradient directions should be symmetrical, in that both opposite
edges of the nanoparticle will exhibit a similar and inverse gradients.
Algorithm
Using the eight points of the compass as opposed to just the four has been proposed
as a method for edge detection [300]. Gradients along the horizontal, vertical and both
diagonals are examined for both their magnitude and direction. This is achieved by
convolution of the smoothed image with a rotating 3x3 kernel, with the direction of each
kernel pointing in one compass direction, as shown in Figure 7.6. The result is maps of
the gradient magnitude and gradient directions, as shown in Figure 7.7.
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Figure 7.6: Robinson kernels for edge detection
The gradient magnitude image already produces useful information on the location of
the edges. With an applied threshold, the magnitude image can act as a mask to limit
the interference of noise in further processing. The gradient direction image can however
also be used to direct the circle detection. For any increasing gradient there should be a
corresponding decrease in the gradient with equal and opposite direction. A composite
image is therefore formed from the magnitude and direction images that incorporates
both sets of information, as illustrated in Figure 7.7.
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(a) Original image
(b) Components of the composite image
Figure 7.7: Illustration of the results of convolution with the compass-gradient kernels,
decomposed into magnitude and direction, then recombined.
Projections are then taken along each compass direction through the composite image,
e.g. Figure 7.8. Whenever two corresponding (equal and opposite) gradients are detected
along the projection, the centre point is calculated and the size noted. When the four
directions are combined these central points form star shapes, with the lines crossing at
the centre of each circle.
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Figure 7.8: Illustration of projections taken across the composite image (left), the con-
sequently detected central points in one direction (centre), and the resulting NP centres
from combining the four directions.
Once tidied up using mathematical morphology and control criteria the circles in the
image are characterised, and a histogram of the sizes can be produced, such as in Figure
7.9.
(a) Original image (b) Histogram of detected nanoparticle radi
Figure 7.9: The results of the CGED algorithm, showing the original image and the
histogram of radii obtained.
Testing
With the use of real data, it was found that the method worked reliably on clean
images consistently as shown in Figure 7.9. Certain flaws in the method were noted with
less ideal images.
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When the particles imaged are of more irregular shapes, the algorithm produced less
reliable results, as shown in Figure 7.10. Multiple particles can be counted as one particle
and small particles are detected which are probably only due to roughness in the particle
surface. The cause of this can be seen in the noisier gradient direction image, since the
edge gradients will not be as well defined with irregular shapes.
Figure 7.10: Problems with the CGED algorithm when tested with more compex data
(original image, with the detected circles marked in blue, and problems highlighted with
yellow arrows), and the corresponding composite image.
In general however, though this method could be of use, it did not contain true in-
formation about the circularity of the particles. This method was therefore combined
with the RCD method above, which provides greater use of the circularity of the particles
detected. The combined algorithm is described below.
7.1.4 Combined algorithms: StarRCD
The methods described above, the CGED and the RCD, improve di erent components
of the analysis. They were therefore combined to produce an e ective method for analysing
TEM images, referred to as the StarRCD method.
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Algorithm
The image intensity values are mapped to values between 0 and 1, then smoothed
using a Gaussian filter to eliminate some of the noise. At this stage, if necessary, further
image processing such as background correction can be carried out. This was generally
unnecessary, but depended on the image quality.
The edges and gradients of the edges are detected as for the compass gradients method
(see section 7.1.3). Briefly, the image is convolved with a rotating 3x3 kernel, which maps
the magnitude and direction of edges.
The magnitude image is segmented by a threshold value, calculated by Otsu’s method,
and the lines are thinned to create more closely fitted edges. The thresholded magnitude
image is then multiplied by the direction map.
Circles in the edges image are detected by the RCD method as described in section
7.1.2 and expended here.
Some threshold values are set:
• A failure threshold is set as an exit criteria in case no circles can be found.
• Thresholds are also set to limit the minimum and maximum distances between the
first three randomly selected pixels. This is included for time benefits, though the values
must be selected carefully so as not to bias the results.
• There is a third threshold set to limit the distance that the 4th randomly selected
pixel can be from the test circle made by the first three.
• The fourth threshold determines the acceptable ratio between the number of edge
pixels on the perimeter of the test circle and the theoretical number of edge pixels of the
test circle’s radius.
Three pixels are then randomly selected from the subset of edge pixels. The circle they
form is determined (referred to as the test circle). A fourth pixel is then also randomly
selected and is tested for whether it also falls on the perimeter of the test circle.
Some false positives need to be filtered out; this method is susceptible to detecting
a circle which encompasses either zero or multiple nanoparticles. Where there is no
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nanoparticle in the circle and the edges are made up of multiple true nanoparticles, the
results can be filtered out by reference to the composite image. Therefore, once a list of
possible circles has been obtained, the gradients around the edges of each of the centres
are verified in the composite image. Potential circles are kept if they have the correct
gradient directions at 2 or more compass points. This threshold could be increased for
greater accuracy but would risk losing some circles with more irregular shapes.
A histogram of the circle radii and a mean radius is then calculated.
Validation
The algorithm was run on a phantom image to test its capabilities. All seven of the
phantom circles were detected, and the radii detected accurately represent the radii of
the circles, see Figure 7.11.
It should be noted however that careful parameter selection is required. Though there
are several checks carried out during the detection, there is a vulnerability to duplicate
detections, as discussed below, if the threshold parameters are too broad.
The average radius detected was 78 pixels, with two separate size peaks at 74 and 100
as expected.
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(a) Detected circles (b) Histogram of radii of detected circles.
Figure 7.11: Results of the star RCD algorithm tested on a model image.
Testing
SiNP images On well-contrasted images, such as those of the RuSiNPs, the al-
gorithm readily detected structures, and the perimeters visually matched well with what
would be selected manually, as shown in Figure 7.12, with the associated histogram shown
in Figure 7.13.
Figure 7.12: Typical images of SiNPs showing the overlaid circles detected by automated
analysis by the StarRCD method. Circle perimeters are shown in red, and centres in blue.
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Figure 7.13: Histogram of the results of SiNP radii by automated analysis by the StarRCD
method.
When measured by the algorithm a mean radius of 37 nm with a standard deviation
of 4 nm was calculated, based on 368 measured NPs.
The mean radius of the particles measured manually is 37nm with a standard deviation
of 17nm when 260 nanoparticles were included. The means are the same for manual
measurement as for the algorithm’s result suggesting that both methods produce similar
results. When measuring manually a wide range of particles were selected. In the images
in Figure 7.12 however, with the results from the algorithm, some of the larger particles
seem to have been missed, which accounts for the smaller standard deviation. This could
be due to parameter selection, as there is no other intrinsic reason the algorithm should
miss them.
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AuNP images AuNPs are also well-contrasted images, since the gold highly atten-
uates the electron beam. The di erence between AuNPs and SiNPs is usually the size,
so it was of interest to also test the algorithm on small particles. While it is possible to
compensate for this by magnification on some microscopes, the scale will be limited for
older models, with AuNPs falling at the low end of the spectrum, and therefore they often
comprise fewer pixels than the SiNPs.
A mean radius of 8 nm, with a standard deviation of 1 nm was found using the
algorithm, which detected 339 NPs. The histogram showing the distribution of sizes is
shown in Figure 7.14.
Figure 7.14: Histogram of the results of AuNP radii by automated analysis by the Star
RCD method. The x-axis was expanded for clarity as the higher radius bins were empty.
The detected particles are shown in Figure 7.15, with the second image zoomed in for
clarity.
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Figure 7.15: Typical images of AuNPs showing overlaid circles detected by automated
analysis by the Star RCD method. Circle perimeters are shown in red, and centres in
blue.
By measuring 100 AuNPs in the same images manually, a radius of 9 nm with a
standard deviation of 4 nm was obtained. These values are similar to each other and
probably within experimental error due to focusing and aberrations, so the di erence
can be considered acceptable and the results of the algorithm for these small particles
comparable to those measured manually.
ASiNP mages For ASiNPs, which had irregular morphologies, the algorithm de-
tected some circles which would be selected manually, but struggled to reliably detect
nanoparticles, see Figures 7.16 and 7.17. This could partly be due to the aggregation and
poor contrast of the particles, which leads to non-discrete shapes on the TEM image.
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Figure 7.16: Histogram of the results of ASiNP radii by automated analysis by the Star
RCD method.
Figure 7.17: Typical images of ASiNPs showing overlaid as circles detected by automated
analysis by the Star RCD method. Circle perimeters are shiwn in red, and centres in
blue.
Automated detection resulted in a mean radius of 34 nm and a standard deviation of
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10 nm, from 618 NPs.
Manual selection of 109 circular structures from the same images however produced
a mean radius of 27 nm with a standard deviation of 14 nm. The mean obtained by the
automated method was within a standard deviation of that found by manual selection,
but there is considerable variation, so this method should be used with caution on such
images. There is some ambiguity in the nanoparticle edges which both measurements will
be subject to, but taking a fraction of the time does add some value to the computational
method.
One compromise between these two methods would be to run the algorithm with loose
parameters then to confirm or reject every selected circle manually. While this is similarly
tedious, it would speed up the task compared to drawing every ROI.
HSNP images In the case of the hollow silica nanoparticles the algorithm was able
to detect the nanoparticle outer edges in a small test sample, as shown in Figures 7.18
and 7.19. None of the inner circles produced by the cavity in the nanoparticle core were
delineated, as expected since the gradient direction is controlled. There are some small
structures delineated, which shifts the histogram and mean. These could be excluded
by parameter selection, but should not be to avoid arbitrary bias. It is clear from this
example though that the algorithm can distinguish overlapping hollow particles as long
as the edges are clear.
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Figure 7.18: Histogram of the results of HSiNP radii by automated analysis by the Star
RCD method.
Figure 7.19: Typical image of HSiNPs showing overlaid as circles detected by automated
analysis by the Star RCD method. Circle perimeters are shiwn in red, and centres in
blue.
Further testing would indicate the limits of this algorithm with respect to hollow
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particles, but this illustrates the e ectiveness of the concept.
Discussion
The StarRCD is rapid and e ective given su cient runs for the selections to be op-
timised. It does however require good edge detection. The use of the compass gradients
then has the advantage of providing the directions too. This means that it is the intrin-
sic image information that is being used to filter out false positives circles rather than
arbitrary distance values.
7.2 Automated relaxation time calculation from MR
images
This section describes the automated sorting and analysis of the proton MRI images
carried out during this project.
7.2.1 Background and overview
Magnetic resonance images are formed through a balance of the e ects of the relaxation
times (T1 and T2) and the proton density of the sample. The relaxation time T1 can be
determined from a series of inversion recovery images with varying inversion time (TI),
or saturation recovery images with varying repetition times [111].
The images in recovery sequences were acquired with the inversion or repetition times
in a non-ordered series. This reduces the risk of accumulating errors from incomplete
relaxation from the previous sequences. The images must therefore be sorted for analysis
according to both the series to which they belong, and the order of the image stack
according to inversion time.
The regions of interest (ROI) can then be segmented and the intensities of the ROIs
averaged for each slice through the stack of images, which is ordered by inversion or
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repetition time.
The intensity of the image at a given coordinate will correspond to the signal intensity
at that point, which will recover through the series according to the equation (7.1) for
inversion recovery, or equation (7.2) for saturation recovery.
Intensitysample,IR(TI) =M0
5
e≠
TI
T1 (≠2 + e≠TRT1 ) + 1
6
(7.1)
Intensitysample,SR(TR) =M0
5
1≠ e≠TRT1 + k
6
(7.2)
The intensity of the image coordinates can therefore be fitted to equations (7.1) or
(7.2) to calculate the T1. This is a complex problem with multiple unknown variables, so
most easily addressed computationally.
One standard method of fitting is to use a Levenberg-Marquart nonlinear-least-squares
minimisation of three parameters [302, 303, 304]. Other methods, such as that used here,
have been reported which can save on computation time and have been found to be more
robust [305].
In this work the intensity data has been fitted to the recovery curve by a Nelder-Mead
simplex minimisation [306] of the squared di erence between theoretical model values
and the experimental data. This is a non-linear multivariate optimisation algorithm, and
while it is a heuristic method, it is relatively simple and produced excellent results for
this purpose.
7.2.2 Algorithm
The algorithm used to sort and analyse the MR images are described below. The meth-
ods for analysing inversion recovery and saturation recovery data are very similar, with
only the model equation for the fitting di ering. Both are therefore presented together
below.
The algorithm is summarised in Figure 7.20.
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Figure 7.20: Workflow for the automated calculation of relaxation times from DICOM
format MR images.
The raw images are sorted according to their DICOM header information. This in-
cludes the sequence name, which is used to distinguish initially whether the images are
relevant for T1 calculations. They are then sorted according to the series they were
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acquired in, and ordered according to their inversion time.
This produces a set of image stacks for each image slice. The optimal slice for selecting
regions of interest is then selected manually. Usually this will be the image with the highest
inversion time as the samples should all be fully relaxed, and therefore show the highest
and most uniform contrast.
A threshold might be directly applicable, but there may also be a need to first apply
mathematical morphology operations to better delineate the regions of interest. The
variables used in these operations are at present set manually as appropriate. The mean
intensity value for each region of interest is then calculated, providing the data for the
curve fitting.
A test function is estimated to model the shape of the relaxation curve, either for
equation (7.1) or (7.2) above depending on whether the sequence was inversion or sat-
uration recovery. Signal recovery estimates for di erent relaxation times are calculated
from this model, which are compared to the real data. The di erence between the test
data and real data is minimised by changes to the test function until either a threshold
number of attempts is exceeded or a minimum is found. The minimisation is carried out
by a Nelder-Mead simplex minimisation [306, 305].
The starting values for the test function must be supplied. Given the knowledge of
MRI sample properties however, reasonable estimates for each value have been used and
consistently provided closely fitted results.
7.2.3 Discussion
In general this algorithm has been highly e ective, and has routinely been used to
analyse MRI images throughout this project. Once a suitable region of interest has been
selected, the sorting and fitting processes produce reliable results which are consistent
with expected values.
Any problems that have arisen have been in region of interest (ROI) segmentation,
especially where there is an uneven background due to other objects in the scanner. For
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example, in one early experiment samples tubes were placed in a sponge for support and
submerged in water to reduce surface-air artefacts. The sponge however created a rough
background, from which it was di cult to segment the sample tubes.
There is also currently no fully automated function for ROI detection integrated into
the algorithm. Parameters must be provided with an approximate size of the ROIs in
order for any morphology operations to be carried out. Future work on this script could
include automating an approximation of the ROI size.
Other problems that have arisen have been due to incomplete data sets. This arose
from samples completely relaxing before the minimum available inversion time. This
would lead to increased error in samples with high contrast agent concentrations, so these
samples should be treated with caution during the analysis.
The other occasion for incomplete data so poor fitting occurred when samples had an
unexpectedly long relaxation time, so were not su ciently relaxed to model the curve.
This was resolved however by re-scanning the samples with increased repetition times.
7.3 Conclusions
In conclusion, two e ective algorithms have been developed during this project that
considerably reduced the processing time for extracting information from the images.
They have been used throughout this report where relevant, and were found, despite
some limitations, to be highly useful tools.
Some problems have been noted and discussed. Overcoming these would be an in-
teresting route for future work since these algorithms could be useful for many people
undertaking such analyses manually or producing their own similar algorithms.
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CHAPTER 8
CONCLUSIONS AND FURTHER WORK
In this work, the possibilities of multimodal imaging of in vivo immune cells have
been investigated on several levels. The design of an appropriate imaging agent system
first required a focus on suitable techniques, then incorporated the many requirements
they entailed. For example, a gadolinium agent should have ready solvent access to allow
e cient exchange, whereas fluorophores are often better protected from the oxygen in the
solvent to avoid quenching.
The most challenging aspect was however incorporating fluorinated agents into the
structure. In order to design a suitable vehicle, one unknown factor was how readily the
agents could be examined by 19F MRI. The capabilities of the MR imaging equipment
available were therefore investigated to help establish the requirements for multimodal
imaging agents to be developed. It was found that the SNR increased linearly with
fluorine concentration for a given compound, as expected. The trend of the SNR against
fluorine concentration between compounds however was not linear, which was attributed
to the properties of the molecules and the medium such as the relaxation times and the
viscosity.
This data suggests a strong caveat for future research, in that the signal may not vary
as expected when comparing two fluorine tracers in di erent tissue compartments, but
also when comparing agents in tissue and in a reference standard.
Another caveat highlighted in this section is the variation in the signal that can arise
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both laterally and vertically with respect to the coil. This is most significant when a vial
adjacent to a sample is used as a reference, since the coil sensitivity may well vary over this
area. While this e ect is most pronounced with a surface coil due to its simple structure,
it was also demonstrated that there can be considerable variation within a birdcage coil
too. Consequently careful thought should be given to mapping the regions of interest onto
a sensitivity profile.
Next the design of a multimodal vehicle was considered. Of the various ways that
imaging agents can be incorporated into a nanoparticle, three were explored in this project:
trapping imaging agents inside the matrix of a particle, binding agents onto a nanoparticle
surface, and trapping agents in the core of nanoparticles. Using multimodal molecules
was briefly explored but their usefulness was limited by the inability to tune the di erent
imaging agent concentrations as required by the di erent techniques.
8.1 Trapping imaging agents in a nanoparticle matrix
A novel dual-modal nanoparticle was created which incorporated both fluorescein for
fluorescence techniques and gadolinium for proton MRI, denoted as FlGdASiNPs. The
particles’ morphologies were investigated by electron microscopy. The shape was found
to be uneven, and with distinguishable but aggregated particles, which explained the
polydispersity observed by light scattering.
The FlGdASiNPs were characterised in relation to their e ectiveness as imaging
agents. The luminescence was spectrally similar to the free dye, though the lifetime
suggested there would be a reduction to the quantum yield. Given the high sensitivity
of fluorophores and fluorescence techniques this was not considered to be a problem since
the particles were visibly fluorescent. The MR relaxivity was comparable to commercially
available MRI contrast agents.
Having shown both luminescence and MR contrast enhancement, PBMCs were treated
with the FlGdASiNPs to assess how they are taken up into the various cell types. Flow
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cytometry indicated that there was uptake both into monocytes and lymphocytes, though
with labelling starting at di erent concentrations. Microscopy however demonstrated
one significant challenge with these nanoparticles, which is that the aggregation severely
increased in cell medium, and that the consequent problems were exacerbated by slide
preparation techniques such as cytospinning. Separation of the aggregates from the cells is
challenging as both settled rapidly, and the cells were used at too low a concentration for
recovery from a density-gradient column. The FlGdASiNP-labelled PBMCs also showed
no contrast enhancement by MRI. This is at least partly explained by the limited uptake
and labelling observed by flow cytometry.
Trapping imaging agents in the matrix has therefore been shown to be of potential
use for cell labelling by fluorescence and novel nanoparticles demonstrating this have been
created in Chapter 3 of this work. The advantage of this method is that it preserves the
structures of the imaging agents with no chemical modification required. It is important
to note that the fluorescence was quenched to some extent by the trapping process, and
although it was not significant in this context it should be borne in mind for future work.
Another aspect to be investigated in future systems with using this method is the
degree of leakage from the nanoparticles. No leakage of fluorescent compounds was evident
by observation either during these experiments or afterwards, but if the system were to
be carried forward this should be investigated thoroughly.
Fluorinated species could not readily be incorporated by trapping in the matrix, which
e ectively limits these particles to being dual-modality agents for the techniques of in-
terest. This was a limitation that led to other methods being explored. In future work
however other designs, such as using SPIOs and negative proton MRI contrast, could re-
place the fluorine MRI and hence the requirement for fluorinated species. This is discussed
further below.
An attempt was made to improve the trapping and increase the surface charge by
using a quaternary aminated silane instead of a primary silane. The method used however
produced only gels which may have some function in other work, but were not considered
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viable for this project since they could not be characterised as nanostructures.
Strategies for improving the trapping of imaging agents in ASiNPs in further work
would therefore include developing the synthesis to achieve colloidal stability in cell
medium. While replacing all of the aminated silane was not useful, if the particles could
be dispersed and coated with a layer of pure silane, the core would still retain the e ec-
tive trapping observed here, while the surface could stabilise the particles and be further
functionalised. The question arising from this would be whether the gadolinium would
still have su cient access to water in the core, or whether it would have to be conjugated
to the surface.
8.2 Binding imaging agents to a nanoparticle surface
Two nanoparticle systems were created in this chapter. Ruthenium-tris-phenanthroline-
doped silica nanoparticles, RuSiNPs were further functionalised with gadolinium to form
RuGdSiNPs. Iridium bipyridyl and gadolinium DTPA-functionalised gold nanoparticles,
IrGdAuNPs, were also explored.
The RuGdSiNPs were useful as a reference point as similar particles have been reported
to show good uptake into cells [236]. The RuGdSiNPs were therefore used for developing
protocols and setting baseline expectations for novel systems.
The RuGdSiNPs showed a regular morphology and low dispersity by both electron
microscopy and light scattering. The luminescence of the ruthenium complex was compa-
rable to literature values and MRI contrast enhancement was comparable to commercially
available contrast agents. Treatment of PBMCs with the RuGdSiNPs resulted in e ective
fluorescence labelling, as measured by flow cytometry and observed by microscopy. The
labelling was not however high enough to observe contrast enhancement by MRI.
The IrGdAuNPs were novel structures, designed in the context of stabilised gold
nanoparticles [261], and o ering a greater surface to volume ratio than the silica nanopar-
ticle. In this system however the gadolinium complexes, instead of a surfactant, stabilised
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the particles before the iridium complexes were incorporated. Electron microscopy and
light scattering showed a regular morphology and low dispersity, as expected with gold
nanoparticles. The luminescence was spectrally comparable with literature values, and
the MR relaxivity was greater than that of current commercially available contrast agents.
When PBMCs were treated with the IrGdAuNPs however, there was no uptake observed
by microscopy, and very limited contrast enhancement by MRI.
The IrGdAuNPs did su er from a limited stability, so further development could be
of interest as a means to improve the interaction with cells.
More generally, binding imaging agents to nanoparticle surfaces is attractive due to
easy characterisation and simple functionalisation reactions. There was however no obvi-
ous way to incorporate fluorinated species into these simple systems without reducing the
19F relaxation time to an undetectable level or without more specialised pulse sequences.
As an approach it is therefore insu cient, alone, to create a trimodal imaging agent for
cell tracking for the modalities of choice in this work, but it is a useful component in the
nanoparticle toolkit.
8.3 Multimodal imaging agent molecules
In this chapter AFC was explored as a potential multimodal agent for fluorescence
techniques and 19F MRI. The fluorescence was found to be in a suitable range for most
fluorescence techniques, and the SNR of the fluorine MRI signal at various concentrations
was measured. Based on the MRI measurements, it was considered unlikely that treatment
of PBMCs with AFC would lead to e ective labelling. Indeed in cell tests it was found
that, while the molecule was very e ective as a cell label for fluorescence techniques, the
labelling of PBMCs was not su cient to allow e ective detection by 19F MRI.
It was noted however that this molecule could be a useful component for future larger
multimodal systems; For example, if a high concentration of the dye could be trapped
inside a nanoparticle shell, there may be su cient signal for observation by fluorine MRI,
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and consequently tracking.
In general combining fluorine MRI and fluorescent agents in one molecule will always
su er from a need to balance the number of fluorines in the structure and the solubility
of molecule. An interesting but complex option would be to develop dendrimers, which
could simultaneously incorporate both agents with tuning of the ratios, have a stabilising
moieties on its surface to improve the solubility, and the added benefit of monodispersity.
The design, synthesis and purification of such a system would however be very challenging.
8.4 Trapping imaging agents in nanoparticle cores
In Chapter 6 nanoparticles were explored further, in this case as hollow shells to be
filled with imaging agents. This method proved more successful, with the development
of a novel dual modal particle by trapping ruthenium tris-phenanthroline suspended in
PFOB in a silica shell, which could be pre-functionalised with gadolinium to add the third
modality of proton MRI contrast. Both the suspension of fluorophores in perfluorocarbons
and its subsequent trapping inside a silica shell has been demonstrated here for the first
time (to the author’s knowledge).
This is an exciting and relatively unexplored area of nanoscience, where the many
opportunities need to be balanced by robustness in the development process. For example,
careful consideration needs to be given to the choice between calcination and solvent
extraction. Solvent extraction is e ective on smaller scale quantities of particles, whereas
calcination has been shown to be more e cient in the removal of organic material. This
is important for confidence in the purity of the shells, where residues of surfactants can
make a significant di erence to the physicochemical properties of the particle such as the
surface charge or the porosity.
Similarly the choice of synthesis would be important for future work as each have
their advantages. In this work latex templating produced interesting results, such as the
positive surface charge and the relative monodispersity and uniform shell thickness. The
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positive surface charge, while potentially improving the cell uptake, does however show
that the poly-l-lysine is thoroughly incorporated into the shell. Calcination would remove
the polymer, so solvent extraction might be preferable, but then there is a concern for
robust characterisation of the shell contents and residual latex in the core reducing the
loading capacity. Another complication of future work is that the latex beads would need
to be produced in-house in order to make the synthesis financially viable, especially when
scaled up.
Homogeneous templating, with selective etching to remove the core of a nanoparticle,
was therefore explored further here. Large scale production was possible, which pro-
duced stocks for further experimentation. These hollow structures were then filled with
perfluorooctyl bromide as a fluorine MRI agent.
It was found that [Ru(phen)3](PF6)2 could be suspended in the PFOB while maintain-
ing its fluorescence, thus creating a dual modal suspension without any further function-
alisation. This [Ru(phen)3](PF6)2-labelled PFOB (RuPFOB) was then introduced into
hollow nanoparticles.
Filling the GdHSNPs with RuPFOB, the suspension mentioned above, led to nanopar-
ticles which could be viewed by proton MRI, fluorine MRI and fluorescence techniques. A
di erence was noted however between the fluorine signal from the Gd-functionalised and
unfunctionalised PFOB-filled HSNPs. This suggests that the gadolinium may be having
a relaxation enhancing e ect on the fluorines in the core, making them relax faster than
they can be observed by standard MR sequences.
Multiple routes for further work could stem from this section. The most pressing
would be to optimise the silica shells themselves. While they show good colloidal stability
after calcination, both surface functionalisation with the gadolinium and filling with the
perfluorocarbon disrupt the stability. Further surface functionalisation would therefore
be useful in order to increase the surface charge. Filling of the nanoparticles poses a
greatest problem in that currently the nanoparticle pores expose the PFOB to the aqueous
medium, so causing aggregation. Capping the particles with either a further silane layer,
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a layer of metal, or a polymer brush to cover the pores, could potentially all improve the
stability of the filled shells.
Another aspect would be incorporating more gadolinium onto the surface to increase
the proton MRI contrast, either through using multiple layers of gadolinium complexes,
through conjugation to a longer structure polymeric structure [236, 195], or through
increasing the surface area to volume ratio. The latter option would however reduce the
volume available for the PFOB, which is also subject to low sensitivity.
A third route is to explore other fluorescent or luminescent dyes and perfluorocarbon
suspensions, especially those with a high hydrophobicity, to find other dyes which might
be incorporated into the silica shells. This, in addition to the capping, would further
minimise the risk of leakage from the shell.
8.5 Image analysis
A large volume of image data was collected over the course of this project, with no
readily available tools for easily carrying out analysis to extract useful information. The
two principal areas where this was found were in electron microscopy and MRI.
8.5.1 Electron microscopy image analysis
For TEM images, the goal was to develop an algorithm to automatically analyse a
stack of microscopy images in order to measure the size of the nanoparticles. Essentially
the required task was circle detection, which was implemented by a rapid randomized
method [299]. The edge detection was not su cient however so a more sophisticated edge
detection method was added, which also provided information on the direction as well
as the magnitude of the gradient. The extra checks the gradient direction information
produced was found to often be e ective at minimising the detection of false-positive
circles. This method was shown to be e ective on a range of nanoparticle images, so
could be a useful tool for others in the analysis of similar images.
237
Future work for this algorithm would be to generalise it so that is can accept a wider
variety of images, and to add a user interface so that it could be used by others without
requiring knowledge of Matlab, or the costly licence fee for the software.
8.5.2 MRI image analysis
In a similar way, T1 mapping is a common task, but there were no readily available
tools which could extract relaxivity information from the image stacks. A method was
therefore developed in Matlab which would accept read in DICOM files, detect regions of
interest, then fit T1 values to the data.
This method was found to provide reliable results, and was used with di erent pulse
sequences. This versatility is useful as the only input needed to measure values from a
new sequence is the equation for the fitting.
This algorithm could also be developed into a more widely applicable tool. Firstly, a
method selecting regions of interest would be required, then a way to input and validate
new equations would be useful. Lastly a user-interface would make this accessible to those
without Matlab licenses.
8.6 Future directions
To develop this project further capping of the pores with imaging agents inside the
shells would be a priority future work. The most important consideration would be
to provide greater colloidal stability by increasing the surface charge, preferably with
a positive charge, while minimising leakage. This would give greater confidence in the
reliability and clinical translatability of the system.
The next steps would involve tuning the size and polydispersity in order to optimise
the surface area to volume ratio, and hence the ratio of agents for proton and fluorine
MRI. This would have to be done in combination with cell studies to ensure that the sizes
are appropriate for e cient uptake and minimal cytotoxicity.
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Another interesting aspect would be to determine whether the quenching of the fluorine
MRI signal by the gadolinium could be reduced with either thicker shells or a spacer
molecule and for example polymer brush adding distance between the gadolinium and
the fluorine species. Alternatively if di erent pulse sequences became available it would
be useful to explore shorter echo times, and hence the use of less mobile fluorine molecules.
An alternative route could involve incorporating SPIOs by trapping them in the matrix
of a nanoparticle shell, as an extension of trapping in the bulk matrix of the particle
[307, 308] or in the core during synthesis as a rattle-type particle [309, 310]. This could
have multiple potential benefits: it would add negative proton MRI contrast to the system;
it could add an extra check of the cell quantification by comparison with the fluorine
quantification result; it would demonstrate that the core was co-localised with the shell
itself; it could also enable magnetic purification of the shells.
To conclude, the main challenge in this work is the low sensitivity of MRI, especially
of fluorine MRI, which may require a technological breakthrough rather than a chemical
solution to make clinical translatability feasible. This work however has systematically
investigated several ways to label immune cells using nanotechnology, and has explored
novel formulations and structures for imaging by multiple modalities. The combination of
the di erent approaches, i.e. trapping in the matrix, binding to the surface, and using the
core of the particle, allows a varied design to accommodate the di erent agents’ needs,
which is crucial for building an e ective system. A proof-of-concept system has been
presented here, which lays important ground work for developing an innovative multi-
modal system for immune cell tracking.
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APPENDIX A
FLOW CYTOMETRY OF IRGDAUNPS IN PBMCS
This appendix illustrates the flow cytometry of IrGdAuNP-treated PBMCs. No sig-
nal was detected, though the limited iridium luminescence around 405nm could be an
important factor in this. The data is included here for completeness.
The forward scatter and side scatter plots of the cells are shown in figure A.1.
(a) Monocytes (b) Lymphocytes
Figure A.1: Forward scatter vs. side scatter plots of PBMCs labelled with IrGdAuNPs.
The overlaid ellipses mark the gates used to define the monocyte and lymphocyte clouds
respectively.
There is no clear trend in this data. A significant point to note is that the count of
labelled lymphocytes appears to be high for the treated cells, suggesting some of the cells
are labelled. This is probably due to a misplaced fluorescence gate however, as supported
by the lack of change in the median channel fluorescence.
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Figure A.2: The percentage of cells with increased fluorescence (the percentage of the
cell count), and the median channel fluorescence (arbitrary scale) of the cells within the
fluorescence gate, if any.
242
APPENDIX B
CHARACTERISATION DATA FOR SYNTHESISED
MOLECULES
This appendix contains the nuclear magnetic resonance spectroscopy (NMR), electro-
spray ionisation mass spectrometry (ESI-MS) and Fourier transform infrared spectroscopy
(FT-IR) spectra which were summarised in the relevant experimental sections.
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B.1 Diethylenetriamine tetraacetic acid 3-amidopropyl
triethoxysilane
B.1.1 NMR
Figure B.1: 1H (top) and 13C (bottom) NMR spectra of APTES-DTPA.
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B.1.2 ESI-MS
Figure B.2: ESI-MS spectrum of APTES-DTPA.
B.1.3 FT-IR
Figure B.3: FT-IR spectra of APTES-DTPA.
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